{"id":6232,"date":"2023-11-21T17:53:23","date_gmt":"2023-11-21T16:53:23","guid":{"rendered":"https:\/\/icoprevencio.cat\/uc\/?page_id=6232"},"modified":"2023-11-21T17:53:24","modified_gmt":"2023-11-21T16:53:24","slug":"publicacions","status":"publish","type":"page","link":"https:\/\/icoprevencio.cat\/uc\/publicacions\/","title":{"rendered":"PUBLICACIONS"},"content":{"rendered":"\n<p><\/p>\n\n\n<div class=\"teachpress_pub_list\"><form name=\"tppublistform\" method=\"get\"><a name=\"tppubs\" id=\"tppubs\"><\/a><div class=\"teachpress_filter\"><select class=\"default\" name=\"yr\" id=\"yr\" tabindex=\"2\" onchange=\"teachpress_jumpMenu('parent',this, 'https:\/\/icoprevencio.cat\/uc\/publicacions\/?')\">\r\n                   <option value=\"tgid=&amp;type=&amp;auth=&amp;usr=&amp;yr=#tppubs\">All years<\/option>\r\n                   <option value = \"tgid=&amp;type=&amp;auth=&amp;usr=&amp;yr=2026#tppubs\" >2026<\/option><option value = \"tgid=&amp;type=&amp;auth=&amp;usr=&amp;yr=2025#tppubs\" >2025<\/option><option value = \"tgid=&amp;type=&amp;auth=&amp;usr=&amp;yr=2024#tppubs\" >2024<\/option><option value = \"tgid=&amp;type=&amp;auth=&amp;usr=&amp;yr=2023#tppubs\" >2023<\/option><option value = \"tgid=&amp;type=&amp;auth=&amp;usr=&amp;yr=2022#tppubs\" >2022<\/option><option value = \"tgid=&amp;type=&amp;auth=&amp;usr=&amp;yr=2021#tppubs\" >2021<\/option><option value = \"tgid=&amp;type=&amp;auth=&amp;usr=&amp;yr=2020#tppubs\" >2020<\/option><option value = \"tgid=&amp;type=&amp;auth=&amp;usr=&amp;yr=2019#tppubs\" >2019<\/option><option value = \"tgid=&amp;type=&amp;auth=&amp;usr=&amp;yr=2018#tppubs\" >2018<\/option><option value = \"tgid=&amp;type=&amp;auth=&amp;usr=&amp;yr=2017#tppubs\" >2017<\/option>\r\n                <\/select><select class=\"default\" name=\"type\" id=\"type\" tabindex=\"3\" onchange=\"teachpress_jumpMenu('parent',this, 'https:\/\/icoprevencio.cat\/uc\/publicacions\/?')\">\r\n                   <option value=\"tgid=&amp;yr=&amp;auth=&amp;usr=&amp;type=#tppubs\">All types<\/option>\r\n                   <option value = \"tgid=&amp;yr=&amp;auth=&amp;usr=&amp;type=article#tppubs\" >Journal Articles<\/option><option value = \"tgid=&amp;yr=&amp;auth=&amp;usr=&amp;type=misc#tppubs\" >Miscellaneous<\/option>\r\n                <\/select><select class=\"default\" name=\"auth\" id=\"auth\" tabindex=\"5\" onchange=\"teachpress_jumpMenu('parent',this, 'https:\/\/icoprevencio.cat\/uc\/publicacions\/?')\">\r\n                   <option value=\"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=#tppubs\">All authors<\/option>\r\n                   <option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=111#tppubs\" >working group Cancer Global Modelling Consortium (CCGMC)  2. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=532#tppubs\" > Aggarwal  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=292#tppubs\" > Agudo  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=324#tppubs\" > Arcusa  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=29#tppubs\" > Arencibia-Dom\u00ednguez  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=418#tppubs\" > Barricarte  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=38#tppubs\" > Ben\u00edtez-Segura  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=205#tppubs\" > Capit\u00e1n  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=86#tppubs\" > Cardona  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=146#tppubs\" > Cardona-Cardona  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=271#tppubs\" > Cartany\u00e0-Hueso  \u00c0. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=273#tppubs\" > Casellas-Grau  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=302#tppubs\" > Castell\u00f3  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=130#tppubs\" > Cayuela  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=335#tppubs\" > Cobo-Calvo  \u00c1. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=232#tppubs\" > D\u00edez-Villanueva  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=456#tppubs\" > Espinosa  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=282#tppubs\" > Faba  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=178#tppubs\" > Farre  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=295#tppubs\" > Fernandez-Somoano  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=117#tppubs\" > Flix-Valle  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=287#tppubs\" > Fonseca-Nunes  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=474#tppubs\" > Gallego Iborra  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=237#tppubs\" > Garc\u00eda-Rodr\u00edguez  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=48#tppubs\" > Garc\u00eda-Tejedor  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=266#tppubs\" > Gonz\u00e1lez-Marr\u00f3n  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=44#tppubs\" > Guma  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=454#tppubs\" > J Cross  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=215#tppubs\" > Karch  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=594#tppubs\" > Ko\u00efvogui  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=521#tppubs\" > Kumar  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=235#tppubs\" > L\u00f3pez  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=19#tppubs\" > Luzardo-Gonz\u00e1lez  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=555#tppubs\" > Mafra  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=577#tppubs\" > Marcos-Delgado  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=338#tppubs\" > Mart\u00ednez-Yelamos  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=236#tppubs\" > Mata  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=35#tppubs\" > Mestre-Jane  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=50#tppubs\" > Molina-Barcel\u00f3  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=263#tppubs\" > Molinuevo  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=161#tppubs\" > Montoliu  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=155#tppubs\" > Morales  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=517#tppubs\" > Nakaganda  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=451#tppubs\" > Olsen  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=412#tppubs\" > Pastor  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=438#tppubs\" > Perez-Cornago  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=311#tppubs\" > Pons  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=188#tppubs\" > Pons-Rodr\u00edguez  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=290#tppubs\" > Roca  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=260#tppubs\" > Roca-Barcel\u00f3  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=42#tppubs\" > Rodr\u00edguez  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=198#tppubs\" > Rodr\u00edguez-Arana  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=600#tppubs\" > Rodriguez-Ortega  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=183#tppubs\" > Romaguera  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=375#tppubs\" > Romero  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=223#tppubs\" > Santiago  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=277#tppubs\" > Sirgo  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=61#tppubs\" > Tard\u00f3n  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=450#tppubs\" > Tj\u00f8nneland  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=310#tppubs\" > Toledo-Ch\u00e1varri  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=439#tppubs\" > Trichopoulou  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=463#tppubs\" > V\u00e1squez-Mej\u00eda  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=531#tppubs\" > Yusuf  A. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=238#tppubs\" > Palomo  AG. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=239#tppubs\" > Molina  AJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=526#tppubs\" > Baker  AL. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=460#tppubs\" > Falc\u00f3  AM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=544#tppubs\" > Ilbawi  AM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=362#tppubs\" > Pedraza-Flechas  AM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=139#tppubs\" > Carvalho  B. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=321#tppubs\" > Cirauqui  B. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=30#tppubs\" > Gonzalez-Pineda  B. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=347#tppubs\" > Lauby-Secretan  B. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=53#tppubs\" > P\u00e9rez-G\u00f3mez  B. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=166#tppubs\" > Serrano  B. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=398#tppubs\" >de Batlle J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=229#tppubs\" > BELE. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=138#tppubs\" > Lissenberg-Witte  BI. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=574#tppubs\" > Gemma  Binefa. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=613#tppubs\" > Tatjana Kofol  Bric. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=473#tppubs\" >de Britos Marsal C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=615#tppubs\" > Jean-Luc  Bulliard. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=608#tppubs\" > Andrea  Buron. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=202#tppubs\" > Agust\u00ed  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=92#tppubs\" > Atencia  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=596#tppubs\" > Balamou  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=142#tppubs\" > Campari  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=498#tppubs\" > Carle  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=328#tppubs\" > Castro  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=313#tppubs\" > Coudray  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=599#tppubs\" > Duclos  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=22#tppubs\" > Falo  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=152#tppubs\" > Folch  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=148#tppubs\" > Forn\u00e9  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=560#tppubs\" > Frick  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=354#tppubs\" > Gonz\u00e1lez-Donquiles  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=131#tppubs\" > Hernando  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=293#tppubs\" > Javierre  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=284#tppubs\" > Lid\u00f3n-Moyano  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=404#tppubs\" > Llorens-Ivorra  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=184#tppubs\" > Mart\u00edn-Cantera  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=103#tppubs\" > Nadeau  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=294#tppubs\" > Natal  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=415#tppubs\" > Navarro  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=221#tppubs\" > Nickson  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=164#tppubs\" > Ochoa  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=113#tppubs\" > Ochoa-Arnedo  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=67#tppubs\" > Orrego  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=253#tppubs\" > Palazuelos  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=306#tppubs\" > Pedraz-Pingarr\u00f3n  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=114#tppubs\" > Prats  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=477#tppubs\" > Requeijo  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=487#tppubs\" > Rocha  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=489#tppubs\" > Rocha Calder\u00f3n  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=307#tppubs\" > S\u00e1nchez-Contador  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=304#tppubs\" > Santamari\u00f1a  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=144#tppubs\" > Senore  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=256#tppubs\" > Suarez-Calleja  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=403#tppubs\" > Urtiaga  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=65#tppubs\" > Valli  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=389#tppubs\" > Vicente  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=12#tppubs\" > Vidal  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=87#tppubs\" > Vidal-Lancis  C. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=414#tppubs\" > Gonzalez  CA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=352#tppubs\" >for Research on International Agency  Cancer Handbook Working Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=587#tppubs\" > Berta  Casas. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=299#tppubs\" >on Colorectal Cancer Screening in Adverse Effects  Catalonia (EACC) Study Working Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=592#tppubs\" > Kircher  CE. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=553#tppubs\" > Loo  CE. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=133#tppubs\" > Forero  CG. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=616#tppubs\" > Jessica  Chubak. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=593#tppubs\" > Goldie  CL. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=513#tppubs\" > McShane  CM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=210#tppubs\" > Cancer Global Modelling  Consortium. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=171#tppubs\" > I-PaRCS  Consortium. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=209#tppubs\" >of the Breast Screening Working Group (WG2)  Covid-19. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=110#tppubs\" > COVID-19. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=340#tppubs\" >de la Cueva Ariza L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=462#tppubs\" > Carvallo-Casta\u00f1eda  D. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=225#tppubs\" > G\u00f3mez  D. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=598#tppubs\" > Novak-Mlakar  D. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=467#tppubs\" > Rigau  D. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=396#tppubs\" > Romaguera  D. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=64#tppubs\" > Salas  D. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=177#tppubs\" > Salas Trejo  D. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=332#tppubs\" > Salas-Trejo  D. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=503#tppubs\" > Abila  DB. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=216#tppubs\" > Vale  DB. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=411#tppubs\" > DDM-Spain\/Var-DDM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=395#tppubs\" > DDM\/Var-DDM-Spain. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=523#tppubs\" > Campbell  DJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=605#tppubs\" > V. Paul  Doria-Rose. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=255#tppubs\" > Ardanaz  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=141#tppubs\" > Dekker  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=119#tppubs\" > Domingo-Gil  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=105#tppubs\" > Feletto  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=185#tppubs\" > Fern\u00e1ndez  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=397#tppubs\" > Gracia-Lavedan  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=212#tppubs\" > Gray  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=285#tppubs\" > Guillam\u00f3  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=234#tppubs\" > Guin\u00f3  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=326#tppubs\" > Jansen  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=127#tppubs\" > Madrid  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=269#tppubs\" > Mart\u00ednez-Mart\u00edn  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=34#tppubs\" > Martinez-Perez  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=151#tppubs\" > Martr\u00f3  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=557#tppubs\" > McFerran  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=436#tppubs\" > Molina-Portillo  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=550#tppubs\" > Muntada  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=470#tppubs\" > Ni\u00f1o-de-Guzm\u00e1n  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=483#tppubs\" > Ni\u00f1o-de-Guzman Quispe  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=465#tppubs\" > Parmelli  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=453#tppubs\" > Riboli  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=134#tppubs\" > Ronda  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=441#tppubs\" > Valanou  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=428#tppubs\" > Weiderpass  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=319#tppubs\" > Zamora  E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=472#tppubs\" > Mart\u00ednez  EC. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=276#tppubs\" > Sumalla  EC. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=506#tppubs\" > O'Dowd  EL. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=581#tppubs\" > Teso  EP. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=610#tppubs\" > Josep A.  Espin\u00e0s. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=535#tppubs\" > Kliewer  EV. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=241#tppubs\" > Belvis  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=349#tppubs\" > Bianchini  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=536#tppubs\" > Bray  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=391#tppubs\" > Casanova  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=289#tppubs\" > Cos  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=129#tppubs\" > Gaillardin  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=268#tppubs\" > Garcia-Alemany  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=325#tppubs\" > Moreno  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=157#tppubs\" > Morey  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=201#tppubs\" > Rodr\u00edguez-Moranta  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=543#tppubs\" > Roitberg  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=11#tppubs\" > Saladie  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=31#tppubs\" > Tormo-Collado  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=525#tppubs\" > Wan  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=502#tppubs\" > Wei  F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=572#tppubs\" > Albert  Farre. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=614#tppubs\" > Rebeca  Font. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=118#tppubs\" >de Frutos ML. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=519#tppubs\" > Moraes  FY. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=174#tppubs\" > Arroyo  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=181#tppubs\" > Bagaria  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=77#tppubs\" > Binefa  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=316#tppubs\" > Buckland  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=43#tppubs\" > Campos  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=504#tppubs\" > Carreras  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=57#tppubs\" > Casta\u00f1o-Vinyals  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=405#tppubs\" > Fern\u00e1ndez-Tard\u00f3n  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=224#tppubs\" > Gnutti  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=90#tppubs\" > Ib\u00e1\u00f1ez-Sanz  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=507#tppubs\" > Lui  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=442#tppubs\" > Masala  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=476#tppubs\" > P\u00e9rez-Gaxiola  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=449#tppubs\" > Skeie  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=125#tppubs\" > Urr\u00fatia  G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=140#tppubs\" > Meijer  GA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=73#tppubs\" >van der Gaag M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=575#tppubs\" > Montse  Garcia. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=466#tppubs\" > Morgano  GP. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=286#tppubs\" > Oviedo  GR. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=488#tppubs\" >de Graaf G. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=378#tppubs\" >study BELE Project  group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=17#tppubs\" >study BELE  group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=297#tppubs\" > Benign Lesion Study  Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=145#tppubs\" > ICSN Colorectal Cancer Screening Working  Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=379#tppubs\" > InforMa  Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=457#tppubs\" > InforMa Study  Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=186#tppubs\" >research LUCAPREV  group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=227#tppubs\" >research Lung Cancer Prevention LUCAPREV  group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=568#tppubs\" > M-TICS Research  Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=208#tppubs\" >research MSIC-SC  group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=95#tppubs\" > On Behalf Of The Msic-Sc Research  Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=112#tppubs\" >on behalf of the MSIC-SC research PhD  group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=149#tppubs\" > Pro-Share  Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=89#tppubs\" > ProShare  Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=251#tppubs\" > STI Surveillance  Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=230#tppubs\" > IRIS Study  Groups. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=97#tppubs\" > On Behalf Of The Bele And Iris Study  Groups. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=571#tppubs\" >de Ena Ni\u00f1o  Guzman. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=68#tppubs\" >de Ni\u00f1o  Guzm\u00e1n E. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=566#tppubs\" >de Ni\u00f1o  Guzm\u00e1n EP. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=475#tppubs\" >de Ni\u00f1o  Guzman Quispe EP. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=516#tppubs\" > Boukheris  H. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=556#tppubs\" > Fink  H. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=492#tppubs\" > Hui  H. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=546#tppubs\" > Mart\u00ednez-Riveros  H. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=26#tppubs\" > P\u00e9rez-Montero  H. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=426#tppubs\" > Ward  HA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=365#tppubs\" >van der Haar R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=250#tppubs\" > Catalan  HIV. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=246#tppubs\" > Barrabeig  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=36#tppubs\" > Campos-Varela  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=518#tppubs\" > Ergin  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=60#tppubs\" > G\u00f3mez-Acebo  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=107#tppubs\" > Lansdorp-Vogelaar  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=370#tppubs\" > Padrol  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=346#tppubs\" > Peir\u00f3  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=500#tppubs\" > Rewais  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=461#tppubs\" > Ricci-Cabello  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=545#tppubs\" > Soerjomataram  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=468#tppubs\" > Sol\u00e0  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=296#tppubs\" > Tor\u00e1-Rocamora  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=195#tppubs\" > Tusquets  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=481#tppubs\" > Urreta-Barallobre  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=3#tppubs\" > V\u00e1zquez  I. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=588#tppubs\" > Gemma  Ib\u00e1\u00f1ez-Sanz. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=191#tppubs\" >en nombre del grupo InforMa. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=312#tppubs\" >with the InforMa Group. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=197#tppubs\" > A Espin\u00e0s  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=336#tppubs\" > \u00c1lamo  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=257#tppubs\" > Alguacil  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=356#tppubs\" > Alonso-Molero  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=409#tppubs\" > Altzibar  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=357#tppubs\" > Bayo-Calero  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=283#tppubs\" > Belmar Prieto  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=244#tppubs\" > Benach  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=484#tppubs\" > Bracchiglione  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=135#tppubs\" > Casabona  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=402#tppubs\" > Castilla  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=377#tppubs\" > Corominas  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=564#tppubs\" > Cylus  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=96#tppubs\" > Del Riego  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=372#tppubs\" > Espin\u00e0s  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=330#tppubs\" > Espinosa  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=196#tppubs\" > Ferrer  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=204#tppubs\" > Fibla  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=361#tppubs\" > Garc\u00eda-P\u00e9rez  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=458#tppubs\" > G\u00f3mez-Matas  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=552#tppubs\" > Hoyos  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=175#tppubs\" > Ib\u00e1\u00f1ez Cabanell  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=265#tppubs\" > Llorca  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=6#tppubs\" > Louro  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=447#tppubs\" > Manjer  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=387#tppubs\" > Maqueda Blasco  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=394#tppubs\" > Miranda-Garc\u00eda  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=172#tppubs\" > Moreno Salas  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=590#tppubs\" > Niyibaga  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=561#tppubs\" > Niyigaba  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=486#tppubs\" > Noordman  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=122#tppubs\" > P\u00e9rez-Bracchiglione  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=45#tppubs\" > Ponce-Sebasti\u00e0  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=137#tppubs\" > Rademakers  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=91#tppubs\" > Rocamora  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=383#tppubs\" > Soler-Gonz\u00e1lez  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=490#tppubs\" > Steinberg  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=33#tppubs\" > Terra  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=591#tppubs\" > Vignat  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=334#tppubs\" > Vioque  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=100#tppubs\" > Worthington  J. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=180#tppubs\" > Espin\u00e0s  JA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=406#tppubs\" > Lorca  JA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=259#tppubs\" > Molero  JA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=567#tppubs\" > Panera  JA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=102#tppubs\" > Lew  JB. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=267#tppubs\" > Mart\u00edn-S\u00e1nchez  JC. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=120#tppubs\" > Medina  JC. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=211#tppubs\" > Figueroa  JD. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=170#tppubs\" > Ein Yong  JH. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=106#tppubs\" > Yong  JHE. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=258#tppubs\" > Jim\u00e9nez-Mole\u00f3n  JJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=344#tppubs\" > Vendrell  JJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=288#tppubs\" > Alamo  JM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=56#tppubs\" > Altzibar  JM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=602#tppubs\" > Borras  JM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=392#tppubs\" > Corominas  JM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=407#tppubs\" > Huerta  JM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=272#tppubs\" > Mart\u00ednez-S\u00e1nchez  JM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=243#tppubs\" > Peric\u00e0s  JM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=603#tppubs\" >de Lucie  Jonge. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=99#tppubs\" >de Jonge L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=262#tppubs\" > V\u00e1zquez  JPF. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=420#tppubs\" > Quir\u00f3s  JR. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=534#tppubs\" > Torode  JS. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=108#tppubs\" > Canfell  K. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=563#tppubs\" > Chiam  K. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=217#tppubs\" > Elder  K. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=71#tppubs\" > Immonen  K. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=434#tppubs\" > Overvad  K. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=480#tppubs\" > Salas-Gama  K. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=351#tppubs\" > Straif  K. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=537#tppubs\" > Chan  KKW. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=167#tppubs\" > Alemany  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=317#tppubs\" > Arribas  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=179#tppubs\" > Benito  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=281#tppubs\" > Bustamante Lobos  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=437#tppubs\" > Cirera  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=247#tppubs\" > Clotet  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=4#tppubs\" > Comerma  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=168#tppubs\" > Costas  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=429#tppubs\" > Dartois  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=228#tppubs\" > Domingo  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=206#tppubs\" > Fern\u00e0ndez-L\u00f3pez  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=128#tppubs\" > Ferrer  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=413#tppubs\" > Lujan-Barroso  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=116#tppubs\" > Marques-Feixa  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=482#tppubs\" > Mart\u00ednez Garc\u00eda  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=469#tppubs\" > Neamtiu  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=72#tppubs\" > Ninov  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=14#tppubs\" > Pe\u00f1alva  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=190#tppubs\" > Perestelo-P\u00e9rez  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=143#tppubs\" > Rabeneck  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=200#tppubs\" > Rodr\u00edguez-Alonso  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=393#tppubs\" > Serrano  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=203#tppubs\" > Villegas  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=359#tppubs\" > Vilorio-Marqu\u00e9s  L. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=604#tppubs\" > Iris  Lansdorp-Vogelaar. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=522#tppubs\" > Force  LM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=471#tppubs\" > Jofra  LS. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=74#tppubs\" > Ballester  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=5#tppubs\" > Bar\u00e9  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=459#tppubs\" > Barenys  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=320#tppubs\" > Bellet  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=25#tppubs\" > Beranuy-Rodriguez  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=162#tppubs\" > Brotons  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=355#tppubs\" > Bustamante  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=371#tppubs\" > Caicoya  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=39#tppubs\" > Campos-Delgado  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=380#tppubs\" > Carles  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=88#tppubs\" > Carles-Lavila  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=496#tppubs\" > Caruana  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=47#tppubs\" > Catas\u00fas-Clav\u00e9  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=248#tppubs\" > Dan\u00e9s  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=495#tppubs\" > David  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=222#tppubs\" > Diaz  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=419#tppubs\" > Dorronsoro  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=58#tppubs\" > Ederra  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=579#tppubs\" > Ederra-Sanza  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=309#tppubs\" > Feijoo-Cid  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=369#tppubs\" > Fernandez  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=182#tppubs\" > Fu  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=280#tppubs\" > Fuentes Alburquenque  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=82#tppubs\" > Garcia  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=24#tppubs\" > Gil-Gil  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=514#tppubs\" > Gizaw  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=27#tppubs\" > Gomila-Sancho  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=385#tppubs\" > Gonz\u00e1lez-S\u00e1nchez  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=384#tppubs\" > Guerra-Balic  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=401#tppubs\" > Guevara  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=136#tppubs\" > Heijmans  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=49#tppubs\" > Hern\u00e1ndez-Garc\u00eda  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=430#tppubs\" > His  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=452#tppubs\" > J Gunter  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=37#tppubs\" > Jaraba-Armas  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=242#tppubs\" > Juli\u00e0  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=63#tppubs\" > Kogevinas  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=322#tppubs\" > Margel\u00ed  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=189#tppubs\" > Mart\u00ednez-Alonso  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=399#tppubs\" > Mendez  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=156#tppubs\" > Mero\u00f1o  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=548#tppubs\" > Montoro-Fernandez  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=509#tppubs\" > Mullooly  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=323#tppubs\" > Mu\u00f1oz  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=220#tppubs\" > Mutabi  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=231#tppubs\" > Ob\u00f3n-Santacana  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=32#tppubs\" > Ort\u00ed-Asencio  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=360#tppubs\" > Pla  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=62#tppubs\" > Poll\u00e1n  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=1#tppubs\" > Posso  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=193#tppubs\" > Prieto  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=368#tppubs\" > Puig  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=417#tppubs\" > Rodr\u00edguez-Barranco  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=8#tppubs\" > Rom\u00e1n  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=343#tppubs\" > Romero Garc\u00eda  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=478#tppubs\" > Roqu\u00e9 I Figuls  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=147#tppubs\" > Rue  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=15#tppubs\" > Sala  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=194#tppubs\" > S\u00e1nchez  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=505#tppubs\" > Santero  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=187#tppubs\" > Sattari  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=121#tppubs\" > Serra-Blasco  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=226#tppubs\" > Trapero-Bertran  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=541#tppubs\" > Van Hemelrijck  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=176#tppubs\" > Vanaclocha Esp\u00ed  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=51#tppubs\" > Vanaclocha-Espi  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=374#tppubs\" > Vernet  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=10#tppubs\" > Vernet-Tomas  M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=364#tppubs\" > Alba  MA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=342#tppubs\" > Martinez Momblan  MA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=424#tppubs\" > Merritt  MA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=508#tppubs\" > Tolani  MA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=431#tppubs\" > Boutron-Ruault  MC. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=363#tppubs\" > Gonz\u00e1lez-Galarzo  MC. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=618#tppubs\" > Bronwen R.  McCurdy. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=261#tppubs\" > Chirlaque  MD. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=331#tppubs\" > Del Pozo  MDP. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=40#tppubs\" > Fern\u00e1ndez-Montol\u00ed  ME. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=233#tppubs\" > Alonso  MH. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=493#tppubs\" > Allsop  MJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=83#tppubs\" > Hern\u00e1ndez-Leal  MJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=501#tppubs\" > Monroy Iglesias  MJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=565#tppubs\" > P\u00e9rez Lacasta  MJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=85#tppubs\" > P\u00e9rez-Lacasta  MJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=23#tppubs\" > Pla  MJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=373#tppubs\" > Quinta  MJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=7#tppubs\" > Quintana  MJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=416#tppubs\" > S\u00e1nchez  MJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=300#tppubs\" > Toribio  MJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=101#tppubs\" > Greuter  MJE. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=435#tppubs\" > Redondo  ML. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=607#tppubs\" > Dominika Novak  Mlakar. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=390#tppubs\" > Moreno  MP. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=264#tppubs\" > Serra  MS. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=367#tppubs\" > Lluch  MT. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=70#tppubs\" > Adrion  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=54#tppubs\" > Aragon\u00e9s  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=303#tppubs\" > Ascunce  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=249#tppubs\" > Borrell  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=274#tppubs\" > Casanovas-Aljaro  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=381#tppubs\" > Codern  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=84#tppubs\" > Codern-Bov\u00e9  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=240#tppubs\" > Font-Casaseca  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=350#tppubs\" > Guha  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=562#tppubs\" > Lasebikan  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=28#tppubs\" > Manent-Molina  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=270#tppubs\" > Matilla-Santander  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=123#tppubs\" > Meza  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=78#tppubs\" > Mil\u00e0  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=213#tppubs\" > Pashayan  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=132#tppubs\" > S\u00e1nchez  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=422#tppubs\" > Sawada  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=520#tppubs\" > Timilshina  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=115#tppubs\" > Travier  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=348#tppubs\" > Vilahur  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=76#tppubs\" > Vives  N. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=554#tppubs\" > Hanna  NM. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=540#tppubs\" > Ginsburg  O. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=485#tppubs\" > Groene  O. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=275#tppubs\" > Herrero  O. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=559#tppubs\" > Langselius  O. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=446#tppubs\" > Melander  O. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=291#tppubs\" > Ni\u00f1o  O. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=81#tppubs\" > Rial  O. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=52#tppubs\" > Zurriaga  \u00d3. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=337#tppubs\" > Ni\u00f1o-Mendez  OA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=245#tppubs\" >de Garcia  Olalla P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=75#tppubs\" > Alonso-Coello  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=55#tppubs\" > Amiano  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=497#tppubs\" > Coxeter  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=341#tppubs\" > Delgado-Hito  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=353#tppubs\" > Fern\u00e1ndez-Navarro  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=315#tppubs\" > Frazier  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=444#tppubs\" > Hm Peeters  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=440#tppubs\" > Lagiou  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=308#tppubs\" > Medina  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=305#tppubs\" > Moreo  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=165#tppubs\" > Peremiquel-Trillas  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=218#tppubs\" > Procopio  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=358#tppubs\" > Rodriguez-Cundin  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=551#tppubs\" > Romano-deGea  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=515#tppubs\" > Selvamuthu  P. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=423#tppubs\" > Wark  PA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=573#tppubs\" > Jon Aritz  Panera. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=199#tppubs\" >de la Pe\u00f1a-Negro LC. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=611#tppubs\" > Julie  Plaine. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=192#tppubs\" >grupo InforMa est\u00e1 formado El  por. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=606#tppubs\" > Isabel  Portillo. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=104#tppubs\" >van den Puttelaar R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=609#tppubs\" > C\u00e9cile  Quintin. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=2#tppubs\" > Alc\u00e1ntara  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=580#tppubs\" > Barrios-Rodr\u00edguez  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=595#tppubs\" > Benamouzig  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=589#tppubs\" > Ghodssighassemabadi  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=163#tppubs\" > Ib\u00e1\u00f1ez  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=433#tppubs\" > Kaaks  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=511#tppubs\" > Landy  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=333#tppubs\" > Llobet  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=9#tppubs\" > Marcos-Gragera  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=79#tppubs\" > Mu\u00f1oz  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=533#tppubs\" > Murillo  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=408#tppubs\" > Olmedo-Requena  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=314#tppubs\" > Palmer  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=455#tppubs\" > Peir\u00f3  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=173#tppubs\" > Peir\u00f3-P\u00e9rez  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=382#tppubs\" > Pla  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=46#tppubs\" > Planas-Balagu\u00e9  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=94#tppubs\" > Sanz-Pamplona  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=530#tppubs\" > Shah  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=527#tppubs\" > Singh  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=542#tppubs\" > Sullivan  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=66#tppubs\" > Su\u00f1ol  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=432#tppubs\" > Turzanski-Fortner  R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=386#tppubs\" > Cort\u00e9s Barrag\u00e1n  RA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=366#tppubs\" > Cort\u00e9s-Barrag\u00e1n  RA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=298#tppubs\" > Hubbard  RA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=528#tppubs\" > Salam  RA. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=619#tppubs\" > Linda  Rabeneck. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=219#tppubs\" >van Ravesteyn NT. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=558#tppubs\" > Acharya  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=388#tppubs\" > Casas  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=214#tppubs\" > Deandrea  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=318#tppubs\" > Del Barco  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=494#tppubs\" > Egger  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=345#tppubs\" > Fernandez-Veledo  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=597#tppubs\" > Hoeck  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=491#tppubs\" > Hughes  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=339#tppubs\" > Mart\u00ednez-Yelamos  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=549#tppubs\" > Moreno-Forn\u00e9s  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=159#tppubs\" > Paytubi  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=538#tppubs\" > Peacock  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=21#tppubs\" > Pernas  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=427#tppubs\" > Rinaldi  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=479#tppubs\" > Rosenbaum  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=18#tppubs\" > Salinas-Huertas  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=158#tppubs\" > Sanjos\u00e9  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=376#tppubs\" > Servitja  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=329#tppubs\" > Stoffel  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=425#tppubs\" > Tsugane  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=20#tppubs\" > V\u00e1zquez-Gallego  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=529#tppubs\" > Yuill  S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=410#tppubs\" >de Sanjos\u00e9 S. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=445#tppubs\" >van der T  Schouw Y. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=620#tppubs\" > Carlo  Senore. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=510#tppubs\" > Lee  SF. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=124#tppubs\" > Bangdiwala  SI. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=448#tppubs\" >da Silva M. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=512#tppubs\" > Hanley  SJB. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=612#tppubs\" > Ana Lucija  \u0160krjanec. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=252#tppubs\" > Dierssen-Sotos  T. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=254#tppubs\" > Fern\u00e1ndez-Villa  T. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=601#tppubs\" > Ferro  T. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=499#tppubs\" > Onyeka  T. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=207#tppubs\" > Platteau  T. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=582#tppubs\" >de la Molina  Torre AJ. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=421#tppubs\" >de la Torre R. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=539#tppubs\" > Hanna  TP. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=586#tppubs\" > Noemie  Travier. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=327#tppubs\" > Chaj\u00e8s  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=400#tppubs\" > D\u00e1vila-Batista  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=150#tppubs\" > Gonz\u00e1lez  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=80#tppubs\" > Guardiola  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=301#tppubs\" > Lope  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=59#tppubs\" > Mart\u00edn  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=578#tppubs\" > Mart\u00edn-S\u00e1nchez  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=93#tppubs\" > Moreno  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=443#tppubs\" > Pala  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=154#tppubs\" > Rodr\u00edguez  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=153#tppubs\" > Saludes  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=69#tppubs\" > Strammiello  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=279#tppubs\" > Stuardo \u00c1vila  V. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=570#tppubs\" > Carmen  Vidal. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=569#tppubs\" > Nuria  Vives. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=109#tppubs\" > Coup\u00e9  VMH. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=98#tppubs\" >van Wifferen F. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=13#tppubs\" > Bargall\u00f3  X. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=126#tppubs\" > Bonfill  X. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=16#tppubs\" > Castells  X. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=160#tppubs\" > Benavente  Y. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=547#tppubs\" > D\u00edaz  Y. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=278#tppubs\" > Valverde  Y. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=41#tppubs\" > Valverde-Alc\u00e1ntara  Y. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=524#tppubs\" > Wang  Y. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=464#tppubs\" > Saz-Parkinson  Z. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=169#tppubs\" > Sun  Z. <\/option><option value = \"tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=617#tppubs\" > Rebecca  Ziebell. <\/option>\r\n                <\/select><\/div><\/form><div class=\"tablenav\"><div class=\"tablenav-pages\"><span class=\"displaying-num\">98 entries<\/span> <a class=\"page-numbers button disabled\">&laquo;<\/a> <a class=\"page-numbers button disabled\">&lsaquo;<\/a> 1 of 2 <a href=\"https:\/\/icoprevencio.cat\/uc\/publicacions\/?limit=2&amp;tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=&amp;tsr=#tppubs\" title=\"next page\" class=\"page-numbers button\">&rsaquo;<\/a> <a href=\"https:\/\/icoprevencio.cat\/uc\/publicacions\/?limit=2&amp;tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=&amp;tsr=#tppubs\" title=\"last page\" class=\"page-numbers button\">&raquo;<\/a> <\/div><\/div><div class=\"teachpress_publication_list\"><h3 class=\"tp_h3\" id=\"tp_h3_2026\">2026<\/h3><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\">de Lucie  Jonge,  Iris  Lansdorp-Vogelaar,  V. Paul  Doria-Rose,  Isabel  Portillo,  Dominika Novak  Mlakar,  Andrea  Buron,  C\u00e9cile  Quintin,  Josep A.  Espin\u00e0s,  Julie  Plaine,  Ana Lucija  \u0160krjanec,  Tatjana Kofol  Bric,  Gemma  Binefa,  Rebeca  Font,  Jean-Luc  Bulliard,  Jessica  Chubak,  Rebecca  Ziebell,  Bronwen R.  McCurdy,  Linda  Rabeneck,  Carlo  Senore. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('102','tp_links')\" style=\"cursor:pointer;\">Global impact of COVID-19 on organized CRC screening programs: lessons learned<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Best Practice &amp; Research Clinical Gastroenterology. <\/span><span class=\"tp_pub_additional_year\">2026<\/span><span class=\"tp_pub_additional_volume\">;80<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_resource_link\"><a id=\"tp_links_sh_102\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('102','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_102\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('102','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_102\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{deJonge2026,<br \/>\r\ntitle = {Global impact of COVID-19 on organized CRC screening programs: lessons learned},<br \/>\r\nauthor = {Lucie de Jonge and Iris Lansdorp-Vogelaar and V. Paul Doria-Rose and Isabel Portillo and Dominika Novak Mlakar and Andrea Buron and C\u00e9cile Quintin and Josep A. Espin\u00e0s and Julie Plaine and Ana Lucija \u0160krjanec and Tatjana Kofol Bric and Gemma Binefa and Rebeca Font and Jean-Luc Bulliard and Jessica Chubak and Rebecca Ziebell and Bronwen R. McCurdy and Linda Rabeneck and Carlo Senore},<br \/>\r\ndoi = {10.1016\/j.bpg.2025.102047},<br \/>\r\nissn = {1521-6918},<br \/>\r\nyear  = {2026},<br \/>\r\ndate = {2026-02-00},<br \/>\r\njournal = {Best Practice & Research Clinical Gastroenterology},<br \/>\r\nvolume = {80},<br \/>\r\npublisher = {Elsevier BV},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('102','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_102\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.bpg.2025.102047\" title=\"Follow DOI:10.1016\/j.bpg.2025.102047\" target=\"_blank\">doi:10.1016\/j.bpg.2025.102047<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('102','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><h3 class=\"tp_h3\" id=\"tp_h3_2025\">2025<\/h3><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Rodriguez-Ortega  A,  Ferro  T,  Ochoa-Arnedo  C,  Campos  G,  Valverde  Y,  Medina  JC,  Borras  JM. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('101','tp_links')\" style=\"cursor:pointer;\">The Evaluation of a Nursing Care Model for Breast Cancer: What Are Women's Priorities?<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">J Nurs Manag. <\/span><span class=\"tp_pub_additional_year\">2025<\/span><span class=\"tp_pub_additional_volume\">;2025<\/span><span class=\"tp_pub_additional_pages\">:8653274<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_101\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('101','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_101\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('101','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_101\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('101','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_101\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid40322742,<br \/>\r\ntitle = {The Evaluation of a Nursing Care Model for Breast Cancer: What Are Women's Priorities?},<br \/>\r\nauthor = {Rodriguez-Ortega A and Ferro T and Ochoa-Arnedo C and Campos G and Valverde Y and Medina JC and Borras JM},<br \/>\r\ndoi = {10.1155\/jonm\/8653274},<br \/>\r\nissn = {1365-2834},<br \/>\r\nyear  = {2025},<br \/>\r\ndate = {2025-01-01},<br \/>\r\njournal = {J Nurs Manag},<br \/>\r\nvolume = {2025},<br \/>\r\npages = {8653274},<br \/>\r\nabstract = { To assess patient satisfaction with the breast care nurse (BCN) model and its adequacy in meeting patients' needs for information and support.  The BCN is a core multidisciplinary member of the breast cancer team. The evaluation of care models is necessary to detect gaps and improve the quality of care.  This cross-sectional descriptive study took place in a breast pathology unit and included patients with early breast cancer seen between 1 July 2016 and 30 June 2017 after finishing their treatment. Between July and December 2018, sociodemographic and clinical variables were collected from the clinical history, and satisfaction was measured using a questionnaire sent to the patients.  Of the 139 patients included, 99.3% reported that the BCN provided information correctly, 96.2% reported that she provided adequate information on self-care at home (96.2%), and 97.8% reported that the words of the BCN helped them feel better. However, some patients were unsure whether the BCN would have been willing to discuss alternative therapies (41%).  Patients were satisfied with the BCN, including her role in meeting information and support needs. However, some issues needed to be sufficiently addressed. Comprehensive, continuous assessment is required to understand patient needs. Training and specific studies on topics that are of interest to patients can help respond to these needs.  BCN functions are being developed in some countries. BCN results make it easier for healthcare managers to commit to this role and for nurses to develop all their competencies. BCN models must respond to international guidelines but are also determined by organizational resources. The evaluation of these models is essential and must be considered by users. Advanced practice nursing roles, including the BCN, are well established in some countries but developing in others. BCN results make it easier for healthcare managers to commit to this role and for nurses to develop all their skills. BCN models must respond to the elements determined by organizations that work to improve the quality of care for patients with breast cancer. However, they are also determined by organizational resources. The evaluation of these models is essential to correct deficiencies and improve the quality of care. An important part of the evaluation must take into account the user who receives the care, in terms of satisfaction and the form of patient-reported outcome measures (PROMs).},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('101','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_101\" style=\"display:none;\"><div class=\"tp_abstract_entry\"> To assess patient satisfaction with the breast care nurse (BCN) model and its adequacy in meeting patients' needs for information and support.  The BCN is a core multidisciplinary member of the breast cancer team. The evaluation of care models is necessary to detect gaps and improve the quality of care.  This cross-sectional descriptive study took place in a breast pathology unit and included patients with early breast cancer seen between 1 July 2016 and 30 June 2017 after finishing their treatment. Between July and December 2018, sociodemographic and clinical variables were collected from the clinical history, and satisfaction was measured using a questionnaire sent to the patients.  Of the 139 patients included, 99.3% reported that the BCN provided information correctly, 96.2% reported that she provided adequate information on self-care at home (96.2%), and 97.8% reported that the words of the BCN helped them feel better. However, some patients were unsure whether the BCN would have been willing to discuss alternative therapies (41%).  Patients were satisfied with the BCN, including her role in meeting information and support needs. However, some issues needed to be sufficiently addressed. Comprehensive, continuous assessment is required to understand patient needs. Training and specific studies on topics that are of interest to patients can help respond to these needs.  BCN functions are being developed in some countries. BCN results make it easier for healthcare managers to commit to this role and for nurses to develop all their competencies. BCN models must respond to international guidelines but are also determined by organizational resources. The evaluation of these models is essential and must be considered by users. Advanced practice nursing roles, including the BCN, are well established in some countries but developing in others. BCN results make it easier for healthcare managers to commit to this role and for nurses to develop all their skills. BCN models must respond to the elements determined by organizations that work to improve the quality of care for patients with breast cancer. However, they are also determined by organizational resources. The evaluation of these models is essential to correct deficiencies and improve the quality of care. An important part of the evaluation must take into account the user who receives the care, in terms of satisfaction and the form of patient-reported outcome measures (PROMs).<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('101','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_101\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1155\/jonm\/8653274\" title=\"Follow DOI:10.1155\/jonm\/8653274\" target=\"_blank\">doi:10.1155\/jonm\/8653274<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('101','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ko\u00efvogui  A,  Benamouzig  R,  Balamou  C,  Binefa  G,  Hoeck  S,  Novak-Mlakar  D,  Duclos  C. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('100','tp_links')\" style=\"cursor:pointer;\">Role of medico-administrative database in the selection of the target population in colorectal cancer screening program<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Therap Adv Gastroenterol. <\/span><span class=\"tp_pub_additional_year\">2025<\/span><span class=\"tp_pub_additional_volume\">;18<\/span><span class=\"tp_pub_additional_pages\">:17562848251342340<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_100\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('100','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_100\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('100','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_100\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('100','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_100\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid40520451,<br \/>\r\ntitle = {Role of medico-administrative database in the selection of the target population in colorectal cancer screening program},<br \/>\r\nauthor = {Ko\u00efvogui A and Benamouzig R and Balamou C and Binefa G and Hoeck S and Novak-Mlakar D and Duclos C},<br \/>\r\ndoi = {10.1177\/17562848251342340},<br \/>\r\nissn = {1756-283X},<br \/>\r\nyear  = {2025},<br \/>\r\ndate = {2025-01-01},<br \/>\r\njournal = {Therap Adv Gastroenterol},<br \/>\r\nvolume = {18},<br \/>\r\npages = {17562848251342340},<br \/>\r\nabstract = {BACKGROUND: Colorectal cancer (CRC) screening in average-risk populations requires filtering a target population based on medical information in population-based CRC screening programs (CRCSP). This study describes the level of consensus in medical exclusion practice and the role of the medico-administrative databases (MADB) in accurately targeting the eligible individuals for CRCSP screening campaigns.nnDESIGN: The descriptive study combined a cross-sectional survey and a non-systematic literature review.nnMETHODS: A cross-sectional survey was conducted among CRCSPs worldwide. Information was collected on the use of MADB for identifying consensus-based exclusion criteria (applied by >50% of CRCSPs). When a MADB was used, the study assessed whether the definition (code lists, medical terminologies) of the exclusion criteria was available. These definitions were compared between programs to evaluate the degree of consensus.nnRESULTS: In all, 20 out of the 31 CRCSPs (Australia, England, Manitoba, Ontario, Washington State, 26 European countries) participating in the survey implemented medical exclusions. Five consensus-based exclusion criteria were identified (personal history of CRC, inflammatory bowel disease, adenoma, recent colonoscopy, genetic risk). However, these criteria were not uniformly defined in MADBs (i.e., CRC phenotype includes ICD-10 codes C18-C21 in Catalonia, while the C21 code was excluded elsewhere). Furthermore, although the MADBs exist and contain relevant information, they remain inaccessible to screening management structures in some countries (e.g., in France).nnCONCLUSION: The number of consensus-based criteria was limited, and they were the least nuanced, likely because they are easier to collect using the current CRCSPs management resources. These consensual criteria can be queried in most MADBs. However, the use of MADBs was not standardized across programs for various reasons (absence of a database, unavailability of information in the database when it exists, inaccessibility of the database when it exists), limiting comparability between them. Standardizing the five consensus criteria across all programs would only be effective if the disparity caused by systemic failures in the organization of each program was controlled.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('100','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_100\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: Colorectal cancer (CRC) screening in average-risk populations requires filtering a target population based on medical information in population-based CRC screening programs (CRCSP). This study describes the level of consensus in medical exclusion practice and the role of the medico-administrative databases (MADB) in accurately targeting the eligible individuals for CRCSP screening campaigns.nnDESIGN: The descriptive study combined a cross-sectional survey and a non-systematic literature review.nnMETHODS: A cross-sectional survey was conducted among CRCSPs worldwide. Information was collected on the use of MADB for identifying consensus-based exclusion criteria (applied by >50% of CRCSPs). When a MADB was used, the study assessed whether the definition (code lists, medical terminologies) of the exclusion criteria was available. These definitions were compared between programs to evaluate the degree of consensus.nnRESULTS: In all, 20 out of the 31 CRCSPs (Australia, England, Manitoba, Ontario, Washington State, 26 European countries) participating in the survey implemented medical exclusions. Five consensus-based exclusion criteria were identified (personal history of CRC, inflammatory bowel disease, adenoma, recent colonoscopy, genetic risk). However, these criteria were not uniformly defined in MADBs (i.e., CRC phenotype includes ICD-10 codes C18-C21 in Catalonia, while the C21 code was excluded elsewhere). Furthermore, although the MADBs exist and contain relevant information, they remain inaccessible to screening management structures in some countries (e.g., in France).nnCONCLUSION: The number of consensus-based criteria was limited, and they were the least nuanced, likely because they are easier to collect using the current CRCSPs management resources. These consensual criteria can be queried in most MADBs. However, the use of MADBs was not standardized across programs for various reasons (absence of a database, unavailability of information in the database when it exists, inaccessibility of the database when it exists), limiting comparability between them. Standardizing the five consensus criteria across all programs would only be effective if the disparity caused by systemic failures in the organization of each program was controlled.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('100','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_100\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1177\/17562848251342340\" title=\"Follow DOI:10.1177\/17562848251342340\" target=\"_blank\">doi:10.1177\/17562848251342340<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('100','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Shah  R,  Hanna  NM,  Loo  CE,  David  M,  Mafra  A,  Fink  H,  McFerran  E,  Garcia  M,  Ghodssighassemabadi  R,  Acharya  S,  Niyibaga  J,  Langselius  O,  Frick  C,  Lasebikan  N,  Vignat  J,  Steinberg  J,  Hughes  S,  Kircher  CE,  Goldie  CL,  Egger  S,  Sullivan  R,  Ginsburg  O,  Bray  F,  Caruana  M,  Hui  H,  Ilbawi  AM,  Canfell  K,  Soerjomataram  I. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('99','tp_links')\" style=\"cursor:pointer;\">The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Nat Cancer. <\/span><span class=\"tp_pub_additional_year\">2025<\/span><span class=\"tp_pub_additional_volume\">;6<\/span><span class=\"tp_pub_additional_pages\">:194\u2013204<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_99\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('99','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_99\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('99','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_99\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('99','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_99\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid39747650,<br \/>\r\ntitle = {The global impact of the COVID-19 pandemic on delays and disruptions in cancer care services: a systematic review and meta-analysis},<br \/>\r\nauthor = {Shah R and Hanna NM and Loo CE and David M and Mafra A and Fink H and McFerran E and Garcia M and Ghodssighassemabadi R and Acharya S and Niyibaga J and Langselius O and Frick C and Lasebikan N and Vignat J and Steinberg J and Hughes S and Kircher CE and Goldie CL and Egger S and Sullivan R and Ginsburg O and Bray F and Caruana M and Hui H and Ilbawi AM and Canfell K and Soerjomataram I},<br \/>\r\ndoi = {10.1038\/s43018-024-00880-4},<br \/>\r\nissn = {2662-1347},<br \/>\r\nyear  = {2025},<br \/>\r\ndate = {2025-01-01},<br \/>\r\njournal = {Nat Cancer},<br \/>\r\nvolume = {6},<br \/>\r\nnumber = {1},<br \/>\r\npages = {194--204},<br \/>\r\nabstract = {The coronavirus disease 2019 pandemic substantially impacted the delivery of cancer services and programs. Here we reviewed and synthesized the global scale and impact of pandemic-related delays and disruptions on cancer services, including diagnosis, diagnostic procedures, screening, treatment and supportive and palliative care. Based on data from 245 articles in 46 countries, we observed declines in the number of cancer screening participation (39.0%), diagnoses (23.0%), diagnostic procedures (24.0%) and treatment (28.0%), ranging from a 15.0% decline for radiotherapy to a 35.0% decline for systemic treatment during the pandemic compared to during the prepandemic period. Medium-human development index (HDI) category countries experienced greater reductions than high- and very-high-HDI countries. Missing data from low-HDI countries emphasize the need for increased investments in cancer surveillance and research in these settings. PROSPERO registration: CRD42022301816.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('99','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_99\" style=\"display:none;\"><div class=\"tp_abstract_entry\">The coronavirus disease 2019 pandemic substantially impacted the delivery of cancer services and programs. Here we reviewed and synthesized the global scale and impact of pandemic-related delays and disruptions on cancer services, including diagnosis, diagnostic procedures, screening, treatment and supportive and palliative care. Based on data from 245 articles in 46 countries, we observed declines in the number of cancer screening participation (39.0%), diagnoses (23.0%), diagnostic procedures (24.0%) and treatment (28.0%), ranging from a 15.0% decline for radiotherapy to a 35.0% decline for systemic treatment during the pandemic compared to during the prepandemic period. Medium-human development index (HDI) category countries experienced greater reductions than high- and very-high-HDI countries. Missing data from low-HDI countries emphasize the need for increased investments in cancer surveillance and research in these settings. PROSPERO registration: CRD42022301816.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('99','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_99\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1038\/s43018-024-00880-4\" title=\"Follow DOI:10.1038\/s43018-024-00880-4\" target=\"_blank\">doi:10.1038\/s43018-024-00880-4<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('99','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Nuria  Vives,  Gemma  Binefa,  Noemie  Travier,  Albert  Farre,  Jon Aritz  Panera,  Berta  Casas,  Carmen  Vidal,  Gemma  Ib\u00e1\u00f1ez-Sanz,  Montse Garcia  and. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('98','tp_links')\" style=\"cursor:pointer;\">Text Messaging Versus Postal Reminders to Improve Participation in a Colorectal Cancer Screening Program: Randomized Controlled Trial<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">JMIR Mhealth Uhealth. <\/span><span class=\"tp_pub_additional_year\">2025<\/span><span class=\"tp_pub_additional_volume\">;13<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_98\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('98','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_98\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('98','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_98\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('98','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_98\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{Vives2025,<br \/>\r\ntitle = {Text Messaging Versus Postal Reminders to Improve Participation in a Colorectal Cancer Screening Program: Randomized Controlled Trial},<br \/>\r\nauthor = {Nuria Vives and Gemma Binefa and Noemie Travier and Albert Farre and Jon Aritz Panera and Berta Casas and Carmen Vidal and Gemma Ib\u00e1\u00f1ez-Sanz and Montse Garcia and },<br \/>\r\ndoi = {10.2196\/64243},<br \/>\r\nissn = {2291-5222},<br \/>\r\nyear  = {2025},<br \/>\r\ndate = {2025-01-01},<br \/>\r\njournal = {JMIR Mhealth Uhealth},<br \/>\r\nvolume = {13},<br \/>\r\npublisher = {JMIR Publications Inc.},<br \/>\r\nabstract = {<jats:sec><br \/>\n            <jats:title>Background<\/jats:title><br \/>\n            <jats:p>Mobile phone SMS text message reminders have shown moderate effects in improving participation rates in ongoing colorectal cancer screening programs.<\/jats:p><br \/>\n          <\/jats:sec><br \/>\n          <jats:sec><br \/>\n            <jats:title>Objective<\/jats:title><br \/>\n            <jats:p>This study aimed to assess the effectiveness of SMS text messages as a replacement for routine postal reminders in a fecal immunochemical test\u2013based colorectal cancer screening program in Catalonia, Spain.<\/jats:p><br \/>\n          <\/jats:sec><br \/>\n          <jats:sec><br \/>\n            <jats:title>Methods<\/jats:title><br \/>\n            <jats:p>We conducted a randomized controlled trial among individuals aged 50 to 69 years who were invited to screening but had not completed their fecal immunochemical test within 6 weeks. The intervention group (n=12,167) received an SMS text message reminder, while the control group (n=12,221) followed the standard procedure of receiving a reminder letter. The primary outcome was participation within 18 weeks of the invitation. The trial was stopped early, and a recovery strategy was implemented for nonparticipants in the intervention group. We performed a final analysis to evaluate the impact of the recovery strategy on the main outcome of the trial. Participation was assessed using a logistic regression model adjusting for potential confounders (sex, age, and deprivation score index) globally and by screening behavior.<\/jats:p><br \/>\n          <\/jats:sec><br \/>\n          <jats:sec><br \/>\n            <jats:title>Results<\/jats:title><br \/>\n            <jats:p>The trial was discontinued early in September 2022 due to the results of the interim analysis. The interim analysis included 5570 individuals who had completed 18 weeks of follow-up (intention-to-treat). The SMS text message group had a participation rate of 17.2% (477\/2781), whereas the control group had a participation rate of 21.9% (610\/2789; odds ratio 0.71, 95% CI 0.62-0.82; P<.001). As a recovery strategy, 7591 (72.7%) out of 10,442 nonparticipants in the SMS text message group had an open screening episode and received a second reminder by letter, reaching a participation rate of 23% (1748\/7591). The final analysis (N=24,388) showed a participation rate of 29.3% (3561\/12,167) in the intervention group, which received 2 reminders, while the participation rate was 26.5% (3235\/12,221) in the control group (odds ratio 1.16, 95% CI 1.09-1.23; P<.001).<\/jats:p><br \/>\n          <\/jats:sec><br \/>\n          <jats:sec><br \/>\n            <jats:title>Conclusions<\/jats:title><br \/>\n            <jats:p>Replacing SMS text messages with reminder letters did not increase the participation rate but also led to a decline in participation among nonparticipants 6 weeks after the invitation. However, sending a second reminder by letter significantly increased participation rates among nonparticipants within 6 weeks in the SMS text message group compared with those who received 1 postal reminder (control group). Additional research is essential to determine the best timing and frequency of reminders to boost participation without being intrusive in their choice of participation.<\/jats:p><br \/>\n          <\/jats:sec><br \/>\n          <jats:sec><br \/>\n            <jats:title>Trial Registration<\/jats:title><br \/>\n            <jats:p>ClinicalTrials.gov NCT04343950; https:\/\/www.clinicaltrials.gov\/study\/NCT04343950<\/jats:p><br \/>\n          <\/jats:sec>},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('98','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_98\" style=\"display:none;\"><div class=\"tp_abstract_entry\"><jats:sec><br \/>\n            <jats:title>Background<\/jats:title><br \/>\n            <jats:p>Mobile phone SMS text message reminders have shown moderate effects in improving participation rates in ongoing colorectal cancer screening programs.<\/jats:p><br \/>\n          <\/jats:sec><br \/>\n          <jats:sec><br \/>\n            <jats:title>Objective<\/jats:title><br \/>\n            <jats:p>This study aimed to assess the effectiveness of SMS text messages as a replacement for routine postal reminders in a fecal immunochemical test\u2013based colorectal cancer screening program in Catalonia, Spain.<\/jats:p><br \/>\n          <\/jats:sec><br \/>\n          <jats:sec><br \/>\n            <jats:title>Methods<\/jats:title><br \/>\n            <jats:p>We conducted a randomized controlled trial among individuals aged 50 to 69 years who were invited to screening but had not completed their fecal immunochemical test within 6 weeks. The intervention group (n=12,167) received an SMS text message reminder, while the control group (n=12,221) followed the standard procedure of receiving a reminder letter. The primary outcome was participation within 18 weeks of the invitation. The trial was stopped early, and a recovery strategy was implemented for nonparticipants in the intervention group. We performed a final analysis to evaluate the impact of the recovery strategy on the main outcome of the trial. Participation was assessed using a logistic regression model adjusting for potential confounders (sex, age, and deprivation score index) globally and by screening behavior.<\/jats:p><br \/>\n          <\/jats:sec><br \/>\n          <jats:sec><br \/>\n            <jats:title>Results<\/jats:title><br \/>\n            <jats:p>The trial was discontinued early in September 2022 due to the results of the interim analysis. The interim analysis included 5570 individuals who had completed 18 weeks of follow-up (intention-to-treat). The SMS text message group had a participation rate of 17.2% (477\/2781), whereas the control group had a participation rate of 21.9% (610\/2789; odds ratio 0.71, 95% CI 0.62-0.82; P&lt;.001). As a recovery strategy, 7591 (72.7%) out of 10,442 nonparticipants in the SMS text message group had an open screening episode and received a second reminder by letter, reaching a participation rate of 23% (1748\/7591). The final analysis (N=24,388) showed a participation rate of 29.3% (3561\/12,167) in the intervention group, which received 2 reminders, while the participation rate was 26.5% (3235\/12,221) in the control group (odds ratio 1.16, 95% CI 1.09-1.23; P&lt;.001).<\/jats:p><br \/>\n          <\/jats:sec><br \/>\n          <jats:sec><br \/>\n            <jats:title>Conclusions<\/jats:title><br \/>\n            <jats:p>Replacing SMS text messages with reminder letters did not increase the participation rate but also led to a decline in participation among nonparticipants 6 weeks after the invitation. However, sending a second reminder by letter significantly increased participation rates among nonparticipants within 6 weeks in the SMS text message group compared with those who received 1 postal reminder (control group). Additional research is essential to determine the best timing and frequency of reminders to boost participation without being intrusive in their choice of participation.<\/jats:p><br \/>\n          <\/jats:sec><br \/>\n          <jats:sec><br \/>\n            <jats:title>Trial Registration<\/jats:title><br \/>\n            <jats:p>ClinicalTrials.gov NCT04343950; https:\/\/www.clinicaltrials.gov\/study\/NCT04343950<\/jats:p><br \/>\n          <\/jats:sec><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('98','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_98\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.2196\/64243\" title=\"Follow DOI:10.2196\/64243\" target=\"_blank\">doi:10.2196\/64243<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('98','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><h3 class=\"tp_h3\" id=\"tp_h3_2024\">2024<\/h3><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Marcos-Delgado  A,  Mart\u00edn-S\u00e1nchez  V,  Molina-Barcel\u00f3  A,  Alonso-Molero  J,  P\u00e9rez-G\u00f3mez  B,  Poll\u00e1n  M,  Aragon\u00e9s  N,  Ederra-Sanza  M,  Fern\u00e1ndez-Tard\u00f3n  G,  Binefa  G,  Moreno  V,  Barrios-Rodr\u00edguez  R,  Amiano  P,  Huerta  JM,  Teso  EP,  Alguacil  J,  Casta\u00f1o-Vinyals  G,  Kogevinas  M, de la Molina  Torre AJ. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('96','tp_links')\" style=\"cursor:pointer;\">Health-Related Quality of Life in Long-Term Colorectal Cancer Survivors<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Healthcare (Basel). <\/span><span class=\"tp_pub_additional_year\">2024<\/span><span class=\"tp_pub_additional_volume\">;12<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_96\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('96','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_96\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('96','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_96\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('96','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_96\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid39408097,<br \/>\r\ntitle = {Health-Related Quality of Life in Long-Term Colorectal Cancer Survivors},<br \/>\r\nauthor = {Marcos-Delgado A and Mart\u00edn-S\u00e1nchez V and Molina-Barcel\u00f3 A and Alonso-Molero J and P\u00e9rez-G\u00f3mez B and Poll\u00e1n M and Aragon\u00e9s N and Ederra-Sanza M and Fern\u00e1ndez-Tard\u00f3n G and Binefa G and Moreno V and Barrios-Rodr\u00edguez R and Amiano P and Huerta JM and Teso EP and Alguacil J and Casta\u00f1o-Vinyals G and Kogevinas M and Molina de la Torre AJ},<br \/>\r\ndoi = {10.3390\/healthcare12191917},<br \/>\r\nissn = {2227-9032},<br \/>\r\nyear  = {2024},<br \/>\r\ndate = {2024-09-01},<br \/>\r\njournal = {Healthcare (Basel)},<br \/>\r\nvolume = {12},<br \/>\r\nnumber = {19},<br \/>\r\nabstract = {The aim of our study is to evaluate the relationship between sociodemographic and clinical characteristics of individuals with Colorectal Cancer (CRC), tumour-intrinsic characteristics and treatment received with health-related quality of life (HRQoL).nnMETHODS: Cross-sectional analysis of data from 805 survivors from the MCC study was conducted. HRQoL was assessed through a general and specific questionnaire, SF-12 and FCSI (Colorectal Symptom Index). Statistical analyses were performed with linear regression with adjustment for sociodemographic variables, stage at diagnosis and histological grade.nnRESULTS: Participants had survived a median of 7.9 years from diagnosis (IQR 7.1-8.5 years). Age at diagnosis, sex and area showed a clear association with HRQoL in both physical and mental dimensions of the SF-12 questionnaire. A direct association between CRC recurrence was also found in the PCS-12 and MCS-12 dimensions and radical surgery in the PCS-12. Regarding the scores in FCSI questionnaire, statistically significant differences were observed by sex, age and area, with older women being the most impaired ( < 0.001).nnCONCLUSIONS: Age, sex and area was associated with lower scores of HRQoL among CRC survivors. Knowing the determinants related to HRQoL would allow us to lay the groundwork to develop strategies that help reduce morbidity and mortality, relapses and increase HRQoL.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('96','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_96\" style=\"display:none;\"><div class=\"tp_abstract_entry\">The aim of our study is to evaluate the relationship between sociodemographic and clinical characteristics of individuals with Colorectal Cancer (CRC), tumour-intrinsic characteristics and treatment received with health-related quality of life (HRQoL).nnMETHODS: Cross-sectional analysis of data from 805 survivors from the MCC study was conducted. HRQoL was assessed through a general and specific questionnaire, SF-12 and FCSI (Colorectal Symptom Index). Statistical analyses were performed with linear regression with adjustment for sociodemographic variables, stage at diagnosis and histological grade.nnRESULTS: Participants had survived a median of 7.9 years from diagnosis (IQR 7.1-8.5 years). Age at diagnosis, sex and area showed a clear association with HRQoL in both physical and mental dimensions of the SF-12 questionnaire. A direct association between CRC recurrence was also found in the PCS-12 and MCS-12 dimensions and radical surgery in the PCS-12. Regarding the scores in FCSI questionnaire, statistically significant differences were observed by sex, age and area, with older women being the most impaired ( < 0.001).nnCONCLUSIONS: Age, sex and area was associated with lower scores of HRQoL among CRC survivors. Knowing the determinants related to HRQoL would allow us to lay the groundwork to develop strategies that help reduce morbidity and mortality, relapses and increase HRQoL.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('96','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_96\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.3390\/healthcare12191917\" title=\"Follow DOI:10.3390\/healthcare12191917\" target=\"_blank\">doi:10.3390\/healthcare12191917<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('96','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Nuria  Vives,  Carmen  Vidal, de Ena Ni\u00f1o  Guzman,  Albert  Farre,  Jon Aritz  Panera,  Gemma  Binefa,  Montse Garcia  and. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('95','tp_links')\" style=\"cursor:pointer;\">The use of text messages as an alternative invitation method for breast cancer screening: A randomized controlled trial (M-TICS study)<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">PLoS ONE. <\/span><span class=\"tp_pub_additional_year\">2024<\/span><span class=\"tp_pub_additional_volume\">;19<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_95\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('95','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_95\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('95','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_95\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('95','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_95\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{Vives2024,<br \/>\r\ntitle = {The use of text messages as an alternative invitation method for breast cancer screening: A randomized controlled trial (M-TICS study)},<br \/>\r\nauthor = {Nuria Vives and Carmen Vidal and Ena Ni\u00f1o de Guzman and Albert Farre and Jon Aritz Panera and Gemma Binefa and Montse Garcia and },<br \/>\r\neditor = {Daniele Ugo Tari},<br \/>\r\ndoi = {10.1371\/journal.pone.0306720},<br \/>\r\nissn = {1932-6203},<br \/>\r\nyear  = {2024},<br \/>\r\ndate = {2024-08-29},<br \/>\r\njournal = {PLoS ONE},<br \/>\r\nvolume = {19},<br \/>\r\nnumber = {8},<br \/>\r\npublisher = {Public Library of Science (PLoS)},<br \/>\r\nabstract = {<jats:p>This study aimed to determine whether a text message is as good as a postal letter as an invitation method for previous screenees in a breast cancer screening program, considering a non-inferiority margin of -2 percent points on participation rate. A non-inferiority randomized control trial was conducted. Women in the intervention group (n = 5,362) were invited by text message, and women in the control group (n = 5,482) were invited by letter, which is the standard invitation procedure of the program. In both groups, the invitation included a fixed appointment for mammography and a text message reminder 96 hours before the appointment. The primary outcome was screening participation rate (completing mammography within 12 weeks of invitation). Secondary outcomes included mammography attendance to initial or rescheduled appointments and cancellation rate. The intention-to-treat analysis showed a participation rate of 87.3% and 86.6% in the control and intervention groups, respectively. The difference in participation rate was -0.7 percentage points (95% confidence interval [CI], -1.8 to \u221e), indicating non-inferiority of text messages compared to letter invitations. The per-protocol analysis showed similar results. Attendance at the initial appointment was higher in women who received the text message invitation compared to those in the control group (P<0.002). Women who received the invitation by letter canceled more the initial appointment scheduled compared to the text message group (21.1% and 15.1%, P<0.007). In conclusion, we found that a text message invitation for women who had previously participated in breast cancer screening was not inferior to the standard letter. This randomized controlled trial provides valuable insights into the use of alternative invitation methods for population-based cancer screening programs. However, further research is needed to determine the best timing and frequency of text messages for better outcomes and identify strategies for facilitating rescheduling or cancellation.<\/jats:p><br \/>\n<jats:p><jats:bold>Trial Registration<\/jats:bold>: Clinicaltrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04343950\" xlink:type=\"simple\">NCT04343950<\/jats:ext-link>, (04\/09\/2020).<\/jats:p>},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('95','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_95\" style=\"display:none;\"><div class=\"tp_abstract_entry\"><jats:p>This study aimed to determine whether a text message is as good as a postal letter as an invitation method for previous screenees in a breast cancer screening program, considering a non-inferiority margin of -2 percent points on participation rate. A non-inferiority randomized control trial was conducted. Women in the intervention group (n = 5,362) were invited by text message, and women in the control group (n = 5,482) were invited by letter, which is the standard invitation procedure of the program. In both groups, the invitation included a fixed appointment for mammography and a text message reminder 96 hours before the appointment. The primary outcome was screening participation rate (completing mammography within 12 weeks of invitation). Secondary outcomes included mammography attendance to initial or rescheduled appointments and cancellation rate. The intention-to-treat analysis showed a participation rate of 87.3% and 86.6% in the control and intervention groups, respectively. The difference in participation rate was -0.7 percentage points (95% confidence interval [CI], -1.8 to \u221e), indicating non-inferiority of text messages compared to letter invitations. The per-protocol analysis showed similar results. Attendance at the initial appointment was higher in women who received the text message invitation compared to those in the control group (P&lt;0.002). Women who received the invitation by letter canceled more the initial appointment scheduled compared to the text message group (21.1% and 15.1%, P&lt;0.007). In conclusion, we found that a text message invitation for women who had previously participated in breast cancer screening was not inferior to the standard letter. This randomized controlled trial provides valuable insights into the use of alternative invitation methods for population-based cancer screening programs. However, further research is needed to determine the best timing and frequency of text messages for better outcomes and identify strategies for facilitating rescheduling or cancellation.<\/jats:p><br \/>\n<jats:p><jats:bold>Trial Registration<\/jats:bold>: Clinicaltrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04343950\" xlink:type=\"simple\">NCT04343950<\/jats:ext-link>, (04\/09\/2020).<\/jats:p><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('95','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_95\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1371\/journal.pone.0306720\" title=\"Follow DOI:10.1371\/journal.pone.0306720\" target=\"_blank\">doi:10.1371\/journal.pone.0306720<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('95','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Vives  N,  Travier  N,  Farre  A,  Binefa  G,  Vidal  C,  P\u00e9rez Lacasta  MJ,  Ib\u00e1\u00f1ez-Sanz  G, de Ni\u00f1o  Guzm\u00e1n EP,  Panera  JA,  Garcia  M,  M-TICS Research  Group. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('94','tp_links')\" style=\"cursor:pointer;\">Effectiveness and Acceptability of Targeted Text Message Reminders in Colorectal Cancer Screening: Randomized Controlled Trial (M-TICS Study)<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">JMIR Public Health Surveill. <\/span><span class=\"tp_pub_additional_year\">2024<\/span><span class=\"tp_pub_additional_volume\">;10<\/span><span class=\"tp_pub_additional_pages\">:e57959<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_94\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('94','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_94\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('94','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_94\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('94','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_94\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid39083331,<br \/>\r\ntitle = {Effectiveness and Acceptability of Targeted Text Message Reminders in Colorectal Cancer Screening: Randomized Controlled Trial (M-TICS Study)},<br \/>\r\nauthor = {Vives N and Travier N and Farre A and Binefa G and Vidal C and P\u00e9rez Lacasta MJ and Ib\u00e1\u00f1ez-Sanz G and Ni\u00f1o de Guzm\u00e1n EP and Panera JA and Garcia M and M-TICS Research Group},<br \/>\r\ndoi = {10.2196\/57959},<br \/>\r\nissn = {2369-2960},<br \/>\r\nyear  = {2024},<br \/>\r\ndate = {2024-07-01},<br \/>\r\njournal = {JMIR Public Health Surveill},<br \/>\r\nvolume = {10},<br \/>\r\npages = {e57959},<br \/>\r\nabstract = {BACKGROUND: Mobile phone-based SMS text message reminders have the potential to improve colorectal cancer screening participation rates.nnOBJECTIVE: This study assessed the effectiveness and acceptability of adding targeted SMS text message reminders to the standard procedure for those who picked up but did not return their screening kit at the pharmacy within 14 days in a colorectal cancer screening program in Catalonia, Spain.nnMETHODS: We performed a randomized control trial among individuals who picked up a fecal immunochemical test (FIT) kit for colorectal cancer screening at the pharmacy but did not return it within 14 days. The intervention group (n=4563) received an SMS text message reminder on the 14th day of kit pick up and the control group (n=4806) received no reminder. A 30-day reminder letter was sent to both groups if necessary. The main primary outcome was the FIT completion rate within 30, 60, and 126 days from FIT kit pick up (intention-to-treat analysis). A telephone survey assessed the acceptability and appropriateness of the intervention. The cost-effectiveness of adding an SMS text message reminder to FIT completion was also performed.nnRESULTS: The intervention group had higher FIT completion rates than the control group at 30 (64.2% vs 53.7%; P<.001), 60 (78.6% vs 72.0%; P<.001), and 126 (82.6% vs 77.7%; P<.001) days. Participation rates were higher in the intervention arm independent of sex, age, socioeconomic level, and previous screening behavior. A total of 339 (89.2%) interviewees considered it important and useful to receive SMS text message reminders for FIT completion and 355 (93.4%) preferred SMS text messages to postal letters. We observed a reduction of US $2.4 per participant gained in the intervention arm for invitation costs compared to the control arm.nnCONCLUSIONS: Adding an SMS text message reminder to the standard procedure significantly increased FIT kit return rates and was a cost-effective strategy. SMS text messages also proved to be an acceptable and appropriate communication channel for cancer screening programs.nnTRIAL REGISTRATION: ClinicalTrials.gov NCT04343950; https:\/\/www.clinicaltrials.gov\/study\/NCT04343950.nnINTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.1371\/journal.pone.0245806.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('94','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_94\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: Mobile phone-based SMS text message reminders have the potential to improve colorectal cancer screening participation rates.nnOBJECTIVE: This study assessed the effectiveness and acceptability of adding targeted SMS text message reminders to the standard procedure for those who picked up but did not return their screening kit at the pharmacy within 14 days in a colorectal cancer screening program in Catalonia, Spain.nnMETHODS: We performed a randomized control trial among individuals who picked up a fecal immunochemical test (FIT) kit for colorectal cancer screening at the pharmacy but did not return it within 14 days. The intervention group (n=4563) received an SMS text message reminder on the 14th day of kit pick up and the control group (n=4806) received no reminder. A 30-day reminder letter was sent to both groups if necessary. The main primary outcome was the FIT completion rate within 30, 60, and 126 days from FIT kit pick up (intention-to-treat analysis). A telephone survey assessed the acceptability and appropriateness of the intervention. The cost-effectiveness of adding an SMS text message reminder to FIT completion was also performed.nnRESULTS: The intervention group had higher FIT completion rates than the control group at 30 (64.2% vs 53.7%; P<.001), 60 (78.6% vs 72.0%; P<.001), and 126 (82.6% vs 77.7%; P<.001) days. Participation rates were higher in the intervention arm independent of sex, age, socioeconomic level, and previous screening behavior. A total of 339 (89.2%) interviewees considered it important and useful to receive SMS text message reminders for FIT completion and 355 (93.4%) preferred SMS text messages to postal letters. We observed a reduction of US $2.4 per participant gained in the intervention arm for invitation costs compared to the control arm.nnCONCLUSIONS: Adding an SMS text message reminder to the standard procedure significantly increased FIT kit return rates and was a cost-effective strategy. SMS text messages also proved to be an acceptable and appropriate communication channel for cancer screening programs.nnTRIAL REGISTRATION: ClinicalTrials.gov NCT04343950; https:\/\/www.clinicaltrials.gov\/study\/NCT04343950.nnINTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.1371\/journal.pone.0245806.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('94','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_94\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.2196\/57959\" title=\"Follow DOI:10.2196\/57959\" target=\"_blank\">doi:10.2196\/57959<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('94','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Shah  R,  Loo  CE,  Hanna  NM,  Hughes  S,  Mafra  A,  Fink  H,  McFerran  E,  Garcia  M,  Acharya  S,  Langselius  O,  Frick  C,  Niyigaba  J,  Lasebikan  N,  Steinberg  J,  Sullivan  R,  Bray  F,  Ilbawi  AM,  Ginsburg  O,  Chiam  K,  Cylus  J,  Caruana  M,  David  M,  Hui  H,  Canfell  K,  Soerjomataram  I. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('93','tp_links')\" style=\"cursor:pointer;\">Global review of COVID-19 mitigation strategies and their impact on cancer service disruptions<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">J Cancer Policy. <\/span><span class=\"tp_pub_additional_year\">2024<\/span><span class=\"tp_pub_additional_volume\">;41<\/span><span class=\"tp_pub_additional_pages\">:100486<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_93\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('93','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_93\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('93','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_93\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('93','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_93\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid38830535,<br \/>\r\ntitle = {Global review of COVID-19 mitigation strategies and their impact on cancer service disruptions},<br \/>\r\nauthor = {Shah R and Loo CE and Hanna NM and Hughes S and Mafra A and Fink H and McFerran E and Garcia M and Acharya S and Langselius O and Frick C and Niyigaba J and Lasebikan N and Steinberg J and Sullivan R and Bray F and Ilbawi AM and Ginsburg O and Chiam K and Cylus J and Caruana M and David M and Hui H and Canfell K and Soerjomataram I},<br \/>\r\ndoi = {10.1016\/j.jcpo.2024.100486},<br \/>\r\nissn = {2213-5383},<br \/>\r\nyear  = {2024},<br \/>\r\ndate = {2024-06-01},<br \/>\r\njournal = {J Cancer Policy},<br \/>\r\nvolume = {41},<br \/>\r\npages = {100486},<br \/>\r\nabstract = {During the COVID-19 pandemic, countries adopted mitigation strategies to reduce disruptions to cancer services. We reviewed their implementation across health system functions and their impact on cancer diagnosis and care during the pandemic. A systematic search was performed using terms related to cancer and COVID-19. Included studies reported on individuals with cancer or cancer care services, focusing on strategies\/programs aimed to reduce delays and disruptions. Extracted data were grouped into four functions (governance, financing, service delivery, and resource generation) and sub-functions of the health system performance assessment framework. We included 30 studies from 16 countries involving 192,233 patients with cancer. Multiple mitigation approaches were implemented, predominantly affecting sub-functions of service delivery to control COVID-19 infection via the suspension of non-urgent cancer care, modified treatment guidelines, and increased telemedicine use in routine cancer care delivery. Resource generation was mainly ensured through adequate workforce supply. However, less emphasis on monitoring or assessing the effectiveness and financing of these strategies was observed. Seventeen studies suggested improved service uptake after mitigation implementation, yet the resulting impact on cancer diagnosis and care has not been established. This review emphasizes the importance of developing effective mitigation strategies across all health system (sub)functions to minimize cancer care service disruptions during crises. Deficiencies were observed in health service delivery (to ensure equity), governance (to monitor and evaluate the implementation of mitigation strategies), and financing. In the wake of future emergencies, implementation research studies that include pre-prepared protocols will be essential to assess mitigation impact across cancer care services.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('93','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_93\" style=\"display:none;\"><div class=\"tp_abstract_entry\">During the COVID-19 pandemic, countries adopted mitigation strategies to reduce disruptions to cancer services. We reviewed their implementation across health system functions and their impact on cancer diagnosis and care during the pandemic. A systematic search was performed using terms related to cancer and COVID-19. Included studies reported on individuals with cancer or cancer care services, focusing on strategies\/programs aimed to reduce delays and disruptions. Extracted data were grouped into four functions (governance, financing, service delivery, and resource generation) and sub-functions of the health system performance assessment framework. We included 30 studies from 16 countries involving 192,233 patients with cancer. Multiple mitigation approaches were implemented, predominantly affecting sub-functions of service delivery to control COVID-19 infection via the suspension of non-urgent cancer care, modified treatment guidelines, and increased telemedicine use in routine cancer care delivery. Resource generation was mainly ensured through adequate workforce supply. However, less emphasis on monitoring or assessing the effectiveness and financing of these strategies was observed. Seventeen studies suggested improved service uptake after mitigation implementation, yet the resulting impact on cancer diagnosis and care has not been established. This review emphasizes the importance of developing effective mitigation strategies across all health system (sub)functions to minimize cancer care service disruptions during crises. Deficiencies were observed in health service delivery (to ensure equity), governance (to monitor and evaluate the implementation of mitigation strategies), and financing. In the wake of future emergencies, implementation research studies that include pre-prepared protocols will be essential to assess mitigation impact across cancer care services.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('93','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_93\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.jcpo.2024.100486\" title=\"Follow DOI:10.1016\/j.jcpo.2024.100486\" target=\"_blank\">doi:10.1016\/j.jcpo.2024.100486<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('93','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Mart\u00ednez-Riveros  H,  D\u00edaz  Y,  Montoro-Fernandez  M,  Moreno-Forn\u00e9s  S,  Gonz\u00e1lez  V,  Muntada  E,  Romano-deGea  P,  Mu\u00f1oz  R,  Hoyos  J,  Casabona  J,  Agust\u00ed  C. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('91','tp_links')\" style=\"cursor:pointer;\">An Online HIV Self-Sampling Strategy for Gay, Bisexual and Other Men Who Have Sex with Men and Trans Women in Spain<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">J Community Health. <\/span><span class=\"tp_pub_additional_year\">2024<\/span><span class=\"tp_pub_additional_volume\">;49<\/span><span class=\"tp_pub_additional_pages\">:535\u2013548<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_91\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('91','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_91\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('91','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_91\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('91','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_91\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid38141149b,<br \/>\r\ntitle = {An Online HIV Self-Sampling Strategy for Gay, Bisexual and Other Men Who Have Sex with Men and Trans Women in Spain},<br \/>\r\nauthor = {Mart\u00ednez-Riveros H and D\u00edaz Y and Montoro-Fernandez M and Moreno-Forn\u00e9s S and Gonz\u00e1lez V and Muntada E and Romano-deGea P and Mu\u00f1oz R and Hoyos J and Casabona J and Agust\u00ed C},<br \/>\r\ndoi = {10.1007\/s10900-023-01311-8},<br \/>\r\nissn = {1573-3610},<br \/>\r\nyear  = {2024},<br \/>\r\ndate = {2024-06-01},<br \/>\r\njournal = {J Community Health},<br \/>\r\nvolume = {49},<br \/>\r\nnumber = {3},<br \/>\r\npages = {535--548},<br \/>\r\nabstract = {We aimed to evaluate the feasibility of an online self-sampling pilot intervention for HIV testing addressed to gay, bisexual, and other men who have sex with men (GBMSM) and trans women (TW) users of dating apps in Spain. The website https:\/\/www.testate.org\/ was designed to offer self-sampling kits for HIV testing and online consultation of the results. It was advertised on gay dating apps. Participants requested the delivery of a saliva self-sampling kit by mail and a postage-paid envelope to send the sample to the reference laboratory. An anonymous acceptability survey was conducted. The cascade of care was estimated. From November 2018 to December 2021, 4623 individual users ordered self-sampling kits, 3097 returned an oral fluid sample to the reference laboratory (67.5% return rate). 87 reactive results were detected. 76 were confirmed to be HIV-positive, we estimated an HIV prevalence of 2.45% (95% CI 1.9-3.0%). 100% of those referred to specialized care are in treatment. 45.8% of participants took more than one test. 23 incident cases were detected among repeat testers, of which 20 were confirmed. The estimated incidence was 1.00 confirmed case per 100 individual-years of follow-up. 98.01% of participants would recommend it to a friend. The most identified advantages were convenience and privacy. We demonstrated that the online offer of oral self-sampling kits for HIV detection and reporting results online among GBMSM and TW users of dating apps is feasible. The intervention counted with a high acceptability and high efficacy (in terms of reactivity, confirmation and linkage to care rates).},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('91','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_91\" style=\"display:none;\"><div class=\"tp_abstract_entry\">We aimed to evaluate the feasibility of an online self-sampling pilot intervention for HIV testing addressed to gay, bisexual, and other men who have sex with men (GBMSM) and trans women (TW) users of dating apps in Spain. The website https:\/\/www.testate.org\/ was designed to offer self-sampling kits for HIV testing and online consultation of the results. It was advertised on gay dating apps. Participants requested the delivery of a saliva self-sampling kit by mail and a postage-paid envelope to send the sample to the reference laboratory. An anonymous acceptability survey was conducted. The cascade of care was estimated. From November 2018 to December 2021, 4623 individual users ordered self-sampling kits, 3097 returned an oral fluid sample to the reference laboratory (67.5% return rate). 87 reactive results were detected. 76 were confirmed to be HIV-positive, we estimated an HIV prevalence of 2.45% (95% CI 1.9-3.0%). 100% of those referred to specialized care are in treatment. 45.8% of participants took more than one test. 23 incident cases were detected among repeat testers, of which 20 were confirmed. The estimated incidence was 1.00 confirmed case per 100 individual-years of follow-up. 98.01% of participants would recommend it to a friend. The most identified advantages were convenience and privacy. We demonstrated that the online offer of oral self-sampling kits for HIV detection and reporting results online among GBMSM and TW users of dating apps is feasible. The intervention counted with a high acceptability and high efficacy (in terms of reactivity, confirmation and linkage to care rates).<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('91','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_91\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1007\/s10900-023-01311-8\" title=\"Follow DOI:10.1007\/s10900-023-01311-8\" target=\"_blank\">doi:10.1007\/s10900-023-01311-8<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('91','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Steinberg  J,  Hughes  S,  Hui  H,  Allsop  MJ,  Egger  S,  David  M,  Caruana  M,  Coxeter  P,  Carle  C,  Onyeka  T,  Rewais  I,  Monroy Iglesias  MJ,  Vives  N,  Wei  F,  Abila  DB,  Carreras  G,  Santero  M,  O'Dowd  EL,  Lui  G,  Tolani  MA,  Mullooly  M,  Lee  SF,  Landy  R,  Hanley  SJB,  Binefa  G,  McShane  CM,  Gizaw  M,  Selvamuthu  P,  Boukheris  H,  Nakaganda  A,  Ergin  I,  Moraes  FY,  Timilshina  N,  Kumar  A,  Vale  DB,  Molina-Barcel\u00f3  A,  Force  LM,  Campbell  DJ,  Wang  Y,  Wan  F,  Baker  AL,  Singh  R,  Salam  RA,  Yuill  S,  Shah  R,  Lansdorp-Vogelaar  I,  Yusuf  A,  Aggarwal  A,  Murillo  R,  Torode  JS,  Kliewer  EV,  Bray  F,  Chan  KKW,  Peacock  S,  Hanna  TP,  Ginsburg  O,  Van Hemelrijck  M,  Sullivan  R,  Roitberg  F,  Ilbawi  AM,  Soerjomataram  I,  Canfell  K. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('92','tp_links')\" style=\"cursor:pointer;\">Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Int J Cancer. <\/span><span class=\"tp_pub_additional_year\">2024<\/span><span class=\"tp_pub_additional_volume\">;154<\/span><span class=\"tp_pub_additional_pages\">:1394\u20131412<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_92\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('92','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_92\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('92','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_92\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('92','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_92\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid38083979b,<br \/>\r\ntitle = {Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis},<br \/>\r\nauthor = {Steinberg J and Hughes S and Hui H and Allsop MJ and Egger S and David M and Caruana M and Coxeter P and Carle C and Onyeka T and Rewais I and Monroy Iglesias MJ and Vives N and Wei F and Abila DB and Carreras G and Santero M and O'Dowd EL and Lui G and Tolani MA and Mullooly M and Lee SF and Landy R and Hanley SJB and Binefa G and McShane CM and Gizaw M and Selvamuthu P and Boukheris H and Nakaganda A and Ergin I and Moraes FY and Timilshina N and Kumar A and Vale DB and Molina-Barcel\u00f3 A and Force LM and Campbell DJ and Wang Y and Wan F and Baker AL and Singh R and Salam RA and Yuill S and Shah R and Lansdorp-Vogelaar I and Yusuf A and Aggarwal A and Murillo R and Torode JS and Kliewer EV and Bray F and Chan KKW and Peacock S and Hanna TP and Ginsburg O and Van Hemelrijck M and Sullivan R and Roitberg F and Ilbawi AM and Soerjomataram I and Canfell K},<br \/>\r\ndoi = {10.1002\/ijc.34798},<br \/>\r\nissn = {1097-0215},<br \/>\r\nyear  = {2024},<br \/>\r\ndate = {2024-04-01},<br \/>\r\njournal = {Int J Cancer},<br \/>\r\nvolume = {154},<br \/>\r\nnumber = {8},<br \/>\r\npages = {1394--1412},<br \/>\r\nabstract = {While previous reviews found a positive association between pre-existing cancer diagnosis and COVID-19-related death, most early studies did not distinguish long-term cancer survivors from those recently diagnosed\/treated, nor adjust for important confounders including age. We aimed to consolidate higher-quality evidence on risk of COVID-19-related death for people with recent\/active cancer (compared to people without) in the pre-COVID-19-vaccination period. We searched the WHO COVID-19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk-of-bias assessment was based on the Newcastle-Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse-variance random-effects models. Random-effects meta-regressions were used to assess associations between effect estimates and time since cancer diagnosis\/treatment. Of 23\u2009773 unique title\/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID-19-related death was higher for people with active or recently diagnosed\/treated cancer (general population: aOR\u2009=\u20091.48, 95% CI: 1.36-1.61, I \u2009=\u20090; people with COVID-19: aOR\u2009=\u20091.58, 95% CI: 1.41-1.77, I \u2009=\u20090.58; inpatients with COVID-19: aOR\u2009=\u20091.66, 95% CI: 1.34-2.06, I \u2009=\u20090.98). Risks were more elevated for lung (general population: aOR\u2009=\u20093.4, 95% CI: 2.4-4.7) and hematological cancers (general population: aOR\u2009=\u20092.13, 95% CI: 1.68-2.68, I \u2009=\u20090.43), and for metastatic cancers. Meta-regression suggested risk of COVID-19-related death decreased with time since diagnosis\/treatment, for example, for any\/solid cancers, fitted aOR\u2009=\u20091.55 (95% CI: 1.37-1.75) at 1\u2009year and aOR\u2009=\u20090.98 (95% CI: 0.80-1.20) at 5\u2009years post-cancer diagnosis\/treatment. In conclusion, before COVID-19-vaccination, risk of COVID-19-related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis\/treatment.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('92','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_92\" style=\"display:none;\"><div class=\"tp_abstract_entry\">While previous reviews found a positive association between pre-existing cancer diagnosis and COVID-19-related death, most early studies did not distinguish long-term cancer survivors from those recently diagnosed\/treated, nor adjust for important confounders including age. We aimed to consolidate higher-quality evidence on risk of COVID-19-related death for people with recent\/active cancer (compared to people without) in the pre-COVID-19-vaccination period. We searched the WHO COVID-19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk-of-bias assessment was based on the Newcastle-Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse-variance random-effects models. Random-effects meta-regressions were used to assess associations between effect estimates and time since cancer diagnosis\/treatment. Of 23\u2009773 unique title\/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID-19-related death was higher for people with active or recently diagnosed\/treated cancer (general population: aOR\u2009=\u20091.48, 95% CI: 1.36-1.61, I \u2009=\u20090; people with COVID-19: aOR\u2009=\u20091.58, 95% CI: 1.41-1.77, I \u2009=\u20090.58; inpatients with COVID-19: aOR\u2009=\u20091.66, 95% CI: 1.34-2.06, I \u2009=\u20090.98). Risks were more elevated for lung (general population: aOR\u2009=\u20093.4, 95% CI: 2.4-4.7) and hematological cancers (general population: aOR\u2009=\u20092.13, 95% CI: 1.68-2.68, I \u2009=\u20090.43), and for metastatic cancers. Meta-regression suggested risk of COVID-19-related death decreased with time since diagnosis\/treatment, for example, for any\/solid cancers, fitted aOR\u2009=\u20091.55 (95% CI: 1.37-1.75) at 1\u2009year and aOR\u2009=\u20090.98 (95% CI: 0.80-1.20) at 5\u2009years post-cancer diagnosis\/treatment. In conclusion, before COVID-19-vaccination, risk of COVID-19-related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis\/treatment.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('92','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_92\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1002\/ijc.34798\" title=\"Follow DOI:10.1002\/ijc.34798\" target=\"_blank\">doi:10.1002\/ijc.34798<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('92','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><h3 class=\"tp_h3\" id=\"tp_h3_2023\">2023<\/h3><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ni\u00f1o-de-Guzm\u00e1n  E,  Bracchiglione  J,  V\u00e1squez-Mej\u00eda  A, de Graaf G,  Rocha Calder\u00f3n  C,  Alonso-Coello  P. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('89','tp_links')\" style=\"cursor:pointer;\">How Do Patients With Type 2 Diabetes Mellitus Value the Importance of Outcomes? An Overview of Reviews<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Value Health. <\/span><span class=\"tp_pub_additional_year\">2023<\/span><span class=\"tp_pub_additional_volume\">;26<\/span><span class=\"tp_pub_additional_pages\">:1782\u20131794<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_89\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('89','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_89\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('89','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_89\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('89','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_89\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid37516195b,<br \/>\r\ntitle = {How Do Patients With Type 2 Diabetes Mellitus Value the Importance of Outcomes? An Overview of Reviews},<br \/>\r\nauthor = {Ni\u00f1o-de-Guzm\u00e1n E and Bracchiglione J and V\u00e1squez-Mej\u00eda A and de Graaf G and Rocha Calder\u00f3n C and Alonso-Coello P},<br \/>\r\ndoi = {10.1016\/j.jval.2023.07.003},<br \/>\r\nissn = {1524-4733},<br \/>\r\nyear  = {2023},<br \/>\r\ndate = {2023-12-01},<br \/>\r\njournal = {Value Health},<br \/>\r\nvolume = {26},<br \/>\r\nnumber = {12},<br \/>\r\npages = {1782--1794},<br \/>\r\nabstract = {OBJECTIVES: We aimed to assess how patients value the importance of type 2 diabetes mellitus (T2DM) related outcomes.nnMETHODS: Overview of systematic reviews (SRs) reporting patients' utilities or disutilities for T2DM outcomes. We searched 3 databases from inception until June 2021. Study selection and data extraction were conducted in pairs. We evaluated the quality of SRs with the Joanna Briggs Institute Checklist, and the overlap with the corrected covered area. We estimated descriptive statistics, and, when possible, conducted metanalysis.nnRESULTS: We identified 11 SRs, including 119 studies and 70 outcomes. Most reviews were high-quality SRs. The outcomes with the lowest utilities were hypoglycemia with very severe symptoms (acute complications), stroke (macrovascular complications), diabetic peripheral neuropathy with severe pain (microvascular complications), extreme obesity (comorbidities), and insulin only or combined (management of diabetes). Good\/excellent glucose control and noninsulin injectable showed higher values than T2DM without complications. The outcomes with the highest disutilities were amputation, depression, major hypoglycemia, stroke, and management using only insulin.nnCONCLUSIONS: We provide standardized, reliable utility values (or associated disutilities) for T2DM, acute, microvascular and macrovascular complications, related comorbidities and treatments that may support judgments when making clinical recommendations, designing decision support tools, and developing interventions and economic analysis.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('89','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_89\" style=\"display:none;\"><div class=\"tp_abstract_entry\">OBJECTIVES: We aimed to assess how patients value the importance of type 2 diabetes mellitus (T2DM) related outcomes.nnMETHODS: Overview of systematic reviews (SRs) reporting patients' utilities or disutilities for T2DM outcomes. We searched 3 databases from inception until June 2021. Study selection and data extraction were conducted in pairs. We evaluated the quality of SRs with the Joanna Briggs Institute Checklist, and the overlap with the corrected covered area. We estimated descriptive statistics, and, when possible, conducted metanalysis.nnRESULTS: We identified 11 SRs, including 119 studies and 70 outcomes. Most reviews were high-quality SRs. The outcomes with the lowest utilities were hypoglycemia with very severe symptoms (acute complications), stroke (macrovascular complications), diabetic peripheral neuropathy with severe pain (microvascular complications), extreme obesity (comorbidities), and insulin only or combined (management of diabetes). Good\/excellent glucose control and noninsulin injectable showed higher values than T2DM without complications. The outcomes with the highest disutilities were amputation, depression, major hypoglycemia, stroke, and management using only insulin.nnCONCLUSIONS: We provide standardized, reliable utility values (or associated disutilities) for T2DM, acute, microvascular and macrovascular complications, related comorbidities and treatments that may support judgments when making clinical recommendations, designing decision support tools, and developing interventions and economic analysis.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('89','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_89\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.jval.2023.07.003\" title=\"Follow DOI:10.1016\/j.jval.2023.07.003\" target=\"_blank\">doi:10.1016\/j.jval.2023.07.003<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('89','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ni\u00f1o-de-Guzman Quispe  E,  Bracchiglione  J,  Ballester  M,  Groene  O,  Heijmans  M,  Mart\u00ednez Garc\u00eda  L,  Noordman  J,  Orrego  C,  Rocha  C,  Su\u00f1ol  R,  Alonso-Coello  P. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('86','tp_links')\" style=\"cursor:pointer;\">Patients' and informal caregivers' perspectives on self-management interventions for type 2 diabetes mellitus outcomes: a mixed-methods overview of 14 years of reviews<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Arch Public Health. <\/span><span class=\"tp_pub_additional_year\">2023<\/span><span class=\"tp_pub_additional_volume\">;81<\/span><span class=\"tp_pub_additional_pages\">:140<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_86\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('86','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_86\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('86','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_86\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('86','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_86\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid37537669,<br \/>\r\ntitle = {Patients' and informal caregivers' perspectives on self-management interventions for type 2 diabetes mellitus outcomes: a mixed-methods overview of 14 years of reviews},<br \/>\r\nauthor = {Ni\u00f1o-de-Guzman Quispe E and Bracchiglione J and Ballester M and Groene O and Heijmans M and Mart\u00ednez Garc\u00eda L and Noordman J and Orrego C and Rocha C and Su\u00f1ol R and Alonso-Coello P},<br \/>\r\ndoi = {10.1186\/s13690-023-01153-9},<br \/>\r\nissn = {0778-7367},<br \/>\r\nyear  = {2023},<br \/>\r\ndate = {2023-08-01},<br \/>\r\nurldate = {2023-08-01},<br \/>\r\njournal = {Arch Public Health},<br \/>\r\nvolume = {81},<br \/>\r\nnumber = {1},<br \/>\r\npages = {140},<br \/>\r\nabstract = {BACKGROUND: Self-management interventions (SMIs) are core components of high-quality care in type 2 diabetes mellitus (T2DM). We aimed to identify and summarise the scientific evidence exploring the perspectives of patients with T2DM and their informal caregivers on outcomes of SMIs, and the key themes to enhance T2DM patient-centred care.nnMETHODS: We conducted a mixed-methods overview of reviews. We searched MEDLINE, CINAHL and PsycINFO, up to June 2021 for systematic reviews (SRs) exploring the perspectives of adults with T2DM and their informal caregivers, regarding self-management. Two reviewers conducted independently study selection, data extraction and quality assessment. We estimated the degree of overlap across SRs. We performed a qualitative analysis using a thematic synthesis approach.nnRESULTS: We identified 54 SRs, corresponding to 939 studies, with a slight overlap. Most SRs (47\/54, 87%) were considered high quality. We developed summaries for 22 outcomes and identified six overarching themes: (1) diabetic identity; (2) accessing healthcare; (3) experience of care; (4) engagement with self-management; (5) outcomes awareness; and (6) challenges adhering to self-management. We found important variability in how patients with T2DM and their informal caregivers value critical outcomes influenced by the disease progression and several contextual factors.nnCONCLUSIONS: Our findings represent what matters most to patients with T2DM and their informal caregivers regarding outcomes of SMIs. Our results can facilitate the development and evaluation of SMIs, and guide decision-making in diabetes care, including the formulation of decisions and recommendations.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('86','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_86\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: Self-management interventions (SMIs) are core components of high-quality care in type 2 diabetes mellitus (T2DM). We aimed to identify and summarise the scientific evidence exploring the perspectives of patients with T2DM and their informal caregivers on outcomes of SMIs, and the key themes to enhance T2DM patient-centred care.nnMETHODS: We conducted a mixed-methods overview of reviews. We searched MEDLINE, CINAHL and PsycINFO, up to June 2021 for systematic reviews (SRs) exploring the perspectives of adults with T2DM and their informal caregivers, regarding self-management. Two reviewers conducted independently study selection, data extraction and quality assessment. We estimated the degree of overlap across SRs. We performed a qualitative analysis using a thematic synthesis approach.nnRESULTS: We identified 54 SRs, corresponding to 939 studies, with a slight overlap. Most SRs (47\/54, 87%) were considered high quality. We developed summaries for 22 outcomes and identified six overarching themes: (1) diabetic identity; (2) accessing healthcare; (3) experience of care; (4) engagement with self-management; (5) outcomes awareness; and (6) challenges adhering to self-management. We found important variability in how patients with T2DM and their informal caregivers value critical outcomes influenced by the disease progression and several contextual factors.nnCONCLUSIONS: Our findings represent what matters most to patients with T2DM and their informal caregivers regarding outcomes of SMIs. Our results can facilitate the development and evaluation of SMIs, and guide decision-making in diabetes care, including the formulation of decisions and recommendations.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('86','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_86\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1186\/s13690-023-01153-9\" title=\"Follow DOI:10.1186\/s13690-023-01153-9\" target=\"_blank\">doi:10.1186\/s13690-023-01153-9<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('86','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Worthington  J, van Wifferen F,  Sun  Z, de Jonge L,  Lew  JB,  Greuter  MJE, van den Puttelaar R,  Feletto  E,  Lansdorp-Vogelaar  I,  Coup\u00e9  VMH,  Ein Yong  JH,  Canfell  K,  I-PaRCS  Consortium. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('19','tp_links')\" style=\"cursor:pointer;\">Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">EClinicalMedicine. <\/span><span class=\"tp_pub_additional_year\">2023<\/span><span class=\"tp_pub_additional_volume\">;62<\/span><span class=\"tp_pub_additional_pages\">:102081<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_19\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('19','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_19\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('19','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_19\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('19','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_19\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid37538541,<br \/>\r\ntitle = {Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening},<br \/>\r\nauthor = {Worthington J and van Wifferen F and Sun Z and de Jonge L and Lew JB and Greuter MJE and van den Puttelaar R and Feletto E and Lansdorp-Vogelaar I and Coup\u00e9 VMH and Ein Yong JH and Canfell K and I-PaRCS Consortium},<br \/>\r\ndoi = {10.1016\/j.eclinm.2023.102081},<br \/>\r\nissn = {2589-5370},<br \/>\r\nyear  = {2023},<br \/>\r\ndate = {2023-08-01},<br \/>\r\njournal = {EClinicalMedicine},<br \/>\r\nvolume = {62},<br \/>\r\npages = {102081},<br \/>\r\nabstract = {BACKGROUND: Screening for colorectal cancer (CRC) decreases cancer burden through removal of precancerous lesions and early detection of cancer. The COVID-19 pandemic has disrupted organised CRC screening programs worldwide, with some programs completely suspending screening and others experiencing significant decreases in participation and diagnostic follow-up. This study estimated the global impact of screening disruptions on CRC outcomes, and potential effects of catch-up screening.nnMETHODS: Organised screening programs were identified in 29 countries, and data on participation rates and COVID-related changes to screening in 2020 were extracted where available. Four independent microsimulation models (ASCCA, MISCAN-Colon, OncoSim, and Policy1-Bowel) were used to estimate the long-term impact on CRC cases and deaths, based on decreases to screening participation in 2020. For countries where 2020 participation data were not available, changes to screening were approximated based on excess mortality rates. Catch-up strategies involving additional screening in 2021 were also simulated.nnFINDINGS: In countries for which direct data were available, organised CRC screening volumes at a country level decreased by an estimated 1.3-40.5% in 2020. Globally, it is estimated that COVID-related screening decreases led to a deficit of 7.4 million fewer faecal screens performed in 2020. In the absence of any organised catch-up screening, this would lead to an estimated 13,000 additional CRC cases and 7,900 deaths globally from 2020 to 2050; 79% of the additional cases and 85% of additional deaths could have been prevented with catch-up screening, respectively.nnINTERPRETATION: COVID-19-related disruptions to screening will cause excess CRC cases and deaths, but appropriately implemented catch-up screening could have reduced the burden by over 80%. Careful management of any disruption is key to improving the resilience of colorectal cancer screening programs.nnFUNDING: The authors disclosed receipt of the following financial support for the research, authorship, and\/or publication of this article: This work was supported by Cancer Council New South Wales, Health Canada, and Dutch National Institute for Public Health and Environment.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('19','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_19\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: Screening for colorectal cancer (CRC) decreases cancer burden through removal of precancerous lesions and early detection of cancer. The COVID-19 pandemic has disrupted organised CRC screening programs worldwide, with some programs completely suspending screening and others experiencing significant decreases in participation and diagnostic follow-up. This study estimated the global impact of screening disruptions on CRC outcomes, and potential effects of catch-up screening.nnMETHODS: Organised screening programs were identified in 29 countries, and data on participation rates and COVID-related changes to screening in 2020 were extracted where available. Four independent microsimulation models (ASCCA, MISCAN-Colon, OncoSim, and Policy1-Bowel) were used to estimate the long-term impact on CRC cases and deaths, based on decreases to screening participation in 2020. For countries where 2020 participation data were not available, changes to screening were approximated based on excess mortality rates. Catch-up strategies involving additional screening in 2021 were also simulated.nnFINDINGS: In countries for which direct data were available, organised CRC screening volumes at a country level decreased by an estimated 1.3-40.5% in 2020. Globally, it is estimated that COVID-related screening decreases led to a deficit of 7.4 million fewer faecal screens performed in 2020. In the absence of any organised catch-up screening, this would lead to an estimated 13,000 additional CRC cases and 7,900 deaths globally from 2020 to 2050; 79% of the additional cases and 85% of additional deaths could have been prevented with catch-up screening, respectively.nnINTERPRETATION: COVID-19-related disruptions to screening will cause excess CRC cases and deaths, but appropriately implemented catch-up screening could have reduced the burden by over 80%. Careful management of any disruption is key to improving the resilience of colorectal cancer screening programs.nnFUNDING: The authors disclosed receipt of the following financial support for the research, authorship, and\/or publication of this article: This work was supported by Cancer Council New South Wales, Health Canada, and Dutch National Institute for Public Health and Environment.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('19','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_19\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.eclinm.2023.102081\" title=\"Follow DOI:10.1016\/j.eclinm.2023.102081\" target=\"_blank\">doi:10.1016\/j.eclinm.2023.102081<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('19','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ricci-Cabello  I,  Carvallo-Casta\u00f1eda  D,  V\u00e1squez-Mej\u00eda  A,  Alonso-Coello  P,  Saz-Parkinson  Z,  Parmelli  E,  Morgano  GP,  Rigau  D,  Sol\u00e0  I,  Neamtiu  L,  Ni\u00f1o-de-Guzm\u00e1n  E. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('84','tp_links')\" style=\"cursor:pointer;\">Characteristics and impact of interventions to support healthcare providers' compliance with guideline recommendations for breast cancer: a systematic literature review<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Implement Sci. <\/span><span class=\"tp_pub_additional_year\">2023<\/span><span class=\"tp_pub_additional_volume\">;18<\/span><span class=\"tp_pub_additional_pages\">:17<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_84\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('84','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_84\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('84','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_84\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('84','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_84\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid37217955,<br \/>\r\ntitle = {Characteristics and impact of interventions to support healthcare providers' compliance with guideline recommendations for breast cancer: a systematic literature review},<br \/>\r\nauthor = {Ricci-Cabello I and Carvallo-Casta\u00f1eda D and V\u00e1squez-Mej\u00eda A and Alonso-Coello P and Saz-Parkinson Z and Parmelli E and Morgano GP and Rigau D and Sol\u00e0 I and Neamtiu L and Ni\u00f1o-de-Guzm\u00e1n E},<br \/>\r\ndoi = {10.1186\/s13012-023-01267-2},<br \/>\r\nissn = {1748-5908},<br \/>\r\nyear  = {2023},<br \/>\r\ndate = {2023-05-01},<br \/>\r\njournal = {Implement Sci},<br \/>\r\nvolume = {18},<br \/>\r\nnumber = {1},<br \/>\r\npages = {17},<br \/>\r\nabstract = {BACKGROUND: Breast cancer clinical practice guidelines (CPGs) offer evidence-based recommendations to improve quality of healthcare for patients. Suboptimal compliance with breast cancer guideline recommendations remains frequent, and has been associated with a decreased survival. The aim of this systematic review was to characterize and determine the impact of available interventions to support healthcare providers' compliance with CPGs recommendations in breast cancer healthcare.nnMETHODS: We searched for systematic reviews and primary studies in PubMed and Embase (from inception to May 2021). We included experimental and observational studies reporting on the use of interventions to support compliance with breast cancer CPGs. Eligibility assessment, data extraction and critical appraisal was conducted by one reviewer, and cross-checked by a second reviewer. Using the same approach, we synthesized the characteristics and the effects of the interventions by type of intervention (according to the EPOC taxonomy), and applied the GRADE framework to assess the certainty of evidence.nnRESULTS: We identified 35 primary studies reporting on 24 different interventions. Most frequently described interventions consisted in computerized decision support systems (12 studies); educational interventions (seven), audit and feedback (two), and multifaceted interventions (nine). There is low quality evidence that educational interventions targeted to healthcare professionals may improve compliance with recommendations concerning breast cancer screening, diagnosis and treatment. There is moderate quality evidence that reminder systems for healthcare professionals improve compliance with recommendations concerning breast cancer screening. There is low quality evidence that multifaceted interventions may improve compliance with recommendations concerning breast cancer screening. The effectiveness of the remaining types of interventions identified have not been evaluated with appropriate study designs for such purpose. There is very limited data on the costs of implementing these interventions.nnCONCLUSIONS: Different types of interventions to support compliance with breast cancer CPGs recommendations are available, and most of them show positive effects. More robust trials are needed to strengthen the available evidence base concerning their efficacy. Gathering data on the costs of implementing the proposed interventions is needed to inform decisions about their widespread implementation.nnTRIAL REGISTRATION: CRD42018092884 (PROSPERO).},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('84','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_84\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: Breast cancer clinical practice guidelines (CPGs) offer evidence-based recommendations to improve quality of healthcare for patients. Suboptimal compliance with breast cancer guideline recommendations remains frequent, and has been associated with a decreased survival. The aim of this systematic review was to characterize and determine the impact of available interventions to support healthcare providers' compliance with CPGs recommendations in breast cancer healthcare.nnMETHODS: We searched for systematic reviews and primary studies in PubMed and Embase (from inception to May 2021). We included experimental and observational studies reporting on the use of interventions to support compliance with breast cancer CPGs. Eligibility assessment, data extraction and critical appraisal was conducted by one reviewer, and cross-checked by a second reviewer. Using the same approach, we synthesized the characteristics and the effects of the interventions by type of intervention (according to the EPOC taxonomy), and applied the GRADE framework to assess the certainty of evidence.nnRESULTS: We identified 35 primary studies reporting on 24 different interventions. Most frequently described interventions consisted in computerized decision support systems (12 studies); educational interventions (seven), audit and feedback (two), and multifaceted interventions (nine). There is low quality evidence that educational interventions targeted to healthcare professionals may improve compliance with recommendations concerning breast cancer screening, diagnosis and treatment. There is moderate quality evidence that reminder systems for healthcare professionals improve compliance with recommendations concerning breast cancer screening. There is low quality evidence that multifaceted interventions may improve compliance with recommendations concerning breast cancer screening. The effectiveness of the remaining types of interventions identified have not been evaluated with appropriate study designs for such purpose. There is very limited data on the costs of implementing these interventions.nnCONCLUSIONS: Different types of interventions to support compliance with breast cancer CPGs recommendations are available, and most of them show positive effects. More robust trials are needed to strengthen the available evidence base concerning their efficacy. Gathering data on the costs of implementing the proposed interventions is needed to inform decisions about their widespread implementation.nnTRIAL REGISTRATION: CRD42018092884 (PROSPERO).<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('84','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_84\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1186\/s13012-023-01267-2\" title=\"Follow DOI:10.1186\/s13012-023-01267-2\" target=\"_blank\">doi:10.1186\/s13012-023-01267-2<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('84','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Jofra  LS,  Alonso-Coello  P,  Mart\u00ednez  EC, de Britos Marsal C,  Gallego Iborra  A, de Ni\u00f1o  Guzman Quispe EP,  P\u00e9rez-Gaxiola  G,  Requeijo  C,  Roqu\u00e9 I Figuls  M,  Rosenbaum  S,  Salas-Gama  K,  Urreta-Barallobre  I,  Mart\u00ednez Garc\u00eda  L. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('85','tp_links')\" style=\"cursor:pointer;\">Piloting the informed health choices resources in Barcelona primary schools: A mixed methods study<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">PLoS One. <\/span><span class=\"tp_pub_additional_year\">2023<\/span><span class=\"tp_pub_additional_volume\">;18<\/span><span class=\"tp_pub_additional_pages\">:e0288082<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_85\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('85','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_85\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('85','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_85\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('85','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_85\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid37418372,<br \/>\r\ntitle = {Piloting the informed health choices resources in Barcelona primary schools: A mixed methods study},<br \/>\r\nauthor = {Jofra LS and Alonso-Coello P and Mart\u00ednez EC and de Britos Marsal C and Gallego Iborra A and Ni\u00f1o de Guzman Quispe EP and P\u00e9rez-Gaxiola G and Requeijo C and Roqu\u00e9 I Figuls M and Rosenbaum S and Salas-Gama K and Urreta-Barallobre I and Mart\u00ednez Garc\u00eda L},<br \/>\r\ndoi = {10.1371\/journal.pone.0288082},<br \/>\r\nissn = {1932-6203},<br \/>\r\nyear  = {2023},<br \/>\r\ndate = {2023-01-01},<br \/>\r\njournal = {PLoS One},<br \/>\r\nvolume = {18},<br \/>\r\nnumber = {7},<br \/>\r\npages = {e0288082},<br \/>\r\nabstract = {INTRODUCTION: The main objective of the Informed Health Choices (IHC) project is to teach people to assess treatment claims and make informed health choices. For this purpose, the IHC learning resources were developed for primary school children. The aim of this study is to explore students' and teachers' experience when using the IHC resources in primary schools in Barcelona (Spain).nnMETHODS: We conducted a mixed methods study for piloting the IHC resources in a convenience sample of primary schools in Barcelona. The intervention included a workshop with teachers, and nine lessons with students. We collected data using multiple approaches. We performed quantitative and qualitative analyses, and integrated the findings in a joint display. Finally, we formulated recommendations for using the IHC resources in this setting.nnRESULTS: Two schools, with a total of 143 students in 4th and 5th grade and six teachers, participated in the study. One school followed the suggested IHC teaching plan and competed all the lessons; the other school modified the plan substantially and did not complete all the lessons. Overall, students and teachers from both schools understood, were interested in, and were able to apply the content of the lessons. During the lessons, the textbook was useful for students; nevertheless, for the teachers, the usefulness of the IHC resources was variable. Teachers adapted the IHC resources to increase student participation and used Information and Communications Technologies tools. We observed more facilitators than barriers to teach the lessons. The teachers suggested some ideas to improve the lessons based on activities they developed and implemented. The integration analysis showed great convergence of the quantitative and qualitative findings. We propose seven recommendations for using the IHC resources in this setting.nnCONCLUSIONS: Students and teachers from primary schools in Barcelona showed a positive experience when using IHC resources; however, these resources should be adapted to promote classroom participation.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('85','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_85\" style=\"display:none;\"><div class=\"tp_abstract_entry\">INTRODUCTION: The main objective of the Informed Health Choices (IHC) project is to teach people to assess treatment claims and make informed health choices. For this purpose, the IHC learning resources were developed for primary school children. The aim of this study is to explore students' and teachers' experience when using the IHC resources in primary schools in Barcelona (Spain).nnMETHODS: We conducted a mixed methods study for piloting the IHC resources in a convenience sample of primary schools in Barcelona. The intervention included a workshop with teachers, and nine lessons with students. We collected data using multiple approaches. We performed quantitative and qualitative analyses, and integrated the findings in a joint display. Finally, we formulated recommendations for using the IHC resources in this setting.nnRESULTS: Two schools, with a total of 143 students in 4th and 5th grade and six teachers, participated in the study. One school followed the suggested IHC teaching plan and competed all the lessons; the other school modified the plan substantially and did not complete all the lessons. Overall, students and teachers from both schools understood, were interested in, and were able to apply the content of the lessons. During the lessons, the textbook was useful for students; nevertheless, for the teachers, the usefulness of the IHC resources was variable. Teachers adapted the IHC resources to increase student participation and used Information and Communications Technologies tools. We observed more facilitators than barriers to teach the lessons. The teachers suggested some ideas to improve the lessons based on activities they developed and implemented. The integration analysis showed great convergence of the quantitative and qualitative findings. We propose seven recommendations for using the IHC resources in this setting.nnCONCLUSIONS: Students and teachers from primary schools in Barcelona showed a positive experience when using IHC resources; however, these resources should be adapted to promote classroom participation.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('85','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_85\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1371\/journal.pone.0288082\" title=\"Follow DOI:10.1371\/journal.pone.0288082\" target=\"_blank\">doi:10.1371\/journal.pone.0288082<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('85','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><h3 class=\"tp_h3\" id=\"tp_h3_2022\">2022<\/h3><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Paytubi  S,  Benavente  Y,  Montoliu  A,  Binefa  G,  Brotons  M,  Ib\u00e1\u00f1ez  R,  Ochoa  C,  Peremiquel-Trillas  P,  Serrano  B,  Travier  N,  Alemany  L,  Costas  L. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('18','tp_links')\" style=\"cursor:pointer;\">Everything causes cancer? Beliefs and attitudes towards cancer prevention among anti-vaxxers, flat earthers, and reptilian conspiracists: online cross sectional survey<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">BMJ. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;379<\/span><span class=\"tp_pub_additional_pages\">:e072561<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_18\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('18','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_18\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('18','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_18\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('18','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_18\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid36543351,<br \/>\r\ntitle = {Everything causes cancer? Beliefs and attitudes towards cancer prevention among anti-vaxxers, flat earthers, and reptilian conspiracists: online cross sectional survey},<br \/>\r\nauthor = {Paytubi S and Benavente Y and Montoliu A and Binefa G and Brotons M and Ib\u00e1\u00f1ez R and Ochoa C and Peremiquel-Trillas P and Serrano B and Travier N and Alemany L and Costas L},<br \/>\r\ndoi = {10.1136\/bmj-2022-072561},<br \/>\r\nissn = {1756-1833},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-12-01},<br \/>\r\njournal = {BMJ},<br \/>\r\nvolume = {379},<br \/>\r\npages = {e072561},<br \/>\r\nabstract = {OBJECTIVE: To evaluate, using an online non-probability sample, the beliefs about and attitudes towards cancer prevention of people professing vaccination scepticism or conspiracy theories.nnDESIGN: Cross sectional survey.nnSETTING: Data collected mainly from ForoCoches (a well known Spanish forum) and other platforms, including Reddit (English), 4Chan (English), HispaChan (Spanish), and a Spanish language website for cancer prevention (mejorsincancer.org) from January to March 2022.nnPARTICIPANTS: Among 1494 responders, 209 were unvaccinated against covid-19, 112 preferred alternative rather than conventional medicine, and 62 reported flat earth or reptilian beliefs.nnMAIN OUTCOME MEASURES: Cancer beliefs assessed using the Cancer Awareness Measure (CAM) and Cancer Awareness Measure Mythical Causes Scale (CAM-MYCS) (both validated tools).nnRESULTS: Awareness of the actual causes of cancer was greater (median CAM score 63.6%) than that of mythical causes (41.7%). The most endorsed mythical causes of cancer were eating food containing additives or sweeteners, feeling stressed, and eating genetically modified food. Awareness of the actual and mythical causes of cancer among the unvaccinated, alternative medicine, and conspiracy groups was lower than among their counterparts. A median of 54.5% of the actual causes was accurately identified among each of the unvaccinated, alternative medicine, and conspiracy groups, and a median of 63.6% was identified in each of the three corresponding counterparts (P=0.13, 0.04, and 0.003, respectively). For mythical causes, medians of 25.0%, 16.7%, and 16.7% were accurately identified in the unvaccinated, alternative medicine, and conspiracy groups, respectively; a median of 41.7% was identified in each of the three corresponding counterparts (P<0.001 in adjusted models for all comparisons). In total, 673 (45.0%) participants agreed with the statement \"It seems like everything causes cancer.\" No significant differences were observed among the unvaccinated (44.0%), conspiracist (41.9%), or alternative medicine groups (35.7%), compared with their counterparts (45.2%, 45.7%, and 45.8%, respectively).nnCONCLUSIONS: Almost half of the participants agreed that \"It seems like everything causes cancer,\" which highlights the difficulty that society encounters in differentiating actual and mythical causes owing to mass information. People who believed in conspiracies, rejected the covid-19 vaccine, or preferred alternative medicine were more likely to endorse the mythical causes of cancer than their counterparts but were less likely to endorse the actual causes of cancer. These results suggest a direct connection between digital misinformation and consequent erroneous health decisions, which may represent a further preventable fraction of cancer.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('18','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_18\" style=\"display:none;\"><div class=\"tp_abstract_entry\">OBJECTIVE: To evaluate, using an online non-probability sample, the beliefs about and attitudes towards cancer prevention of people professing vaccination scepticism or conspiracy theories.nnDESIGN: Cross sectional survey.nnSETTING: Data collected mainly from ForoCoches (a well known Spanish forum) and other platforms, including Reddit (English), 4Chan (English), HispaChan (Spanish), and a Spanish language website for cancer prevention (mejorsincancer.org) from January to March 2022.nnPARTICIPANTS: Among 1494 responders, 209 were unvaccinated against covid-19, 112 preferred alternative rather than conventional medicine, and 62 reported flat earth or reptilian beliefs.nnMAIN OUTCOME MEASURES: Cancer beliefs assessed using the Cancer Awareness Measure (CAM) and Cancer Awareness Measure Mythical Causes Scale (CAM-MYCS) (both validated tools).nnRESULTS: Awareness of the actual causes of cancer was greater (median CAM score 63.6%) than that of mythical causes (41.7%). The most endorsed mythical causes of cancer were eating food containing additives or sweeteners, feeling stressed, and eating genetically modified food. Awareness of the actual and mythical causes of cancer among the unvaccinated, alternative medicine, and conspiracy groups was lower than among their counterparts. A median of 54.5% of the actual causes was accurately identified among each of the unvaccinated, alternative medicine, and conspiracy groups, and a median of 63.6% was identified in each of the three corresponding counterparts (P=0.13, 0.04, and 0.003, respectively). For mythical causes, medians of 25.0%, 16.7%, and 16.7% were accurately identified in the unvaccinated, alternative medicine, and conspiracy groups, respectively; a median of 41.7% was identified in each of the three corresponding counterparts (P<0.001 in adjusted models for all comparisons). In total, 673 (45.0%) participants agreed with the statement \"It seems like everything causes cancer.\" No significant differences were observed among the unvaccinated (44.0%), conspiracist (41.9%), or alternative medicine groups (35.7%), compared with their counterparts (45.2%, 45.7%, and 45.8%, respectively).nnCONCLUSIONS: Almost half of the participants agreed that \"It seems like everything causes cancer,\" which highlights the difficulty that society encounters in differentiating actual and mythical causes owing to mass information. People who believed in conspiracies, rejected the covid-19 vaccine, or preferred alternative medicine were more likely to endorse the mythical causes of cancer than their counterparts but were less likely to endorse the actual causes of cancer. These results suggest a direct connection between digital misinformation and consequent erroneous health decisions, which may represent a further preventable fraction of cancer.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('18','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_18\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1136\/bmj-2022-072561\" title=\"Follow DOI:10.1136\/bmj-2022-072561\" target=\"_blank\">doi:10.1136\/bmj-2022-072561<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('18','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Hern\u00e1ndez-Leal  MJ,  P\u00e9rez-Lacasta  MJ,  Cardona-Cardona  A,  Codern-Bov\u00e9  N,  Vidal-Lancis  C,  Rue  M,  Forn\u00e9  C,  Carles-Lavila  M,  Pro-Share  Group. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('16','tp_links')\" style=\"cursor:pointer;\">Women's preference to apply shared decision-making in breast cancer screening: a discrete choice experiment<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">BMJ Open. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;12<\/span><span class=\"tp_pub_additional_pages\">:e064488<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_16\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('16','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_16\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('16','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_16\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('16','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_16\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid36351714,<br \/>\r\ntitle = {Women's preference to apply shared decision-making in breast cancer screening: a discrete choice experiment},<br \/>\r\nauthor = {Hern\u00e1ndez-Leal MJ and P\u00e9rez-Lacasta MJ and Cardona-Cardona A and Codern-Bov\u00e9 N and Vidal-Lancis C and Rue M and Forn\u00e9 C and Carles-Lavila M and Pro-Share Group},<br \/>\r\ndoi = {10.1136\/bmjopen-2022-064488},<br \/>\r\nissn = {2044-6055},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-11-01},<br \/>\r\njournal = {BMJ Open},<br \/>\r\nvolume = {12},<br \/>\r\nnumber = {11},<br \/>\r\npages = {e064488},<br \/>\r\nabstract = {OBJECTIVE: To analyse women's stated preferences for establishing the relative importance of each attribute of shared decision-making (SDM) and their willingness to pay (WTP) for more participatory care in breast cancer screening programmes (BCSP).nnDESIGN: A discrete choice experiment was designed with 12 questions (choice tasks). It included three attributes: 'How the information is obtained', regarding benefits and harms; whether there is a 'Dialogue for scheduled mammography' between the healthcare professional and the woman; and, 'Who makes the decision', regarding participation in BCSP. Data were obtained using a survey that included 12 choice tasks, 1 question on WTP and 7 socioeconomic-related questions. The analysis was performed using conditional mixed-effect logit regression and stratification according to WTP.nnSETTING: Data collection related to BCSP was conducted between June and November 2021 in Catalonia, Spain.nnPARTICIPANTS: Sixty-five women aged between 50 and 60.nnMAIN OUTCOME MEASURES: Women's perceived utility of each attribute, trade-off on these attributes and WTP for SDM in BCSP.nnRESULT: The only significant attribute was 'Who makes the decision'. The decision made alone (coefficient=2.879; 95% CI=2.297 to 3.461) and the decision made together with a healthcare professional (2.375; 95% CI=1.573 to 3.177) were the options preferred by women. The former contributes 21% more utility than the latter. Moreover, 52.3% of the women stated a WTP of \u20ac10 or more for SDM. Women's preferences regarding attributes did not influence their WTP.nnCONCLUSIONS: The participant women refused a current paternalistic model and preferred either SDM or informed decision-making in BCSP.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('16','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_16\" style=\"display:none;\"><div class=\"tp_abstract_entry\">OBJECTIVE: To analyse women's stated preferences for establishing the relative importance of each attribute of shared decision-making (SDM) and their willingness to pay (WTP) for more participatory care in breast cancer screening programmes (BCSP).nnDESIGN: A discrete choice experiment was designed with 12 questions (choice tasks). It included three attributes: 'How the information is obtained', regarding benefits and harms; whether there is a 'Dialogue for scheduled mammography' between the healthcare professional and the woman; and, 'Who makes the decision', regarding participation in BCSP. Data were obtained using a survey that included 12 choice tasks, 1 question on WTP and 7 socioeconomic-related questions. The analysis was performed using conditional mixed-effect logit regression and stratification according to WTP.nnSETTING: Data collection related to BCSP was conducted between June and November 2021 in Catalonia, Spain.nnPARTICIPANTS: Sixty-five women aged between 50 and 60.nnMAIN OUTCOME MEASURES: Women's perceived utility of each attribute, trade-off on these attributes and WTP for SDM in BCSP.nnRESULT: The only significant attribute was 'Who makes the decision'. The decision made alone (coefficient=2.879; 95% CI=2.297 to 3.461) and the decision made together with a healthcare professional (2.375; 95% CI=1.573 to 3.177) were the options preferred by women. The former contributes 21% more utility than the latter. Moreover, 52.3% of the women stated a WTP of \u20ac10 or more for SDM. Women's preferences regarding attributes did not influence their WTP.nnCONCLUSIONS: The participant women refused a current paternalistic model and preferred either SDM or informed decision-making in BCSP.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('16','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_16\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1136\/bmjopen-2022-064488\" title=\"Follow DOI:10.1136\/bmjopen-2022-064488\" target=\"_blank\">doi:10.1136\/bmjopen-2022-064488<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('16','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\">van Wifferen F,  Greuter  MJE,  Lissenberg-Witte  BI,  Carvalho  B,  Meijer  GA,  Dekker  E,  Campari  C,  Garcia  M,  Rabeneck  L,  Lansdorp-Vogelaar  I,  Senore  C,  Coup\u00e9  VMH,  ICSN Colorectal Cancer Screening Working  Group. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('15','tp_links')\" style=\"cursor:pointer;\">Guidance for setting international standards on reporting longitudinal adherence to stool-based colorectal cancer screening<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Prev Med. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;164<\/span><span class=\"tp_pub_additional_pages\">:107187<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_15\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('15','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_15\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('15','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_15\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('15','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_15\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid35963311,<br \/>\r\ntitle = {Guidance for setting international standards on reporting longitudinal adherence to stool-based colorectal cancer screening},<br \/>\r\nauthor = {van Wifferen F and Greuter MJE and Lissenberg-Witte BI and Carvalho B and Meijer GA and Dekker E and Campari C and Garcia M and Rabeneck L and Lansdorp-Vogelaar I and Senore C and Coup\u00e9 VMH and ICSN Colorectal Cancer Screening Working Group},<br \/>\r\ndoi = {10.1016\/j.ypmed.2022.107187},<br \/>\r\nissn = {1096-0260},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-11-01},<br \/>\r\njournal = {Prev Med},<br \/>\r\nvolume = {164},<br \/>\r\npages = {107187},<br \/>\r\nabstract = {Longitudinal adherence to colorectal cancer (CRC) screening is reported using different summarizing measures, which hampers international comparison. We provide evidence to guide recommendations on which longitudinal adherence measure to report. Using adherence data over four stool-based CRC screening rounds in three countries, we calculated six summarizing adherence measures; adherence over all rounds, adherence per round, rescreening, full programme adherence (yes\/no), regularity (never\/inconsistent\/consistent screenees) and number of times participated. For each measure, we calculated the accuracy in capturing the observed adherence patterns. Using the ASCCA model, we predicted screening effectiveness when using summarizing measures as model input versus the observed adherence patterns. Adherence over all rounds in the Italian, Spanish and Dutch cohorts was 64.9%, 42.8% and 61.5%, respectively, and the proportion of consistent screenees was 50.9%, 26.3% and 45.7%. Number of times participated and regularity were most accurate and resulted in similar model-predicted screening effectiveness as simulating the observed adherence patterns of Italy, Spain and the Netherlands (mortality reductions: 24.4%, 16.9% and 23.5%). Adherence over all rounds and adherence per round were least accurate. Screening effectiveness was overestimated when using adherence over all rounds (mortality reductions: 26.8%, 19.4% and 25.7%) and adherence per round (mortality reductions: 26.8%, 19.5% and 25.9%). To conclude, number of times participated and regularity were most accurate and resulted in similar model-predicted screening effectiveness as using the observed adherence patterns. However they require longitudinal data. To facilitate international comparison of CRC screening programme performance, consensus on an accurate adherence measure to report should be reached.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('15','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_15\" style=\"display:none;\"><div class=\"tp_abstract_entry\">Longitudinal adherence to colorectal cancer (CRC) screening is reported using different summarizing measures, which hampers international comparison. We provide evidence to guide recommendations on which longitudinal adherence measure to report. Using adherence data over four stool-based CRC screening rounds in three countries, we calculated six summarizing adherence measures; adherence over all rounds, adherence per round, rescreening, full programme adherence (yes\/no), regularity (never\/inconsistent\/consistent screenees) and number of times participated. For each measure, we calculated the accuracy in capturing the observed adherence patterns. Using the ASCCA model, we predicted screening effectiveness when using summarizing measures as model input versus the observed adherence patterns. Adherence over all rounds in the Italian, Spanish and Dutch cohorts was 64.9%, 42.8% and 61.5%, respectively, and the proportion of consistent screenees was 50.9%, 26.3% and 45.7%. Number of times participated and regularity were most accurate and resulted in similar model-predicted screening effectiveness as simulating the observed adherence patterns of Italy, Spain and the Netherlands (mortality reductions: 24.4%, 16.9% and 23.5%). Adherence over all rounds and adherence per round were least accurate. Screening effectiveness was overestimated when using adherence over all rounds (mortality reductions: 26.8%, 19.4% and 25.7%) and adherence per round (mortality reductions: 26.8%, 19.5% and 25.9%). To conclude, number of times participated and regularity were most accurate and resulted in similar model-predicted screening effectiveness as using the observed adherence patterns. However they require longitudinal data. To facilitate international comparison of CRC screening programme performance, consensus on an accurate adherence measure to report should be reached.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('15','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_15\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.ypmed.2022.107187\" title=\"Follow DOI:10.1016\/j.ypmed.2022.107187\" target=\"_blank\">doi:10.1016\/j.ypmed.2022.107187<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('15','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ferrer  L,  Gonz\u00e1lez  V,  Martr\u00f3  E,  Folch  C,  Saludes  V,  Mu\u00f1oz  R,  Rodr\u00edguez  V,  Morales  A,  Mero\u00f1o  M,  Morey  F,  Sanjos\u00e9  S,  Casabona  J. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('17','tp_links')\" style=\"cursor:pointer;\">High HIV\/STI prevalence among cisgender men and transgender women sex workers attending community-based centres in Barcelona, Spain: The Sweetie Project<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Int J STD AIDS. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;33<\/span><span class=\"tp_pub_additional_pages\">:1045\u20131053<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_17\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('17','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_17\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('17','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_17\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('17','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_17\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid36113447,<br \/>\r\ntitle = {High HIV\/STI prevalence among cisgender men and transgender women sex workers attending community-based centres in Barcelona, Spain: The Sweetie Project},<br \/>\r\nauthor = {Ferrer L and Gonz\u00e1lez V and Martr\u00f3 E and Folch C and Saludes V and Mu\u00f1oz R and Rodr\u00edguez V and Morales A and Mero\u00f1o M and Morey F and Sanjos\u00e9 S and Casabona J},<br \/>\r\ndoi = {10.1177\/09564624221116536},<br \/>\r\nissn = {1758-1052},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-10-01},<br \/>\r\njournal = {Int J STD AIDS},<br \/>\r\nvolume = {33},<br \/>\r\nnumber = {12},<br \/>\r\npages = {1045--1053},<br \/>\r\nabstract = {BACKGROUND: The aim of this study was to describe the socio-demographics, and the sexual and health-seeking behaviours of cisgender men and transgender women sex workers (M & TWSW) attending community-based organisations (CBOs) in Barcelona, Spain, as well as to estimate the prevalence of HIV, hepatitis B virus (HBV), hepatitis C virus (HCV),  (CT) and  (NG) among them at different anatomical sites.nnMETHODS: The Sweetie Project was a community-based cross-sectional study of 147\u00a0M & TWSW recruited in two CBOs in Barcelona between 2017 and 2018. A nurse collected biological samples from rectum, pharynx and urethra from the subjects at each CBO and the participants self-completed an epidemiological questionnaire.nnRESULTS: The highest prevalence observed was for HIV infection (25.3%) followed by bacterial STIs (NG 19.2% and CT 10.3%). The most prevalent anatomical site was pharyngeal (17.7%) followed by rectal (13.8%). More than half of participants who had a pharyngeal infection presented an isolated pharyngeal infection (57.7%) and half of those who had a rectal or urethral infection presented an isolated infection respectively. The seroprevalence of HCV and HBV was 2.4% and 34.2% respectively. There was a poor but statistically significant correlation between HIV and rectal CT infection ( = 0.31), previous exposure to HCV ( = 0.27) or self-reported STI ( = 0.23), as well as between previous exposure to HCV and rectal CT ( = 0.21) or self-reported STI ( = 0.20).nnDISCUSSION: The Sweetie Project confirms the high burden of HIV and bacterial STIs among a sample of M&TWSW recruited in CBOs and reinforces the need to routinely screen them at all exposed anatomical sites.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('17','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_17\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: The aim of this study was to describe the socio-demographics, and the sexual and health-seeking behaviours of cisgender men and transgender women sex workers (M & TWSW) attending community-based organisations (CBOs) in Barcelona, Spain, as well as to estimate the prevalence of HIV, hepatitis B virus (HBV), hepatitis C virus (HCV),  (CT) and  (NG) among them at different anatomical sites.nnMETHODS: The Sweetie Project was a community-based cross-sectional study of 147\u00a0M & TWSW recruited in two CBOs in Barcelona between 2017 and 2018. A nurse collected biological samples from rectum, pharynx and urethra from the subjects at each CBO and the participants self-completed an epidemiological questionnaire.nnRESULTS: The highest prevalence observed was for HIV infection (25.3%) followed by bacterial STIs (NG 19.2% and CT 10.3%). The most prevalent anatomical site was pharyngeal (17.7%) followed by rectal (13.8%). More than half of participants who had a pharyngeal infection presented an isolated pharyngeal infection (57.7%) and half of those who had a rectal or urethral infection presented an isolated infection respectively. The seroprevalence of HCV and HBV was 2.4% and 34.2% respectively. There was a poor but statistically significant correlation between HIV and rectal CT infection ( = 0.31), previous exposure to HCV ( = 0.27) or self-reported STI ( = 0.23), as well as between previous exposure to HCV and rectal CT ( = 0.21) or self-reported STI ( = 0.20).nnDISCUSSION: The Sweetie Project confirms the high burden of HIV and bacterial STIs among a sample of M&TWSW recruited in CBOs and reinforces the need to routinely screen them at all exposed anatomical sites.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('17','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_17\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1177\/09564624221116536\" title=\"Follow DOI:10.1177\/09564624221116536\" target=\"_blank\">doi:10.1177\/09564624221116536<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('17','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\">van Wifferen F, de Jonge L,  Worthington  J,  Greuter  MJE,  Lew  JB,  Nadeau  C, van den Puttelaar R,  Feletto  E,  Yong  JHE,  Lansdorp-Vogelaar  I,  Canfell  K,  Coup\u00e9  VMH,  COVID-19, working group Cancer Global Modelling Consortium (CCGMC)  2. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('9','tp_links')\" style=\"cursor:pointer;\">Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">J Med Screen. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;29<\/span><span class=\"tp_pub_additional_pages\">:72\u201383<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_9\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('9','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_9\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('9','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_9\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('9','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_9\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid35100894,<br \/>\r\ntitle = {Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study},<br \/>\r\nauthor = {van Wifferen F and de Jonge L and Worthington J and Greuter MJE and Lew JB and Nadeau C and van den Puttelaar R and Feletto E and Yong JHE and Lansdorp-Vogelaar I and Canfell K and Coup\u00e9 VMH and COVID-19 and Cancer Global Modelling Consortium (CCGMC) working group 2},<br \/>\r\ndoi = {10.1177\/09691413211056777},<br \/>\r\nissn = {1475-5793},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-06-01},<br \/>\r\njournal = {J Med Screen},<br \/>\r\nvolume = {29},<br \/>\r\nnumber = {2},<br \/>\r\npages = {72--83},<br \/>\r\nabstract = {OBJECTIVES: Colorectal cancer (CRC) screening with a faecal immunochemical test (FIT) has been disrupted in many countries during the COVID-19 pandemic. Performing catch-up of missed screens while maintaining regular screening services requires additional colonoscopy capacity that may not be available. This study aimed to compare strategies that clear the screening backlog using limited colonoscopy resources.nnMETHODS: A range of strategies were simulated using four country-specific CRC natural-history models: Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) and MIcrosimulation SCreening ANalysis for CRC (MISCAN-Colon) (both in the Netherlands), Policy1-Bowel (Australia) and OncoSim (Canada). Strategies assumed a 3-month screening disruption with varying recovery period lengths (6, 12, and 24 months) and varying FIT thresholds for diagnostic colonoscopy. Increasing the FIT threshold reduces the number of referrals to diagnostic colonoscopy. Outcomes for each strategy were colonoscopy demand and excess CRC-related deaths due to the disruption.nnRESULTS: Performing catch-up using the regular FIT threshold in 6, 12 and 24 months could prevent most excess CRC-related deaths, but required 50%, 25% and 12.5% additional colonoscopy demand, respectively. Without exceeding usual colonoscopy demand, up to 60% of excess CRC-related deaths can be prevented by increasing the FIT threshold for 12 or 24 months. Large increases in FIT threshold could lead to additional deaths rather than preventing them.nnCONCLUSIONS: Clearing the screening backlog in 24 months could avert most excess CRC-related deaths due to a 3-month disruption but would require a small increase in colonoscopy demand. Increasing the FIT threshold slightly over 24 months could ease the pressure on colonoscopy resources.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('9','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_9\" style=\"display:none;\"><div class=\"tp_abstract_entry\">OBJECTIVES: Colorectal cancer (CRC) screening with a faecal immunochemical test (FIT) has been disrupted in many countries during the COVID-19 pandemic. Performing catch-up of missed screens while maintaining regular screening services requires additional colonoscopy capacity that may not be available. This study aimed to compare strategies that clear the screening backlog using limited colonoscopy resources.nnMETHODS: A range of strategies were simulated using four country-specific CRC natural-history models: Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) and MIcrosimulation SCreening ANalysis for CRC (MISCAN-Colon) (both in the Netherlands), Policy1-Bowel (Australia) and OncoSim (Canada). Strategies assumed a 3-month screening disruption with varying recovery period lengths (6, 12, and 24 months) and varying FIT thresholds for diagnostic colonoscopy. Increasing the FIT threshold reduces the number of referrals to diagnostic colonoscopy. Outcomes for each strategy were colonoscopy demand and excess CRC-related deaths due to the disruption.nnRESULTS: Performing catch-up using the regular FIT threshold in 6, 12 and 24 months could prevent most excess CRC-related deaths, but required 50%, 25% and 12.5% additional colonoscopy demand, respectively. Without exceeding usual colonoscopy demand, up to 60% of excess CRC-related deaths can be prevented by increasing the FIT threshold for 12 or 24 months. Large increases in FIT threshold could lead to additional deaths rather than preventing them.nnCONCLUSIONS: Clearing the screening backlog in 24 months could avert most excess CRC-related deaths due to a 3-month disruption but would require a small increase in colonoscopy demand. Increasing the FIT threshold slightly over 24 months could ease the pressure on colonoscopy resources.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('9','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_9\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1177\/09691413211056777\" title=\"Follow DOI:10.1177\/09691413211056777\" target=\"_blank\">doi:10.1177\/09691413211056777<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('9','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> P\u00e9rez-Bracchiglione  J,  Meza  N,  Bangdiwala  SI, de Ni\u00f1o  Guzm\u00e1n E,  Urr\u00fatia  G,  Bonfill  X,  Madrid  E. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('12','tp_links')\" style=\"cursor:pointer;\">Graphical Representation of Overlap for OVErviews: GROOVE tool<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Res Synth Methods. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;13<\/span><span class=\"tp_pub_additional_pages\">:381\u2013388<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_12\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('12','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_12\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('12','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_12\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('12','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_12\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid35278030,<br \/>\r\ntitle = {Graphical Representation of Overlap for OVErviews: GROOVE tool},<br \/>\r\nauthor = {P\u00e9rez-Bracchiglione J and Meza N and Bangdiwala SI and Ni\u00f1o de Guzm\u00e1n E and Urr\u00fatia G and Bonfill X and Madrid E},<br \/>\r\ndoi = {10.1002\/jrsm.1557},<br \/>\r\nissn = {1759-2887},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-05-01},<br \/>\r\njournal = {Res Synth Methods},<br \/>\r\nvolume = {13},<br \/>\r\nnumber = {3},<br \/>\r\npages = {381--388},<br \/>\r\nabstract = {Overlap of primary studies among systematic reviews (SRs) is\u00a0one of the main methodological challenges when conducting overviews. If not assessed properly, overlapped primary studies may mislead findings, since they may have a major influence either in qualitative analyses or in statistical weight. Moreover, overlapping SRs may represent the existence of duplicated efforts. Matrices of evidence and the calculation of the overall corrected covered area (CCA) are appropriate methods to address this issue, but they seem to be not comprehensive enough. In this article we present Graphical Representation of Overlap for OVErviews (GROOVE), an easy-to-use tool for overview authors. Starting from a matrix of evidence, GROOVE provides the number of included primary studies and SRs included in the matrix; the absolute number of overlapped and non-overlapped primary studies; and an overall CCA assessment. The tool also provides a detailed CCA assessment for each possible pair of SRs (or \"nodes\"), with a graphical and easy-to-read representation of these results. Additionally, it includes an advanced optional usage, incorporating structural missingness in the matrix. In this article, we show the details about how to use GROOVE, what results it achieves and how the tool obtains these results. GROOVE is intended to improve the overlap assessment by making it easier, faster, and more friendly for both authors and readers. The tool is freely available at http:\/\/doi.org\/10.17605\/OSF.IO\/U2MS4 and https:\/\/es.cochrane.org\/es\/groovetool.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('12','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_12\" style=\"display:none;\"><div class=\"tp_abstract_entry\">Overlap of primary studies among systematic reviews (SRs) is\u00a0one of the main methodological challenges when conducting overviews. If not assessed properly, overlapped primary studies may mislead findings, since they may have a major influence either in qualitative analyses or in statistical weight. Moreover, overlapping SRs may represent the existence of duplicated efforts. Matrices of evidence and the calculation of the overall corrected covered area (CCA) are appropriate methods to address this issue, but they seem to be not comprehensive enough. In this article we present Graphical Representation of Overlap for OVErviews (GROOVE), an easy-to-use tool for overview authors. Starting from a matrix of evidence, GROOVE provides the number of included primary studies and SRs included in the matrix; the absolute number of overlapped and non-overlapped primary studies; and an overall CCA assessment. The tool also provides a detailed CCA assessment for each possible pair of SRs (or \"nodes\"), with a graphical and easy-to-read representation of these results. Additionally, it includes an advanced optional usage, incorporating structural missingness in the matrix. In this article, we show the details about how to use GROOVE, what results it achieves and how the tool obtains these results. GROOVE is intended to improve the overlap assessment by making it easier, faster, and more friendly for both authors and readers. The tool is freely available at http:\/\/doi.org\/10.17605\/OSF.IO\/U2MS4 and https:\/\/es.cochrane.org\/es\/groovetool.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('12','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_12\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1002\/jrsm.1557\" title=\"Follow DOI:10.1002\/jrsm.1557\" target=\"_blank\">doi:10.1002\/jrsm.1557<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('12','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Rom\u00e1n  M,  Louro  J,  Posso  M,  Vidal  C,  Bargall\u00f3  X,  V\u00e1zquez  I,  Quintana  MJ,  Alc\u00e1ntara  R,  Saladi\u00e9  F,  Del Riego  J,  Pe\u00f1alva  L,  Sala  M,  Castells  X,  On Behalf Of The Bele And Iris Study  Groups. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('8','tp_links')\" style=\"cursor:pointer;\">Long-Term Risk of Breast Cancer after Diagnosis of Benign Breast Disease by Screening Mammography<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Int J Environ Res Public Health. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;19<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_8\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('8','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_8\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('8','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_8\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('8','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_8\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid35270331,<br \/>\r\ntitle = {Long-Term Risk of Breast Cancer after Diagnosis of Benign Breast Disease by Screening Mammography},<br \/>\r\nauthor = {Rom\u00e1n M and Louro J and Posso M and Vidal C and Bargall\u00f3 X and V\u00e1zquez I and Quintana MJ and Alc\u00e1ntara R and Saladi\u00e9 F and Del Riego J and Pe\u00f1alva L and Sala M and Castells X and On Behalf Of The Bele And Iris Study Groups },<br \/>\r\ndoi = {10.3390\/ijerph19052625},<br \/>\r\nissn = {1660-4601},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-02-01},<br \/>\r\njournal = {Int J Environ Res Public Health},<br \/>\r\nvolume = {19},<br \/>\r\nnumber = {5},<br \/>\r\nabstract = {Assessing the long-term risk of breast cancer after diagnosis of benign breast disease by mammography is of utmost importance to design personalised screening strategies. We analysed individual-level data from 778,306 women aged 50-69 years with at least one mammographic screening participation in any of ten breast cancer screening centers in Spain from 1996 to 2015, and followed-up until 2017. We used Poisson regression to compare the rates of incident breast cancer among women with and without benign breast disease. During a median follow-up of 7.6 years, 11,708 (1.5%) women had an incident of breast cancer and 17,827 (2.3%) had a benign breast disease. The risk of breast cancer was 1.77 times higher among women with benign breast disease than among those without (95% CI: 1.61 to 1.95). The relative risk increased to 1.99 among women followed for less than four years, and remained elevated for two decades, with relative risk 1.96 (95% CI: 1.32 to 2.92) for those followed from 12 to 20 years. Benign breast disease is a long-term risk factor for breast cancer. Women with benign breast disease could benefit from closer surveillance and personalized screening strategies.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('8','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_8\" style=\"display:none;\"><div class=\"tp_abstract_entry\">Assessing the long-term risk of breast cancer after diagnosis of benign breast disease by mammography is of utmost importance to design personalised screening strategies. We analysed individual-level data from 778,306 women aged 50-69 years with at least one mammographic screening participation in any of ten breast cancer screening centers in Spain from 1996 to 2015, and followed-up until 2017. We used Poisson regression to compare the rates of incident breast cancer among women with and without benign breast disease. During a median follow-up of 7.6 years, 11,708 (1.5%) women had an incident of breast cancer and 17,827 (2.3%) had a benign breast disease. The risk of breast cancer was 1.77 times higher among women with benign breast disease than among those without (95% CI: 1.61 to 1.95). The relative risk increased to 1.99 among women followed for less than four years, and remained elevated for two decades, with relative risk 1.96 (95% CI: 1.32 to 2.92) for those followed from 12 to 20 years. Benign breast disease is a long-term risk factor for breast cancer. Women with benign breast disease could benefit from closer surveillance and personalized screening strategies.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('8','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_8\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.3390\/ijerph19052625\" title=\"Follow DOI:10.3390\/ijerph19052625\" target=\"_blank\">doi:10.3390\/ijerph19052625<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('8','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ib\u00e1\u00f1ez-Sanz  G,  Mil\u00e0  N,  Vives  N,  Vidal  C,  Binefa  G,  Rocamora  J,  Atencia  C,  Moreno  V,  Sanz-Pamplona  R,  Garcia  M,  On Behalf Of The Msic-Sc Research  Group. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('7','tp_links')\" style=\"cursor:pointer;\">Diagnostic Performance of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program According to Ambient Temperature and Humidity<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Cancers (Basel). <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;14<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_7\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('7','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_7\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('7','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_7\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('7','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_7\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid35267461,<br \/>\r\ntitle = {Diagnostic Performance of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program According to Ambient Temperature and Humidity},<br \/>\r\nauthor = {Ib\u00e1\u00f1ez-Sanz G and Mil\u00e0 N and Vives N and Vidal C and Binefa G and Rocamora J and Atencia C and Moreno V and Sanz-Pamplona R and Garcia M and On Behalf Of The Msic-Sc Research Group },<br \/>\r\ndoi = {10.3390\/cancers14051153},<br \/>\r\nissn = {2072-6694},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-02-01},<br \/>\r\njournal = {Cancers (Basel)},<br \/>\r\nvolume = {14},<br \/>\r\nnumber = {5},<br \/>\r\nabstract = {Exposure of the fecal immunochemical test (FIT) to different ambient temperatures and humidity is unavoidable in population-based screening programs in Southern European countries, and it could lead to a decrease in target colorectal lesions. The objective was to evaluate the effect of ambient temperature and humidity on the FIT sensitivity in a population-based screening program for colorectal cancer (CRC) using an ecological design. The retrospective cohort included individuals aged 50\u221269 years who participated in CRC screening (Barcelona) from 2010\u22122015, and were followed until 2017 to identify interval CRCs. The positivity rate, and detection rates for advanced polyps and CRC were compared according to ambient temperature, humidity, and quarters of the year. A positive FIT was defined as the detection of \u226520 \u03bcg Hb\/g in feces. The monthly ambient temperature and humidity were recorded on the day that the FIT was performed. In total, 92,273 FIT results from 53,860 participants were analyzed. The FIT positivity rate was lower at >24 \u00b0C than at \u226424 \u00b0C (p = 0.005) but was not affected by humidity. The temperature\u2019s impact on positivity did not lead to a decrease in the FIT detection rate for advanced neoplasia or the interval cancer detection rate in a program where the samples were refrigerated until the analysis and screening invitations were discontinued in July and August.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('7','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_7\" style=\"display:none;\"><div class=\"tp_abstract_entry\">Exposure of the fecal immunochemical test (FIT) to different ambient temperatures and humidity is unavoidable in population-based screening programs in Southern European countries, and it could lead to a decrease in target colorectal lesions. The objective was to evaluate the effect of ambient temperature and humidity on the FIT sensitivity in a population-based screening program for colorectal cancer (CRC) using an ecological design. The retrospective cohort included individuals aged 50\u221269 years who participated in CRC screening (Barcelona) from 2010\u22122015, and were followed until 2017 to identify interval CRCs. The positivity rate, and detection rates for advanced polyps and CRC were compared according to ambient temperature, humidity, and quarters of the year. A positive FIT was defined as the detection of \u226520 \u03bcg Hb\/g in feces. The monthly ambient temperature and humidity were recorded on the day that the FIT was performed. In total, 92,273 FIT results from 53,860 participants were analyzed. The FIT positivity rate was lower at >24 \u00b0C than at \u226424 \u00b0C (p = 0.005) but was not affected by humidity. The temperature\u2019s impact on positivity did not lead to a decrease in the FIT detection rate for advanced neoplasia or the interval cancer detection rate in a program where the samples were refrigerated until the analysis and screening invitations were discontinued in July and August.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('7','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_7\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.3390\/cancers14051153\" title=\"Follow DOI:10.3390\/cancers14051153\" target=\"_blank\">doi:10.3390\/cancers14051153<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('7','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Hern\u00e1ndez-Leal  MJ,  Codern-Bov\u00e9  N,  P\u00e9rez-Lacasta  MJ,  Cardona  A,  Vidal-Lancis  C,  Carles-Lavila  M,  ProShare  Group. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('6','tp_links')\" style=\"cursor:pointer;\">Development of support material for health professionals who are implementing Shared Decision-making in breast cancer screening: validation using the Delphi technique<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">BMJ Open. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;12<\/span><span class=\"tp_pub_additional_pages\">:e052566<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_6\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('6','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_6\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('6','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_6\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('6','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_6\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid35105575,<br \/>\r\ntitle = {Development of support material for health professionals who are implementing Shared Decision-making in breast cancer screening: validation using the Delphi technique},<br \/>\r\nauthor = {Hern\u00e1ndez-Leal MJ and Codern-Bov\u00e9 N and P\u00e9rez-Lacasta MJ and Cardona A and Vidal-Lancis C and Carles-Lavila M and ProShare Group},<br \/>\r\ndoi = {10.1136\/bmjopen-2021-052566},<br \/>\r\nissn = {2044-6055},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-02-01},<br \/>\r\njournal = {BMJ Open},<br \/>\r\nvolume = {12},<br \/>\r\nnumber = {2},<br \/>\r\npages = {e052566},<br \/>\r\nabstract = {BACKGROUND: The Literature is no report support material on Shared Decision-making applied to breast cancer screening that is intended for Spanish health professionals. The researcher created both a handbook and a guide for this topic using an adaption of the Three-talk model.nnOBJECTIVE: A Delphi method will be used to reach an agreement among experts on the contents and design of a manual and guide, designed by the research team, and to be used by health professionals in the application of SDM in breast cancer screening.nnDESIGN: A qualitative study. The content and design of the handbook and the guide was discussed by 20 experts. The Delphi techniques was in an online mode between July and October 2020 and researchers used Google forms in three rounds with open and closed questions. The criterion established for consensus was a coefficient of concordance (Cc) above 75, for questions using a Likert scale of 1-6-in which 1 meant 'completely disagree' and 6 'completely agree'-with a cut-off point equal to or higher than 4.nnRESULTS: Participants considered the Three-talk model suitable for the screening context. The handbook sections and level of detail were considered satisfactory (Cc=90). The summary provided by the clinical practice guide was considered necessary (Cc=75), as it was the self-assessment tool for professionals (Cc=85). Content was added: addressing the limitations of the SDM model; extending the number of sample dialogues for health professionals; providing supplementary resources on using Patient Decisions aids and adding references on communication skills.nnCONCLUSIONS AND APPLICATIONS: The first handbook and clinical practice guide providing unique SDM support material for health professionals have been developed. The handbook and guide are useful and innovative as supporting material for health professionals, but training strategies for SDM and a piloting plan for the use of materials are requested, in order to facilitate its implementation.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('6','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_6\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: The Literature is no report support material on Shared Decision-making applied to breast cancer screening that is intended for Spanish health professionals. The researcher created both a handbook and a guide for this topic using an adaption of the Three-talk model.nnOBJECTIVE: A Delphi method will be used to reach an agreement among experts on the contents and design of a manual and guide, designed by the research team, and to be used by health professionals in the application of SDM in breast cancer screening.nnDESIGN: A qualitative study. The content and design of the handbook and the guide was discussed by 20 experts. The Delphi techniques was in an online mode between July and October 2020 and researchers used Google forms in three rounds with open and closed questions. The criterion established for consensus was a coefficient of concordance (Cc) above 75, for questions using a Likert scale of 1-6-in which 1 meant 'completely disagree' and 6 'completely agree'-with a cut-off point equal to or higher than 4.nnRESULTS: Participants considered the Three-talk model suitable for the screening context. The handbook sections and level of detail were considered satisfactory (Cc=90). The summary provided by the clinical practice guide was considered necessary (Cc=75), as it was the self-assessment tool for professionals (Cc=85). Content was added: addressing the limitations of the SDM model; extending the number of sample dialogues for health professionals; providing supplementary resources on using Patient Decisions aids and adding references on communication skills.nnCONCLUSIONS AND APPLICATIONS: The first handbook and clinical practice guide providing unique SDM support material for health professionals have been developed. The handbook and guide are useful and innovative as supporting material for health professionals, but training strategies for SDM and a piloting plan for the use of materials are requested, in order to facilitate its implementation.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('6','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_6\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1136\/bmjopen-2021-052566\" title=\"Follow DOI:10.1136\/bmjopen-2021-052566\" target=\"_blank\">doi:10.1136\/bmjopen-2021-052566<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('6','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Vives  N,  Binefa  G,  Vidal  C,  Mil\u00e0  N,  Mu\u00f1oz  R,  Guardiola  V,  Rial  O,  Garcia  M. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('5','tp_links')\" style=\"cursor:pointer;\">Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain)<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Prev Med. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;155<\/span><span class=\"tp_pub_additional_pages\">:106929<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_5\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('5','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_5\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('5','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_5\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('5','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_5\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid34954239,<br \/>\r\ntitle = {Short-term impact of the COVID-19 pandemic on a population-based screening program for colorectal cancer in Catalonia (Spain)},<br \/>\r\nauthor = {Vives N and Binefa G and Vidal C and Mil\u00e0 N and Mu\u00f1oz R and Guardiola V and Rial O and Garcia M},<br \/>\r\ndoi = {10.1016\/j.ypmed.2021.106929},<br \/>\r\nissn = {1096-0260},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-02-01},<br \/>\r\njournal = {Prev Med},<br \/>\r\nvolume = {155},<br \/>\r\npages = {106929},<br \/>\r\nabstract = {The COVID-19 pandemic caused the suspension at all levels of the Catalan FIT-based CRC screening program on March 12, 2020. Screening invitations to FIT were resumed on September 1, 2020. We aimed to assess the short-term impact of the pandemic and describe strategies implemented to minimize harm by the disruption of the FIT-based CRC screening in the Metropolitan Area of Barcelona. We analyzed participation rate, colonoscopy adherence, time intervals to colonoscopy, detection rates, and advanced-stage cancers in 2019 and 2020. To identify perceived distress levels during the suspension of the screening we conducted a phone interview. As a result of the suspension, 43% of the individuals due for screening did not receive their invitation by December 31, 2020. A percent decrease of 5.1% in participation and of 8.9% in colonoscopy adherence among invitees between January-March was observed, with a recovery to 2019 levels when the screening activities were restarted. The time interval between a positive test to colonoscopy was longer in 2020 than in 2019. A decrease in advanced neoplasia rate and an increase in later stages of CRC were also observed. Individuals with a positive test did not report higher levels of perceived distress compared to those with a negative test. Although the disruption of screening had a temporary impact on participation and colonoscopy adherence, timing delay continues and a large backlog in the invitation of the target population remains. Thus, it is critical to implement strategies to minimize the long-term effects.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('5','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_5\" style=\"display:none;\"><div class=\"tp_abstract_entry\">The COVID-19 pandemic caused the suspension at all levels of the Catalan FIT-based CRC screening program on March 12, 2020. Screening invitations to FIT were resumed on September 1, 2020. We aimed to assess the short-term impact of the pandemic and describe strategies implemented to minimize harm by the disruption of the FIT-based CRC screening in the Metropolitan Area of Barcelona. We analyzed participation rate, colonoscopy adherence, time intervals to colonoscopy, detection rates, and advanced-stage cancers in 2019 and 2020. To identify perceived distress levels during the suspension of the screening we conducted a phone interview. As a result of the suspension, 43% of the individuals due for screening did not receive their invitation by December 31, 2020. A percent decrease of 5.1% in participation and of 8.9% in colonoscopy adherence among invitees between January-March was observed, with a recovery to 2019 levels when the screening activities were restarted. The time interval between a positive test to colonoscopy was longer in 2020 than in 2019. A decrease in advanced neoplasia rate and an increase in later stages of CRC were also observed. Individuals with a positive test did not report higher levels of perceived distress compared to those with a negative test. Although the disruption of screening had a temporary impact on participation and colonoscopy adherence, timing delay continues and a large backlog in the invitation of the target population remains. Thus, it is critical to implement strategies to minimize the long-term effects.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('5','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_5\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.ypmed.2021.106929\" title=\"Follow DOI:10.1016\/j.ypmed.2021.106929\" target=\"_blank\">doi:10.1016\/j.ypmed.2021.106929<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('5','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Valli  C,  Su\u00f1ol  R,  Orrego  C, de Ni\u00f1o  Guzm\u00e1n E,  Strammiello  V,  Adrion  N,  Immonen  K,  Ninov  L, van der Gaag M,  Ballester  M,  Alonso-Coello  P. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('4','tp_links')\" style=\"cursor:pointer;\">The development of a core outcomes set for self-management interventions for patients living with obesity<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Clin Obes. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;12<\/span><span class=\"tp_pub_additional_pages\">:e12489<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_4\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('4','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_4\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('4','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_4\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('4','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_4\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid34617681,<br \/>\r\ntitle = {The development of a core outcomes set for self-management interventions for patients living with obesity},<br \/>\r\nauthor = {Valli C and Su\u00f1ol R and Orrego C and Ni\u00f1o de Guzm\u00e1n E and Strammiello V and Adrion N and Immonen K and Ninov L and van der Gaag M and Ballester M and Alonso-Coello P},<br \/>\r\ndoi = {10.1111\/cob.12489},<br \/>\r\nissn = {1758-8111},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-02-01},<br \/>\r\njournal = {Clin Obes},<br \/>\r\nvolume = {12},<br \/>\r\nnumber = {1},<br \/>\r\npages = {e12489},<br \/>\r\nabstract = {Self-management interventions (SMIs) can improve the life of patients living with obesity. However, there is variability in the outcomes used to assess the effectiveness of SMIs and these are often not relevant for patients. In the context of COMPAR-EU, our aim was to develop a core outcome set (COS) for the evaluation of SMIs for patients with obesity. We followed a four steps multimethod approach: (1) the development of the initial catalogue of outcomes; (2) a scoping review of reviews on patients' values and preferences on outcomes of self-management (SM); (3) a Delphi survey including patients and patient representatives to rate the importance of outcomes; and (4) a 2-day consensus workshop with patients, patient representatives, healthcare professionals and researchers. The initial catalogue included 82 outcomes. Ten patients and patient's representatives participated in the Delphi survey. We identified 16 themes through the thematic synthesis of the scoping review that informed 37.80% of the outcomes on initial catalogue. Five patients, five healthcare professionals, and four researchers participated in the consensus workshop. After the consensus process, 15 outcomes were selected to be part of the final COS, and five supplementary outcomes were also provided. We developed a COS for the evaluation of SMIs in obesity with a significant involvement of patients and other key stakeholders. This COS will help improving data synthesis and increasing the value of SM research data in healthcare decision making.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('4','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_4\" style=\"display:none;\"><div class=\"tp_abstract_entry\">Self-management interventions (SMIs) can improve the life of patients living with obesity. However, there is variability in the outcomes used to assess the effectiveness of SMIs and these are often not relevant for patients. In the context of COMPAR-EU, our aim was to develop a core outcome set (COS) for the evaluation of SMIs for patients with obesity. We followed a four steps multimethod approach: (1) the development of the initial catalogue of outcomes; (2) a scoping review of reviews on patients' values and preferences on outcomes of self-management (SM); (3) a Delphi survey including patients and patient representatives to rate the importance of outcomes; and (4) a 2-day consensus workshop with patients, patient representatives, healthcare professionals and researchers. The initial catalogue included 82 outcomes. Ten patients and patient's representatives participated in the Delphi survey. We identified 16 themes through the thematic synthesis of the scoping review that informed 37.80% of the outcomes on initial catalogue. Five patients, five healthcare professionals, and four researchers participated in the consensus workshop. After the consensus process, 15 outcomes were selected to be part of the final COS, and five supplementary outcomes were also provided. We developed a COS for the evaluation of SMIs in obesity with a significant involvement of patients and other key stakeholders. This COS will help improving data synthesis and increasing the value of SM research data in healthcare decision making.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('4','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_4\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1111\/cob.12489\" title=\"Follow DOI:10.1111\/cob.12489\" target=\"_blank\">doi:10.1111\/cob.12489<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('4','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\">van der Gaag M,  Heijmans  M,  Ballester  M,  Orrego  C, de Ni\u00f1o  Guzm\u00e1n E,  Ninov  L,  Rademakers  J. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('14','tp_links')\" style=\"cursor:pointer;\">Preferences Regarding Self-Management Intervention Outcomes of Dutch Chronically Ill Patients With Limited Health Literacy<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Front Public Health. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;10<\/span><span class=\"tp_pub_additional_pages\">:842462<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_14\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('14','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_14\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('14','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_14\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('14','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_14\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid35646791,<br \/>\r\ntitle = {Preferences Regarding Self-Management Intervention Outcomes of Dutch Chronically Ill Patients With Limited Health Literacy},<br \/>\r\nauthor = {van der Gaag M and Heijmans M and Ballester M and Orrego C and Ni\u00f1o de Guzm\u00e1n E and Ninov L and Rademakers J},<br \/>\r\ndoi = {10.3389\/fpubh.2022.842462},<br \/>\r\nissn = {2296-2565},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-01-01},<br \/>\r\njournal = {Front Public Health},<br \/>\r\nvolume = {10},<br \/>\r\npages = {842462},<br \/>\r\nabstract = {BACKGROUND: For many chronically ill patients self-management of their disease is difficult. This may be especially true for people with limited health literacy as they are faced with additional challenges in the day-to-day management of their disease. Research has shown that self-management support is most effective when tailored to the needs and preferences of patients. Therefore, this study explores the preferences regarding self-management outcomes of chronically ill patients with limited health literacy.nnMETHODS: A total of 35 patients with limited health literacy were invited to a concept-mapping procedure consisting of two card sorting tasks. Patients ranked 60 outcomes, which are often found in literature in relation to self-management, to the level that was important for themselves. Means were calculated for each outcome and domain, and differences within the group were analyzed.nnRESULTS: For patients with limited health literacy, satisfaction with care is the most important outcome domain. This domain includes overall satisfaction, the communication with health care providers, the provision of information and trust. At an outcome level, outcomes related to symptom management and improving competences to self-management scored very high. No differences between patient groups for age and sex were found.nnCONCLUSION: Chronically ill patients with limited health literacy prefer a wide variety of outcomes for their self-management. Next to health related outcomes, patients mostly prefer to work on their competences for self-management. For health care professionals, acting on these patient preferences and building a solid relationship will enhance successful self-management.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('14','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_14\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: For many chronically ill patients self-management of their disease is difficult. This may be especially true for people with limited health literacy as they are faced with additional challenges in the day-to-day management of their disease. Research has shown that self-management support is most effective when tailored to the needs and preferences of patients. Therefore, this study explores the preferences regarding self-management outcomes of chronically ill patients with limited health literacy.nnMETHODS: A total of 35 patients with limited health literacy were invited to a concept-mapping procedure consisting of two card sorting tasks. Patients ranked 60 outcomes, which are often found in literature in relation to self-management, to the level that was important for themselves. Means were calculated for each outcome and domain, and differences within the group were analyzed.nnRESULTS: For patients with limited health literacy, satisfaction with care is the most important outcome domain. This domain includes overall satisfaction, the communication with health care providers, the provision of information and trust. At an outcome level, outcomes related to symptom management and improving competences to self-management scored very high. No differences between patient groups for age and sex were found.nnCONCLUSION: Chronically ill patients with limited health literacy prefer a wide variety of outcomes for their self-management. Next to health related outcomes, patients mostly prefer to work on their competences for self-management. For health care professionals, acting on these patient preferences and building a solid relationship will enhance successful self-management.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('14','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_14\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.3389\/fpubh.2022.842462\" title=\"Follow DOI:10.3389\/fpubh.2022.842462\" target=\"_blank\">doi:10.3389\/fpubh.2022.842462<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('14','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ferrer  L,  Gaillardin  F,  Cayuela  A,  Hernando  C,  Mu\u00f1oz  R,  S\u00e1nchez  N,  Forero  CG,  Ronda  E,  Casabona  J. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('13','tp_links')\" style=\"cursor:pointer;\">[Health status among immigrant in Catalonia from a gender perspective: PELFI project]<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Gac Sanit. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;36<\/span><span class=\"tp_pub_additional_pages\">:368\u2013375<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_13\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('13','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_13\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('13','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_13\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('13','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_13\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid33896656,<br \/>\r\ntitle = {[Health status among immigrant in Catalonia from a gender perspective: PELFI project]},<br \/>\r\nauthor = {Ferrer L and Gaillardin F and Cayuela A and Hernando C and Mu\u00f1oz R and S\u00e1nchez N and Forero CG and Ronda E and Casabona J},<br \/>\r\ndoi = {10.1016\/j.gaceta.2021.02.010},<br \/>\r\nissn = {1578-1283},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-01-01},<br \/>\r\njournal = {Gac Sanit},<br \/>\r\nvolume = {36},<br \/>\r\nnumber = {4},<br \/>\r\npages = {368--375},<br \/>\r\nabstract = {OBJECTIVE: The objective of the study is to assess the health status of immigrant men and women from non-EU countries living in the Metropolitan Area of Barcelona (Catalonia, Spain) and to identify the social determinants of health from a gender perspective.nnMETHOD: Cross-sectional analysis from a cohort of immigrant families recruited in Badalona and Santa Coloma de Gramenet, in Spain (PELFI cohort). In 2015-2016, 167 immigrants answered the baseline epidemiological questionnaire and the 5-level EuroQol instrument (EQ-5D) which measures health status. To identify health determinants, Tobit models were constructed to the EQ-5D index.nnRESULTS: Women rated poorer self-perceived health (p=0.005). To be diagnosed with and illness was only associated with poor self-perceived health among men (p<0.05). Length of residence, domestic work, and especially double workload deteriorated women's health. After adjusting models by demographics and social determinants, permanent administrative status (-0.136; p=0.015) and social support (0.182; p=0.02) were associated with health status in both sexes. To have a job was associated with better health only in men.nnCONCLUSIONS: Non-EU immigrants living in the Metropolitan Area of Barcelona are a socially vulnerable group of population and present inequalities in health by sex. Social support and occupation are key factors of their health status. Interventions to reduce immigrant vulnerabilities and inequalities in health should promote their social inclusion and cohesion from a gender perspective.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('13','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_13\" style=\"display:none;\"><div class=\"tp_abstract_entry\">OBJECTIVE: The objective of the study is to assess the health status of immigrant men and women from non-EU countries living in the Metropolitan Area of Barcelona (Catalonia, Spain) and to identify the social determinants of health from a gender perspective.nnMETHOD: Cross-sectional analysis from a cohort of immigrant families recruited in Badalona and Santa Coloma de Gramenet, in Spain (PELFI cohort). In 2015-2016, 167 immigrants answered the baseline epidemiological questionnaire and the 5-level EuroQol instrument (EQ-5D) which measures health status. To identify health determinants, Tobit models were constructed to the EQ-5D index.nnRESULTS: Women rated poorer self-perceived health (p=0.005). To be diagnosed with and illness was only associated with poor self-perceived health among men (p<0.05). Length of residence, domestic work, and especially double workload deteriorated women's health. After adjusting models by demographics and social determinants, permanent administrative status (-0.136; p=0.015) and social support (0.182; p=0.02) were associated with health status in both sexes. To have a job was associated with better health only in men.nnCONCLUSIONS: Non-EU immigrants living in the Metropolitan Area of Barcelona are a socially vulnerable group of population and present inequalities in health by sex. Social support and occupation are key factors of their health status. Interventions to reduce immigrant vulnerabilities and inequalities in health should promote their social inclusion and cohesion from a gender perspective.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('13','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_13\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.gaceta.2021.02.010\" title=\"Follow DOI:10.1016\/j.gaceta.2021.02.010\" target=\"_blank\">doi:10.1016\/j.gaceta.2021.02.010<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('13','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ochoa-Arnedo  C,  Prats  C,  Travier  N,  Marques-Feixa  L,  Flix-Valle  A, de Frutos ML,  Domingo-Gil  E,  Medina  JC,  Serra-Blasco  M. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('11','tp_links')\" style=\"cursor:pointer;\">Stressful Life Events and Distress in Breast Cancer: A 5-Years Follow-Up<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Int J Clin Health Psychol. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;22<\/span><span class=\"tp_pub_additional_pages\">:100303<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_11\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('11','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_11\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('11','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_11\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('11','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_11\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid35572072,<br \/>\r\ntitle = {Stressful Life Events and Distress in Breast Cancer: A 5-Years Follow-Up},<br \/>\r\nauthor = {Ochoa-Arnedo C and Prats C and Travier N and Marques-Feixa L and Flix-Valle A and de Frutos ML and Domingo-Gil E and Medina JC and Serra-Blasco M},<br \/>\r\ndoi = {10.1016\/j.ijchp.2022.100303},<br \/>\r\nissn = {2174-0852},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-01-01},<br \/>\r\njournal = {Int J Clin Health Psychol},<br \/>\r\nvolume = {22},<br \/>\r\nnumber = {2},<br \/>\r\npages = {100303},<br \/>\r\nabstract = {BACKGROUND\/OBJECTIVE: Environmental factors such as psychosocial stress have demonstrated to have an impact on the breast cancer (BC) course. This study aims to explore the impact of psychotherapy and stressful life events (SLE) on BC survivors' illness trajectories.nnMETHOD: 68 women with BC underwent Positive Psychotherapy or Cognitive-Behavioral Stress Management and 37 patients were included as a control group. The effects of distress reduction and SLE on their 5-year recurrence were investigated. Additional analyses examined the effect of receiving vs. not receiving psychotherapy and of the type of therapy on survival and disease-free interval, DFI.nnRESULTS: A one-point decrease of the Hospital Anxiety and Depression Scale (HADS) after psychotherapy predicted a lower risk of 5-year recurrence, \u00a0=\u00a00.84, \u00a0=\u00a0.037, 95% \u00a0=\u00a00.71-0.99). Also, a one point-increase in the number threatening SLE (\u00a0=\u00a01.92; \u00a0=\u00a0.028, 95% \u00a0=\u00a01.07-3.43) was related to higher 5-year recurrence.nnCONCLUSIONS: The findings highlight the necessity of studying not only a given situation (i.e., psychotherapy, SLE) but its specific impact on individuals.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('11','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_11\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND\/OBJECTIVE: Environmental factors such as psychosocial stress have demonstrated to have an impact on the breast cancer (BC) course. This study aims to explore the impact of psychotherapy and stressful life events (SLE) on BC survivors' illness trajectories.nnMETHOD: 68 women with BC underwent Positive Psychotherapy or Cognitive-Behavioral Stress Management and 37 patients were included as a control group. The effects of distress reduction and SLE on their 5-year recurrence were investigated. Additional analyses examined the effect of receiving vs. not receiving psychotherapy and of the type of therapy on survival and disease-free interval, DFI.nnRESULTS: A one-point decrease of the Hospital Anxiety and Depression Scale (HADS) after psychotherapy predicted a lower risk of 5-year recurrence, \u00a0=\u00a00.84, \u00a0=\u00a0.037, 95% \u00a0=\u00a00.71-0.99). Also, a one point-increase in the number threatening SLE (\u00a0=\u00a01.92; \u00a0=\u00a0.028, 95% \u00a0=\u00a01.07-3.43) was related to higher 5-year recurrence.nnCONCLUSIONS: The findings highlight the necessity of studying not only a given situation (i.e., psychotherapy, SLE) but its specific impact on individuals.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('11','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_11\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.ijchp.2022.100303\" title=\"Follow DOI:10.1016\/j.ijchp.2022.100303\" target=\"_blank\">doi:10.1016\/j.ijchp.2022.100303<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('11','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ib\u00e1\u00f1ez-Sanz  G,  Sanz-Pamplona  R,  Garcia  M, on behalf of the MSIC-SC research PhD  group. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('10','tp_links')\" style=\"cursor:pointer;\">Post-polypectomy colonoscopy surveillance: Can we improve the diagnostic yield?<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Gastroenterol Hepatol. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;45<\/span><span class=\"tp_pub_additional_pages\">:474\u2013487<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_10\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('10','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_10\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('10','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_10\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('10','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_10\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid34848307,<br \/>\r\ntitle = {Post-polypectomy colonoscopy surveillance: Can we improve the diagnostic yield?},<br \/>\r\nauthor = {Ib\u00e1\u00f1ez-Sanz G and Sanz-Pamplona R and Garcia M and PhD on behalf of the MSIC-SC research group},<br \/>\r\ndoi = {10.1016\/j.gastrohep.2021.11.005},<br \/>\r\nissn = {0210-5705},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-01-01},<br \/>\r\njournal = {Gastroenterol Hepatol},<br \/>\r\nvolume = {45},<br \/>\r\nnumber = {6},<br \/>\r\npages = {474--487},<br \/>\r\nabstract = {Although adenomas and serrated polyps are the preneoplastic lesions of colorectal cancer, only few of them will eventually progress to cancer. This review provides a comprehensive overview of the present and future of post-polypectomy colonoscopy surveillance. Post-polypectomy surveillance guidelines have recently been updated and all share the aim towards more selective and less frequent surveillance. We have examined these current guidelines and compared the recommendations of each of them. To improve the diagnostic yield of post-polypectomy surveillance it is important to find predictors of metachronous polyps that better identify high-risk individuals of developing advanced neoplasia. For this reason, we have also conducted a literature review of the molecular biomarkers of metachronous advanced colorectal polyps. Finally, we have discussed future directions of post-polypectomy surveillance and identified possible strategies to improve the use of endoscopic resources with the COVID-19 pandemic.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('10','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_10\" style=\"display:none;\"><div class=\"tp_abstract_entry\">Although adenomas and serrated polyps are the preneoplastic lesions of colorectal cancer, only few of them will eventually progress to cancer. This review provides a comprehensive overview of the present and future of post-polypectomy colonoscopy surveillance. Post-polypectomy surveillance guidelines have recently been updated and all share the aim towards more selective and less frequent surveillance. We have examined these current guidelines and compared the recommendations of each of them. To improve the diagnostic yield of post-polypectomy surveillance it is important to find predictors of metachronous polyps that better identify high-risk individuals of developing advanced neoplasia. For this reason, we have also conducted a literature review of the molecular biomarkers of metachronous advanced colorectal polyps. Finally, we have discussed future directions of post-polypectomy surveillance and identified possible strategies to improve the use of endoscopic resources with the COVID-19 pandemic.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('10','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_10\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.gastrohep.2021.11.005\" title=\"Follow DOI:10.1016\/j.gastrohep.2021.11.005\" target=\"_blank\">doi:10.1016\/j.gastrohep.2021.11.005<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('10','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Hern\u00e1ndez-Garc\u00eda  M,  Molina-Barcel\u00f3  A,  Vanaclocha-Espi  M,  Zurriaga  \u00d3,  P\u00e9rez-G\u00f3mez  B,  Aragon\u00e9s  N,  Amiano  P,  Altzibar  JM,  Casta\u00f1o-Vinyals  G,  Sala  M,  Ederra  M,  Mart\u00edn  V,  G\u00f3mez-Acebo  I,  Vidal  C,  Tard\u00f3n  A,  Marcos-Gragera  R,  Poll\u00e1n  M,  Kogevinas  M,  Salas  D. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('3','tp_links')\" style=\"cursor:pointer;\">Differences in breast cancer-risk factors between screen-detected and non-screen-detected cases (MCC-Spain study)<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Cancer Causes Control. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;33<\/span><span class=\"tp_pub_additional_pages\">:125\u2013136<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_3\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('3','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_3\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('3','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_3\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('3','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_3\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid34817770,<br \/>\r\ntitle = {Differences in breast cancer-risk factors between screen-detected and non-screen-detected cases (MCC-Spain study)},<br \/>\r\nauthor = {Hern\u00e1ndez-Garc\u00eda M and Molina-Barcel\u00f3 A and Vanaclocha-Espi M and Zurriaga \u00d3 and P\u00e9rez-G\u00f3mez B and Aragon\u00e9s N and Amiano P and Altzibar JM and Casta\u00f1o-Vinyals G and Sala M and Ederra M and Mart\u00edn V and G\u00f3mez-Acebo I and Vidal C and Tard\u00f3n A and Marcos-Gragera R and Poll\u00e1n M and Kogevinas M and Salas D},<br \/>\r\ndoi = {10.1007\/s10552-021-01511-4},<br \/>\r\nissn = {1573-7225},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-01-01},<br \/>\r\njournal = {Cancer Causes Control},<br \/>\r\nvolume = {33},<br \/>\r\nnumber = {1},<br \/>\r\npages = {125--136},<br \/>\r\nabstract = {PURPOSE: The variation in breast cancer (BC)-risk factor associations between screen-detected (SD) and non-screen-detected (NSD) tumors has been poorly studied, despite the interest of this aspect in risk assessment and prevention. This study analyzes the differences in breast cancer-risk factor associations according to detection method and tumor phenotype in Spanish women aged between 50 and 69.nnMETHODS: We examined 900 BC cases and 896 controls aged between 50 and 69, recruited in the multicase-control MCC-Spain study. With regard to the cases, 460 were detected by screening mammography, whereas 144 were diagnosed by other means. By tumor phenotype, 591 were HR+, 153 were HER2+, and 58 were TN. Lifestyle, reproductive factors, family history of BC, and tumor characteristics were analyzed. Logistic regression models were used to compare cases vs. controls and SD vs. NSD cases. Multinomial regression models (controls used as a reference) were adjusted for case analysis according to phenotype and detection method.nnRESULTS: TN was associated with a lower risk of SD BC (OR 0.30 IC 0.10-0.89), as were intermediate (OR 0.18 IC 0.07-0.44) and advanced stages at diagnosis (OR 0.11 IC 0.03-0.34). Nulliparity in postmenopausal women and age at menopause were related to an increased risk of SD BC (OR 1.60 IC 1.08-2.36; OR 1.48 IC 1.09-2.00, respectively). Nulliparity in postmenopausal women was associated with a higher risk of HR+ (OR 1.66 IC 1.15-2.40). Age at menopause was related to a greater risk of HR+ (OR 1.60 IC 1.22-2.11) and HER2+ (OR 1.59 IC 1.03-2.45) tumors.nnCONCLUSION: Reproductive risk factors are associated with SD BC, as are HR+ tumors. Differences in BC-risk factor associations according to detection method may be related to prevailing phenotypes among categories.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('3','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_3\" style=\"display:none;\"><div class=\"tp_abstract_entry\">PURPOSE: The variation in breast cancer (BC)-risk factor associations between screen-detected (SD) and non-screen-detected (NSD) tumors has been poorly studied, despite the interest of this aspect in risk assessment and prevention. This study analyzes the differences in breast cancer-risk factor associations according to detection method and tumor phenotype in Spanish women aged between 50 and 69.nnMETHODS: We examined 900 BC cases and 896 controls aged between 50 and 69, recruited in the multicase-control MCC-Spain study. With regard to the cases, 460 were detected by screening mammography, whereas 144 were diagnosed by other means. By tumor phenotype, 591 were HR+, 153 were HER2+, and 58 were TN. Lifestyle, reproductive factors, family history of BC, and tumor characteristics were analyzed. Logistic regression models were used to compare cases vs. controls and SD vs. NSD cases. Multinomial regression models (controls used as a reference) were adjusted for case analysis according to phenotype and detection method.nnRESULTS: TN was associated with a lower risk of SD BC (OR 0.30 IC 0.10-0.89), as were intermediate (OR 0.18 IC 0.07-0.44) and advanced stages at diagnosis (OR 0.11 IC 0.03-0.34). Nulliparity in postmenopausal women and age at menopause were related to an increased risk of SD BC (OR 1.60 IC 1.08-2.36; OR 1.48 IC 1.09-2.00, respectively). Nulliparity in postmenopausal women was associated with a higher risk of HR+ (OR 1.66 IC 1.15-2.40). Age at menopause was related to a greater risk of HR+ (OR 1.60 IC 1.22-2.11) and HER2+ (OR 1.59 IC 1.03-2.45) tumors.nnCONCLUSION: Reproductive risk factors are associated with SD BC, as are HR+ tumors. Differences in BC-risk factor associations according to detection method may be related to prevailing phenotypes among categories.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('3','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_3\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1007\/s10552-021-01511-4\" title=\"Follow DOI:10.1007\/s10552-021-01511-4\" target=\"_blank\">doi:10.1007\/s10552-021-01511-4<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('3','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Salinas-Huertas  S,  Luzardo-Gonz\u00e1lez  A,  V\u00e1zquez-Gallego  S,  Pernas  S,  Falo  C,  Pla  MJ,  Gil-Gil  M,  Beranuy-Rodriguez  M,  P\u00e9rez-Montero  H,  Gomila-Sancho  M,  Manent-Molina  N,  Arencibia-Dom\u00ednguez  A,  Gonzalez-Pineda  B,  Tormo-Collado  F,  Ort\u00ed-Asencio  M,  Terra  J,  Martinez-Perez  E,  Mestre-Jane  A,  Campos-Varela  I,  Jaraba-Armas  M,  Ben\u00edtez-Segura  A,  Campos-Delgado  M,  Fern\u00e1ndez-Montol\u00ed  ME,  Valverde-Alc\u00e1ntara  Y,  Rodr\u00edguez  A,  Campos  G,  Guma  A,  Ponce-Sebasti\u00e0  J,  Planas-Balagu\u00e9  R,  Catas\u00fas-Clav\u00e9  M,  Garc\u00eda-Tejedor  A. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('2','tp_links')\" style=\"cursor:pointer;\">Risk factors for lymphedema after breast surgery: A prospective cohort study in the era of sentinel lymph node biopsy<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Breast Dis. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;41<\/span><span class=\"tp_pub_additional_pages\">:97\u2013108<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_2\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('2','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_2\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('2','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_2\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('2','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_2\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid34542055,<br \/>\r\ntitle = {Risk factors for lymphedema after breast surgery: A prospective cohort study in the era of sentinel lymph node biopsy},<br \/>\r\nauthor = {Salinas-Huertas S and Luzardo-Gonz\u00e1lez A and V\u00e1zquez-Gallego S and Pernas S and Falo C and Pla MJ and Gil-Gil M and Beranuy-Rodriguez M and P\u00e9rez-Montero H and Gomila-Sancho M and Manent-Molina N and Arencibia-Dom\u00ednguez A and Gonzalez-Pineda B and Tormo-Collado F and Ort\u00ed-Asencio M and Terra J and Martinez-Perez E and Mestre-Jane A and Campos-Varela I and Jaraba-Armas M and Ben\u00edtez-Segura A and Campos-Delgado M and Fern\u00e1ndez-Montol\u00ed ME and Valverde-Alc\u00e1ntara Y and Rodr\u00edguez A and Campos G and Guma A and Ponce-Sebasti\u00e0 J and Planas-Balagu\u00e9 R and Catas\u00fas-Clav\u00e9 M and Garc\u00eda-Tejedor A},<br \/>\r\ndoi = {10.3233\/BD-210043},<br \/>\r\nissn = {1558-1551},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-01-01},<br \/>\r\njournal = {Breast Dis},<br \/>\r\nvolume = {41},<br \/>\r\nnumber = {1},<br \/>\r\npages = {97--108},<br \/>\r\nabstract = {INTRODUCTION: The Objective was to investigate the incidence of lymphedema after breast cancer treatment and to analyze the risk factors involved in a tertiary level hospital.nnMETHODS: Prospective longitudinal observational study over 3 years post-breast surgery. 232 patients undergoing surgery for breast cancer at our institution between September 2013 and February 2018. Sentinel lymph node biopsy (SLNB) or axillary lymphadenectomy (ALND) were mandatory in this cohort. In total, 201 patients met the inclusion criteria and had a median follow-up of 31 months (range, 1-54 months). Lymphedema was diagnosed by circumferential measurements and truncated cone calculations. Patients and tumor characteristics, shoulder range of motion limitation and local and systemic therapies were analyzed as possible risk factors for lymphedema.nnRESULTS: Most cases of lymphedema appeared in the first 2 years. 13.9% of patients developed lymphedema: 31% after ALND and 4.6% after SLNB (p <\u00a00.01), and 46.7% after mastectomy and 11.3% after breast-conserving surgery (p <\u00a00.01). The lymphedema rate increased when axillary radiotherapy (RT) was added to radical surgery: 4.3% for SLNB alone, 6.7% for SLNB + RT, 17.6% for ALND alone, and 35.2% for ALND + RT (p <\u00a00.01). In the multivariate analysis, the only risk factors associated with the development of lymphedema were ALND and mastectomy, which had hazard ratios (95% confidence intervals) of 7.28 (2.92-18.16) and 3.9 (1.60-9.49) respectively.nnCONCLUSIONS: The main risk factors for lymphedema were the more radical surgeries (ALND and mastectomy). The risk associated with these procedures appeared to be worsened by the addition of axillary radiotherapy. A follow-up protocol in patients with ALND lasting at least two years, in which special attention is paid to these risk factors, is necessary to guarantee a comprehensive control of lymphedema that provides early detection and treatment.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('2','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_2\" style=\"display:none;\"><div class=\"tp_abstract_entry\">INTRODUCTION: The Objective was to investigate the incidence of lymphedema after breast cancer treatment and to analyze the risk factors involved in a tertiary level hospital.nnMETHODS: Prospective longitudinal observational study over 3 years post-breast surgery. 232 patients undergoing surgery for breast cancer at our institution between September 2013 and February 2018. Sentinel lymph node biopsy (SLNB) or axillary lymphadenectomy (ALND) were mandatory in this cohort. In total, 201 patients met the inclusion criteria and had a median follow-up of 31 months (range, 1-54 months). Lymphedema was diagnosed by circumferential measurements and truncated cone calculations. Patients and tumor characteristics, shoulder range of motion limitation and local and systemic therapies were analyzed as possible risk factors for lymphedema.nnRESULTS: Most cases of lymphedema appeared in the first 2 years. 13.9% of patients developed lymphedema: 31% after ALND and 4.6% after SLNB (p <\u00a00.01), and 46.7% after mastectomy and 11.3% after breast-conserving surgery (p <\u00a00.01). The lymphedema rate increased when axillary radiotherapy (RT) was added to radical surgery: 4.3% for SLNB alone, 6.7% for SLNB + RT, 17.6% for ALND alone, and 35.2% for ALND + RT (p <\u00a00.01). In the multivariate analysis, the only risk factors associated with the development of lymphedema were ALND and mastectomy, which had hazard ratios (95% confidence intervals) of 7.28 (2.92-18.16) and 3.9 (1.60-9.49) respectively.nnCONCLUSIONS: The main risk factors for lymphedema were the more radical surgeries (ALND and mastectomy). The risk associated with these procedures appeared to be worsened by the addition of axillary radiotherapy. A follow-up protocol in patients with ALND lasting at least two years, in which special attention is paid to these risk factors, is necessary to guarantee a comprehensive control of lymphedema that provides early detection and treatment.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('2','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_2\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.3233\/BD-210043\" title=\"Follow DOI:10.3233\/BD-210043\" target=\"_blank\">doi:10.3233\/BD-210043<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('2','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Posso  M,  Alc\u00e1ntara  R,  V\u00e1zquez  I,  Comerma  L,  Bar\u00e9  M,  Louro  J,  Quintana  MJ,  Rom\u00e1n  M,  Marcos-Gragera  R,  Vernet-Tomas  M,  Saladie  F,  Vidal  C,  Bargall\u00f3  X,  Pe\u00f1alva  L,  Sala  M,  Castells  X, study BELE  group. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('1','tp_links')\" style=\"cursor:pointer;\">Mammographic features of benign breast lesions and risk of subsequent breast cancer in women attending breast cancer screening<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Eur Radiol. <\/span><span class=\"tp_pub_additional_year\">2022<\/span><span class=\"tp_pub_additional_volume\">;32<\/span><span class=\"tp_pub_additional_pages\">:621\u2013629<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_1\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('1','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_1\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('1','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_1\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('1','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_1\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid34156554,<br \/>\r\ntitle = {Mammographic features of benign breast lesions and risk of subsequent breast cancer in women attending breast cancer screening},<br \/>\r\nauthor = {Posso M and Alc\u00e1ntara R and V\u00e1zquez I and Comerma L and Bar\u00e9 M and Louro J and Quintana MJ and Rom\u00e1n M and Marcos-Gragera R and Vernet-Tomas M and Saladie F and Vidal C and Bargall\u00f3 X and Pe\u00f1alva L and Sala M and Castells X and BELE study group},<br \/>\r\ndoi = {10.1007\/s00330-021-08118-y},<br \/>\r\nissn = {1432-1084},<br \/>\r\nyear  = {2022},<br \/>\r\ndate = {2022-01-01},<br \/>\r\njournal = {Eur Radiol},<br \/>\r\nvolume = {32},<br \/>\r\nnumber = {1},<br \/>\r\npages = {621--629},<br \/>\r\nabstract = {OBJECTIVES: To evaluate the mammographic features in women with benign breast disease (BBD) and the risk of subsequent breast cancer according to their mammographic findings.nnMETHODS: We analyzed data from a Spanish cohort of women screened from 1995 to 2015 and followed up until December 2017 (median follow-up, 5.9 years). We included 10,650 women who had both histologically confirmed BBD and mammographic findings. We evaluated proliferative and nonproliferative BBD subtypes, and their mammographic features: architectural distortion, asymmetries, calcifications, masses, and multiple findings. The adjusted hazard ratios (aHR) and 95% confidence intervals (95% CI) for breast cancer were estimated using a Cox proportional hazards model. We plotted the adjusted cumulative incidence curves.nnRESULTS: Calcifications were more frequent in proliferative disease with atypia (43.9%) than without atypia (36.8%) or nonproliferative disease (22.2%; p value < 0.05). Masses were more frequent in nonproliferative lesions (59.1%) than in proliferative lesions without atypia (35.1%) or with atypia (30.0%; p value < 0.05). Multiple findings and architectural distortion were more likely in proliferative disease (16.1% and 4.7%) than in nonproliferative disease (12.8% and 1.9%). Subsequent breast cancer occurred in 268 (2.5%) women. Compared with women who had masses, the highest risk of subsequent breast cancer was found in those with architectural distortions (aHR, 2.21; 95% CI, 1.16-4.22), followed by those with multiple findings (aHR, 1.89; 95% CI, 1.34-2.66), asymmetries (aHR, 1.66; 95% CI, 0.84-3.28), and calcifications (aHR, 1.60; 95% CI, 1.21-2.12).nnCONCLUSION: BBD subtypes showed distinct mammographic findings. The risk of subsequent breast cancer was high in those who have shown architectural distortion, multiple findings, asymmetries, and calcifications than in women with masses.nnKEY POINTS: \u2022 The presence of mammographic findings in women attending breast cancer screening helps clinicians to assess women with benign breast disease (BBD). \u2022 Calcifications were frequent in BBDs with atypia, which are the ones with a high breast cancer risk, while masses were common in low-risk BBDs. \u2022 The excess risk of subsequent breast cancer in women with BBD was higher in those who showed architectural distortion compared to those with masses.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('1','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_1\" style=\"display:none;\"><div class=\"tp_abstract_entry\">OBJECTIVES: To evaluate the mammographic features in women with benign breast disease (BBD) and the risk of subsequent breast cancer according to their mammographic findings.nnMETHODS: We analyzed data from a Spanish cohort of women screened from 1995 to 2015 and followed up until December 2017 (median follow-up, 5.9 years). We included 10,650 women who had both histologically confirmed BBD and mammographic findings. We evaluated proliferative and nonproliferative BBD subtypes, and their mammographic features: architectural distortion, asymmetries, calcifications, masses, and multiple findings. The adjusted hazard ratios (aHR) and 95% confidence intervals (95% CI) for breast cancer were estimated using a Cox proportional hazards model. We plotted the adjusted cumulative incidence curves.nnRESULTS: Calcifications were more frequent in proliferative disease with atypia (43.9%) than without atypia (36.8%) or nonproliferative disease (22.2%; p value < 0.05). Masses were more frequent in nonproliferative lesions (59.1%) than in proliferative lesions without atypia (35.1%) or with atypia (30.0%; p value < 0.05). Multiple findings and architectural distortion were more likely in proliferative disease (16.1% and 4.7%) than in nonproliferative disease (12.8% and 1.9%). Subsequent breast cancer occurred in 268 (2.5%) women. Compared with women who had masses, the highest risk of subsequent breast cancer was found in those with architectural distortions (aHR, 2.21; 95% CI, 1.16-4.22), followed by those with multiple findings (aHR, 1.89; 95% CI, 1.34-2.66), asymmetries (aHR, 1.66; 95% CI, 0.84-3.28), and calcifications (aHR, 1.60; 95% CI, 1.21-2.12).nnCONCLUSION: BBD subtypes showed distinct mammographic findings. The risk of subsequent breast cancer was high in those who have shown architectural distortion, multiple findings, asymmetries, and calcifications than in women with masses.nnKEY POINTS: \u2022 The presence of mammographic findings in women attending breast cancer screening helps clinicians to assess women with benign breast disease (BBD). \u2022 Calcifications were frequent in BBDs with atypia, which are the ones with a high breast cancer risk, while masses were common in low-risk BBDs. \u2022 The excess risk of subsequent breast cancer in women with BBD was higher in those who showed architectural distortion compared to those with masses.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('1','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_1\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1007\/s00330-021-08118-y\" title=\"Follow DOI:10.1007\/s00330-021-08118-y\" target=\"_blank\">doi:10.1007\/s00330-021-08118-y<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('1','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><h3 class=\"tp_h3\" id=\"tp_h3_2021\">2021<\/h3><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ob\u00f3n-Santacana  M,  D\u00edez-Villanueva  A,  Alonso  MH,  Ib\u00e1\u00f1ez-Sanz  G,  Guin\u00f3  E,  L\u00f3pez  A,  Rodr\u00edguez-Alonso  L,  Mata  A,  Garc\u00eda-Rodr\u00edguez  A,  Palomo  AG,  Molina  AJ,  Garcia  M,  Binefa  G,  Mart\u00edn  V,  Moreno  V. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('34','tp_links')\" style=\"cursor:pointer;\">Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">BMC Med. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;19<\/span><span class=\"tp_pub_additional_pages\">:261<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_34\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('34','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_34\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('34','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_34\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('34','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_34\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid34743725,<br \/>\r\ntitle = {Polygenic risk score across distinct colorectal cancer screening outcomes: from premalignant polyps to colorectal cancer},<br \/>\r\nauthor = {Ob\u00f3n-Santacana M and D\u00edez-Villanueva A and Alonso MH and Ib\u00e1\u00f1ez-Sanz G and Guin\u00f3 E and L\u00f3pez A and Rodr\u00edguez-Alonso L and Mata A and Garc\u00eda-Rodr\u00edguez A and Palomo AG and Molina AJ and Garcia M and Binefa G and Mart\u00edn V and Moreno V},<br \/>\r\ndoi = {10.1186\/s12916-021-02134-x},<br \/>\r\nissn = {1741-7015},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-11-01},<br \/>\r\njournal = {BMC Med},<br \/>\r\nvolume = {19},<br \/>\r\nnumber = {1},<br \/>\r\npages = {261},<br \/>\r\nabstract = {BACKGROUND: Different risk-based colorectal cancer (CRC) screening strategies, such as the use of polygenic risk scores (PRS), have been evaluated to improve effectiveness of these programs. However, few studies have previously assessed its usefulness in a fecal immunochemical test (FIT)-based screening study.nnMETHODS: A PRS of 133 single nucleotide polymorphisms was assessed for 3619 participants: population controls, screening controls, low-risk lesions (LRL), intermediate-risk (IRL), high-risk (HRL), CRC screening program cases, and clinically diagnosed CRC cases. The PRS was compared between the subset of cases (n = 648; IRL+HRL+CRC) and controls (n = 956; controls+LRL) recruited within a FIT-based screening program. Positive predictive values (PPV), negative predictive values (NPV), and the area under the receiver operating characteristic curve (aROC) were estimated using cross-validation.nnRESULTS: The overall PRS range was 110-156. PRS values increased along the CRC tumorigenesis pathway (Mann-Kendall P value 0.007). Within the screening subset, the PRS ranged 110-151 and was associated with higher risk-lesions and CRC risk (OR 1.92, 95% CI 1.22-3.03). The cross-validated aROC of the PRS for cases and controls was 0.56 (95% CI 0.53-0.59). Discrimination was equal when restricted to positive FIT (aROC 0.56), but lower among negative FIT (aROC 0.55). The overall PPV among positive FIT was 0.48. PPV were dependent on the number of risk alleles for positive FIT (PPVp10-p90 0.48-0.57).nnCONCLUSIONS: PRS plays an important role along the CRC tumorigenesis pathway; however, in practice, its utility to stratify the general population or as a second test after a FIT positive result is still doubtful. Currently, PRS is not able to safely stratify the general population since the improvement on PPV values is scarce.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('34','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_34\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: Different risk-based colorectal cancer (CRC) screening strategies, such as the use of polygenic risk scores (PRS), have been evaluated to improve effectiveness of these programs. However, few studies have previously assessed its usefulness in a fecal immunochemical test (FIT)-based screening study.nnMETHODS: A PRS of 133 single nucleotide polymorphisms was assessed for 3619 participants: population controls, screening controls, low-risk lesions (LRL), intermediate-risk (IRL), high-risk (HRL), CRC screening program cases, and clinically diagnosed CRC cases. The PRS was compared between the subset of cases (n = 648; IRL+HRL+CRC) and controls (n = 956; controls+LRL) recruited within a FIT-based screening program. Positive predictive values (PPV), negative predictive values (NPV), and the area under the receiver operating characteristic curve (aROC) were estimated using cross-validation.nnRESULTS: The overall PRS range was 110-156. PRS values increased along the CRC tumorigenesis pathway (Mann-Kendall P value 0.007). Within the screening subset, the PRS ranged 110-151 and was associated with higher risk-lesions and CRC risk (OR 1.92, 95% CI 1.22-3.03). The cross-validated aROC of the PRS for cases and controls was 0.56 (95% CI 0.53-0.59). Discrimination was equal when restricted to positive FIT (aROC 0.56), but lower among negative FIT (aROC 0.55). The overall PPV among positive FIT was 0.48. PPV were dependent on the number of risk alleles for positive FIT (PPVp10-p90 0.48-0.57).nnCONCLUSIONS: PRS plays an important role along the CRC tumorigenesis pathway; however, in practice, its utility to stratify the general population or as a second test after a FIT positive result is still doubtful. Currently, PRS is not able to safely stratify the general population since the improvement on PPV values is scarce.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('34','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_34\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1186\/s12916-021-02134-x\" title=\"Follow DOI:10.1186\/s12916-021-02134-x\" target=\"_blank\">doi:10.1186\/s12916-021-02134-x<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('34','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\">of the Breast Screening Working Group (WG2)  Covid-19,  Cancer Global Modelling  Consortium,  Figueroa  JD,  Gray  E,  Pashayan  N,  Deandrea  S,  Karch  A,  Vale  DB,  Elder  K,  Procopio  P, van Ravesteyn NT,  Mutabi  M,  Canfell  K,  Nickson  C. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('31','tp_links')\" style=\"cursor:pointer;\">The impact of the Covid-19 pandemic on breast cancer early detection and screening<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Prev Med. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;151<\/span><span class=\"tp_pub_additional_pages\">:106585<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_31\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('31','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_31\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('31','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_31\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('31','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_31\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid34217412,<br \/>\r\ntitle = {The impact of the Covid-19 pandemic on breast cancer early detection and screening},<br \/>\r\nauthor = {Breast Screening Working Group (WG2) of the Covid-19 and Cancer Global Modelling Consortium and Figueroa JD and Gray E and Pashayan N and Deandrea S and Karch A and Vale DB and Elder K and Procopio P and van Ravesteyn NT and Mutabi M and Canfell K and Nickson C},<br \/>\r\ndoi = {10.1016\/j.ypmed.2021.106585},<br \/>\r\nissn = {1096-0260},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-10-01},<br \/>\r\njournal = {Prev Med},<br \/>\r\nvolume = {151},<br \/>\r\npages = {106585},<br \/>\r\nabstract = {The COVID-19 pandemic affects mortality and morbidity, with disruptions expected to continue for some time, with access to timely cancer-related services a concern. For breast cancer, early detection and treatment is key to improved survival and longer-term quality of life. Health services generally have been strained and in many settings with population breast mammography screening, efforts to diagnose and treat breast cancers earlier have been paused or have had reduced capacity. The resulting delays to diagnosis and treatment may lead to more intensive treatment requirements and, potentially, increased mortality. Modelled evaluations can support responses to the pandemic by estimating short- and long-term outcomes for various scenarios. Multiple calibrated and validated models exist for breast cancer screening, and some have been applied in 2020 to estimate the impact of breast screening disruptions and compare options for recovery, in a range of international settings. On behalf of the Covid and Cancer Modelling Consortium (CCGMC) Working Group 2 (Breast Cancer), we summarize and provide examples of such in a range of settings internationally, and propose priorities for future modelling exercises. International expert collaborations from the CCGMC Working Group 2 (Breast Cancer) will conduct analyses and modelling studies needed to inform key stakeholders recovery efforts in order to mitigate the impact of the pandemic on early diagnosis and treatment of breast cancer.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('31','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_31\" style=\"display:none;\"><div class=\"tp_abstract_entry\">The COVID-19 pandemic affects mortality and morbidity, with disruptions expected to continue for some time, with access to timely cancer-related services a concern. For breast cancer, early detection and treatment is key to improved survival and longer-term quality of life. Health services generally have been strained and in many settings with population breast mammography screening, efforts to diagnose and treat breast cancers earlier have been paused or have had reduced capacity. The resulting delays to diagnosis and treatment may lead to more intensive treatment requirements and, potentially, increased mortality. Modelled evaluations can support responses to the pandemic by estimating short- and long-term outcomes for various scenarios. Multiple calibrated and validated models exist for breast cancer screening, and some have been applied in 2020 to estimate the impact of breast screening disruptions and compare options for recovery, in a range of international settings. On behalf of the Covid and Cancer Modelling Consortium (CCGMC) Working Group 2 (Breast Cancer), we summarize and provide examples of such in a range of settings internationally, and propose priorities for future modelling exercises. International expert collaborations from the CCGMC Working Group 2 (Breast Cancer) will conduct analyses and modelling studies needed to inform key stakeholders recovery efforts in order to mitigate the impact of the pandemic on early diagnosis and treatment of breast cancer.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('31','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_31\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.ypmed.2021.106585\" title=\"Follow DOI:10.1016\/j.ypmed.2021.106585\" target=\"_blank\">doi:10.1016\/j.ypmed.2021.106585<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('31','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Diaz  M,  Garcia  M,  Vidal  C,  Santiago  A,  Gnutti  G,  G\u00f3mez  D,  Trapero-Bertran  M,  Fu  M, research Lung Cancer Prevention LUCAPREV  group. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('32','tp_links')\" style=\"cursor:pointer;\">Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Lung Cancer. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;159<\/span><span class=\"tp_pub_additional_pages\">:153\u2013161<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_32\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('32','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_32\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('32','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_32\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('32','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_32\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid34352591,<br \/>\r\ntitle = {Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis},<br \/>\r\nauthor = {Diaz M and Garcia M and Vidal C and Santiago A and Gnutti G and G\u00f3mez D and Trapero-Bertran M and Fu M and Lung Cancer Prevention LUCAPREV research group},<br \/>\r\ndoi = {10.1016\/j.lungcan.2021.06.027},<br \/>\r\nissn = {1872-8332},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-09-01},<br \/>\r\njournal = {Lung Cancer},<br \/>\r\nvolume = {159},<br \/>\r\npages = {153--161},<br \/>\r\nabstract = {OBJECTIVES: Robust economic evaluations are needed to identify efficient strategies for lung cancer prevention that combine brief and intensive smoking cessation intervention programmes with screening using low-dose computed tomography (LDCT) at different ages, frequencies, and coverages. We aimed to assess the cost-effectiveness of smoking cessation approaches combined with lung cancer screening in the European context at a population level from a societal perspective.nnMATERIALS AND METHODS: A microsimulation model that describes the natural history of lung cancer and incorporates several prevention strategies was developed. Discounted lifetime QALYs and costs at a rate of 3% were used to calculate incremental cost-effectiveness ratios, defined as additional costs in 2017 Euros per QALY gained.nnRESULTS: Smoking cessation interventions reduce the incidence of lung cancer by 8%-46% and are consistently more effective and cost-effective when starting at younger ages. Screening reduces lung cancer mortality by 1%-24% and is generally less effective and more costly than smoking cessation interventions. The most cost-effective strategy would be to implement intensive smoking cessation interventions at ages 35, 40 and 45, combined with screening every three years between the ages of 55 and 65.nnCONCLUSIONS: Combining smoking cessation interventions with LDCT screening is a very attractive prevention strategy that substantially diminishes the burden of lung cancer. These combined prevention strategies, especially when providing several intensive interventions for smoking cessation at early ages, are more cost-effective than both approaches separately and allow for a more intensified LDCT without losing efficiency.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('32','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_32\" style=\"display:none;\"><div class=\"tp_abstract_entry\">OBJECTIVES: Robust economic evaluations are needed to identify efficient strategies for lung cancer prevention that combine brief and intensive smoking cessation intervention programmes with screening using low-dose computed tomography (LDCT) at different ages, frequencies, and coverages. We aimed to assess the cost-effectiveness of smoking cessation approaches combined with lung cancer screening in the European context at a population level from a societal perspective.nnMATERIALS AND METHODS: A microsimulation model that describes the natural history of lung cancer and incorporates several prevention strategies was developed. Discounted lifetime QALYs and costs at a rate of 3% were used to calculate incremental cost-effectiveness ratios, defined as additional costs in 2017 Euros per QALY gained.nnRESULTS: Smoking cessation interventions reduce the incidence of lung cancer by 8%-46% and are consistently more effective and cost-effective when starting at younger ages. Screening reduces lung cancer mortality by 1%-24% and is generally less effective and more costly than smoking cessation interventions. The most cost-effective strategy would be to implement intensive smoking cessation interventions at ages 35, 40 and 45, combined with screening every three years between the ages of 55 and 65.nnCONCLUSIONS: Combining smoking cessation interventions with LDCT screening is a very attractive prevention strategy that substantially diminishes the burden of lung cancer. These combined prevention strategies, especially when providing several intensive interventions for smoking cessation at early ages, are more cost-effective than both approaches separately and allow for a more intensified LDCT without losing efficiency.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('32','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_32\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.lungcan.2021.06.027\" title=\"Follow DOI:10.1016\/j.lungcan.2021.06.027\" target=\"_blank\">doi:10.1016\/j.lungcan.2021.06.027<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('32','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Rom\u00e1n  M,  Louro  J,  Posso  M,  Alc\u00e1ntara  R,  Pe\u00f1alva  L,  Sala  M,  Del Riego  J,  Prieto  M,  Vidal  C,  S\u00e1nchez  M,  Bargall\u00f3  X,  Tusquets  I,  Castells  X. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('26','tp_links')\" style=\"cursor:pointer;\">Breast density, benign breast disease, and risk of breast cancer over time<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Eur Radiol. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;31<\/span><span class=\"tp_pub_additional_pages\">:4839\u20134847<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_26\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('26','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_26\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('26','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_26\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('26','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_26\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid33409776,<br \/>\r\ntitle = {Breast density, benign breast disease, and risk of breast cancer over time},<br \/>\r\nauthor = {Rom\u00e1n M and Louro J and Posso M and Alc\u00e1ntara R and Pe\u00f1alva L and Sala M and Del Riego J and Prieto M and Vidal C and S\u00e1nchez M and Bargall\u00f3 X and Tusquets I and Castells X},<br \/>\r\ndoi = {10.1007\/s00330-020-07490-5},<br \/>\r\nissn = {1432-1084},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-07-01},<br \/>\r\njournal = {Eur Radiol},<br \/>\r\nvolume = {31},<br \/>\r\nnumber = {7},<br \/>\r\npages = {4839--4847},<br \/>\r\nabstract = {OBJECTIVES: Assessing the combined effect of mammographic density and benign breast disease is of utmost importance to design personalized screening strategies.nnMETHODS: We analyzed individual-level data from 294,943 women aged 50-69 years with at least one mammographic screening participation in any of four areas of the Spanish Breast Cancer Screening Program from 1995 to 2015, and followed up until 2017. We used partly conditional Cox models to assess the association between benign breast disease, breast density, and the risk of breast cancer.nnRESULTS: During a median follow-up of 8.0 years, 3697 (1.25%) women had a breast cancer diagnosis and 5941 (2.01%) had a benign breast disease. More than half of screened women had scattered fibroglandular density (55.0%). The risk of breast cancer independently increased with the presence of benign breast disease and with the increase in breast density (p for interaction = 0.84). Women with benign breast disease and extremely dense breasts had a threefold elevated risk of breast cancer compared with those with scattered fibroglandular density and without benign breast disease (hazard ratio [HR] = 3.07; 95%CI = 2.01-4.68). Heterogeneous density and benign breast disease was associated with nearly a 2.5 elevated risk (HR = 2.48; 95%CI = 1.66-3.70). Those with extremely dense breast without a benign breast disease had a 2.27 increased risk (95%CI = 2.07-2.49).nnCONCLUSIONS: Women with benign breast disease had an elevated risk for over 15 years independently of their breast density category. Women with benign breast disease and dense breasts are at high risk for future breast cancer.nnKEY POINTS: \u2022 Benign breast disease and breast density were independently associated with breast cancer. \u2022 Women with benign breast disease had an elevated risk for up to 15 years independently of their mammographic density category.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('26','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_26\" style=\"display:none;\"><div class=\"tp_abstract_entry\">OBJECTIVES: Assessing the combined effect of mammographic density and benign breast disease is of utmost importance to design personalized screening strategies.nnMETHODS: We analyzed individual-level data from 294,943 women aged 50-69 years with at least one mammographic screening participation in any of four areas of the Spanish Breast Cancer Screening Program from 1995 to 2015, and followed up until 2017. We used partly conditional Cox models to assess the association between benign breast disease, breast density, and the risk of breast cancer.nnRESULTS: During a median follow-up of 8.0 years, 3697 (1.25%) women had a breast cancer diagnosis and 5941 (2.01%) had a benign breast disease. More than half of screened women had scattered fibroglandular density (55.0%). The risk of breast cancer independently increased with the presence of benign breast disease and with the increase in breast density (p for interaction = 0.84). Women with benign breast disease and extremely dense breasts had a threefold elevated risk of breast cancer compared with those with scattered fibroglandular density and without benign breast disease (hazard ratio [HR] = 3.07; 95%CI = 2.01-4.68). Heterogeneous density and benign breast disease was associated with nearly a 2.5 elevated risk (HR = 2.48; 95%CI = 1.66-3.70). Those with extremely dense breast without a benign breast disease had a 2.27 increased risk (95%CI = 2.07-2.49).nnCONCLUSIONS: Women with benign breast disease had an elevated risk for over 15 years independently of their breast density category. Women with benign breast disease and dense breasts are at high risk for future breast cancer.nnKEY POINTS: \u2022 Benign breast disease and breast density were independently associated with breast cancer. \u2022 Women with benign breast disease had an elevated risk for up to 15 years independently of their mammographic density category.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('26','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_26\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1007\/s00330-020-07490-5\" title=\"Follow DOI:10.1007\/s00330-020-07490-5\" target=\"_blank\">doi:10.1007\/s00330-020-07490-5<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('26','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Vives  N,  Mil\u00e0  N,  Binefa  G,  Travier  N,  Farre  A,  Vidal  C,  Sattari  M,  Bagaria  G,  Garcia  M. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('24','tp_links')\" style=\"cursor:pointer;\">Role of community pharmacies in a population-based colorectal cancer screening program<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Prev Med. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;145<\/span><span class=\"tp_pub_additional_pages\">:106420<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_24\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('24','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_24\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('24','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_24\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('24','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_24\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid33422578,<br \/>\r\ntitle = {Role of community pharmacies in a population-based colorectal cancer screening program},<br \/>\r\nauthor = {Vives N and Mil\u00e0 N and Binefa G and Travier N and Farre A and Vidal C and Sattari M and Bagaria G and Garcia M},<br \/>\r\ndoi = {10.1016\/j.ypmed.2021.106420},<br \/>\r\nissn = {1096-0260},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-04-01},<br \/>\r\njournal = {Prev Med},<br \/>\r\nvolume = {145},<br \/>\r\npages = {106420},<br \/>\r\nabstract = {In Catalonia (Spain), population-based colorectal cancer (CRC) screening offers biennial fecal occult blood testing to men and women aged 50-69\u00a0years old. The program is organized in screening hubs, most of which use a pharmacy-based model to distribute and collect fecal immunochemical test (FIT) kits The comprehensive evaluation of CRC screening programs, which include the role and implications of pharmacy involvement, is essential to ensure program quality and identify areas for further improvement. The present study aimed to assess the adherence of community pharmacies to the CRC screening program and to analyze data on FIT kit distribution and collection in the Metropolitan area of Barcelona (Catalonia, Spain). Time to FIT completion was assessed by Kaplan-Meier estimation, and with the log-rank test. A Cox regression model was used to adjust for other variables associated with the completion of FIT such as sex, age, deprivation score index and previous screening behavior. Overall, 82.4% of pharmacies adhered with CRC screening program. Out of 82,902 FIT kits distributed to screening invitees 77,524 completed FIT kits were returned to pharmacies (93.5%) with a participation of 39.8% among the 193,766 invitees. From those who completed a FIT, the median time to return the kit was 3\u00a0days. FIT completion time was significantly lower among women, older age, high deprivation score index and previous CRC screening (p\u00a0<\u00a00.005). Our findings highlight the large involvement of community pharmacists with CRC screening program as well as a high quality in the process of FIT distribution and collection.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('24','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_24\" style=\"display:none;\"><div class=\"tp_abstract_entry\">In Catalonia (Spain), population-based colorectal cancer (CRC) screening offers biennial fecal occult blood testing to men and women aged 50-69\u00a0years old. The program is organized in screening hubs, most of which use a pharmacy-based model to distribute and collect fecal immunochemical test (FIT) kits The comprehensive evaluation of CRC screening programs, which include the role and implications of pharmacy involvement, is essential to ensure program quality and identify areas for further improvement. The present study aimed to assess the adherence of community pharmacies to the CRC screening program and to analyze data on FIT kit distribution and collection in the Metropolitan area of Barcelona (Catalonia, Spain). Time to FIT completion was assessed by Kaplan-Meier estimation, and with the log-rank test. A Cox regression model was used to adjust for other variables associated with the completion of FIT such as sex, age, deprivation score index and previous screening behavior. Overall, 82.4% of pharmacies adhered with CRC screening program. Out of 82,902 FIT kits distributed to screening invitees 77,524 completed FIT kits were returned to pharmacies (93.5%) with a participation of 39.8% among the 193,766 invitees. From those who completed a FIT, the median time to return the kit was 3\u00a0days. FIT completion time was significantly lower among women, older age, high deprivation score index and previous CRC screening (p\u00a0<\u00a00.005). Our findings highlight the large involvement of community pharmacists with CRC screening program as well as a high quality in the process of FIT distribution and collection.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('24','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_24\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.ypmed.2021.106420\" title=\"Follow DOI:10.1016\/j.ypmed.2021.106420\" target=\"_blank\">doi:10.1016\/j.ypmed.2021.106420<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('24','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ib\u00e1\u00f1ez-Sanz  G,  Sanz-Pamplona  R,  Garcia  M,  On Behalf Of The Msic-Sc Research  Group. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('20','tp_links')\" style=\"cursor:pointer;\">Future Prospects of Colorectal Cancer Screening: Characterizing Interval Cancers<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Cancers (Basel). <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;13<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_20\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('20','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_20\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('20','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_20\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('20','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_20\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid33809520,<br \/>\r\ntitle = {Future Prospects of Colorectal Cancer Screening: Characterizing Interval Cancers},<br \/>\r\nauthor = {Ib\u00e1\u00f1ez-Sanz G and Sanz-Pamplona R and Garcia M and On Behalf Of The Msic-Sc Research Group },<br \/>\r\ndoi = {10.3390\/cancers13061328},<br \/>\r\nissn = {2072-6694},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-03-01},<br \/>\r\njournal = {Cancers (Basel)},<br \/>\r\nvolume = {13},<br \/>\r\nnumber = {6},<br \/>\r\nabstract = {Tumors that are not detected by screening tests are known as interval cancers and are diagnosed clinically after a negative result in the screening episode but before the next screening invitation. Clinical characteristics associated with interval colorectal cancers have been studied, but few molecular data are available that describe interval colorectal cancers. A better understanding of the clinical and biological characteristics associated with interval colorectal cancer may provide new insights into how to prevent this disease more effectively. This review aimed to summarize the current literature concerning interval colorectal cancer and its epidemiological, clinical, and molecular features.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('20','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_20\" style=\"display:none;\"><div class=\"tp_abstract_entry\">Tumors that are not detected by screening tests are known as interval cancers and are diagnosed clinically after a negative result in the screening episode but before the next screening invitation. Clinical characteristics associated with interval colorectal cancers have been studied, but few molecular data are available that describe interval colorectal cancers. A better understanding of the clinical and biological characteristics associated with interval colorectal cancer may provide new insights into how to prevent this disease more effectively. This review aimed to summarize the current literature concerning interval colorectal cancer and its epidemiological, clinical, and molecular features.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('20','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_20\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.3390\/cancers13061328\" title=\"Follow DOI:10.3390\/cancers13061328\" target=\"_blank\">doi:10.3390\/cancers13061328<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('20','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Vernet-Tom\u00e1s  M,  Louro  J,  Rom\u00e1n  M,  Saladi\u00e9  F,  Posso  M,  Prieto  M,  V\u00e1zquez  I,  Bar\u00e9  M,  Pe\u00f1alva  L,  Vidal  C,  Bargall\u00f3  X,  S\u00e1nchez  M,  Ferrer  J,  A Espin\u00e0s  J,  Quintana  MJ,  Rodr\u00edguez-Arana  A,  Castells  X, study BELE  group. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('27','tp_links')\" style=\"cursor:pointer;\">Risk of breast cancer two years after a benign biopsy depends on the mammographic feature prompting recall<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Maturitas. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;144<\/span><span class=\"tp_pub_additional_pages\">:53\u201359<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_27\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('27','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_27\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('27','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_27\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('27','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_27\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid33358209,<br \/>\r\ntitle = {Risk of breast cancer two years after a benign biopsy depends on the mammographic feature prompting recall},<br \/>\r\nauthor = {Vernet-Tom\u00e1s M and Louro J and Rom\u00e1n M and Saladi\u00e9 F and Posso M and Prieto M and V\u00e1zquez I and Bar\u00e9 M and Pe\u00f1alva L and Vidal C and Bargall\u00f3 X and S\u00e1nchez M and Ferrer J and A Espin\u00e0s J and Quintana MJ and Rodr\u00edguez-Arana A and Castells X and BELE study group},<br \/>\r\ndoi = {10.1016\/j.maturitas.2020.10.024},<br \/>\r\nissn = {1873-4111},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-02-01},<br \/>\r\njournal = {Maturitas},<br \/>\r\nvolume = {144},<br \/>\r\npages = {53--59},<br \/>\r\nabstract = {OBJECTIVE: We aimed to explore whether the type of mammographic feature prompting a false-positive recall (FPR) during mammography screening influences the risk and timing of breast cancer diagnosis, particularly if assessed with invasive procedures.nnSTUDY DESIGN: We included information on women screened and recalled for further assessment in Spain between 1994 and 2015, with follow-up until 2017, categorizing FPRs by the assessment (noninvasive or invasive) and mammographic feature prompting the recall.nnMAIN OUTCOME MEASURES: Breast cancer rates in the first two years after FPR (first period) and after two years (second period).nnRESULTS: The study included 99,825 women with FPRs. In both periods, the breast cancer rate was higher in the invasive assessment group than in the noninvasive group (first period 12 \u2030 vs 1.9 \u2030, p\u202f<\u202f0.001; second period 4.4\u2030 vs 3.1\u2030, p\u202f<\u202f0.001). During the first period, the invasive assessment group showed diverse breast cancer rates for each type of mammographic feature, with a higher rate for asymmetric density (31.9\u2030). When the second period was compared with the first, the breast cancer rate decreased in the invasive assessment group (from 12\u2030 to 4.4\u2030, p\u202f<\u202f0.001) and increased in the noninvasive assessment group (from 1.9\u2030 to 3.1\u2030, p\u202f<\u202f0.001).nnCONCLUSION: In the context of mammography screening, the risk of breast cancer diagnosis during the first two years after FPR was particularly high for women undergoing invasive assessment; importantly, the risk was modified by type of mammographic feature prompting the recall. This information could help to individualize follow-up after exclusion of malignancy.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('27','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_27\" style=\"display:none;\"><div class=\"tp_abstract_entry\">OBJECTIVE: We aimed to explore whether the type of mammographic feature prompting a false-positive recall (FPR) during mammography screening influences the risk and timing of breast cancer diagnosis, particularly if assessed with invasive procedures.nnSTUDY DESIGN: We included information on women screened and recalled for further assessment in Spain between 1994 and 2015, with follow-up until 2017, categorizing FPRs by the assessment (noninvasive or invasive) and mammographic feature prompting the recall.nnMAIN OUTCOME MEASURES: Breast cancer rates in the first two years after FPR (first period) and after two years (second period).nnRESULTS: The study included 99,825 women with FPRs. In both periods, the breast cancer rate was higher in the invasive assessment group than in the noninvasive group (first period 12 \u2030 vs 1.9 \u2030, p\u202f<\u202f0.001; second period 4.4\u2030 vs 3.1\u2030, p\u202f<\u202f0.001). During the first period, the invasive assessment group showed diverse breast cancer rates for each type of mammographic feature, with a higher rate for asymmetric density (31.9\u2030). When the second period was compared with the first, the breast cancer rate decreased in the invasive assessment group (from 12\u2030 to 4.4\u2030, p\u202f<\u202f0.001) and increased in the noninvasive assessment group (from 1.9\u2030 to 3.1\u2030, p\u202f<\u202f0.001).nnCONCLUSION: In the context of mammography screening, the risk of breast cancer diagnosis during the first two years after FPR was particularly high for women undergoing invasive assessment; importantly, the risk was modified by type of mammographic feature prompting the recall. This information could help to individualize follow-up after exclusion of malignancy.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('27','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_27\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.maturitas.2020.10.024\" title=\"Follow DOI:10.1016\/j.maturitas.2020.10.024\" target=\"_blank\">doi:10.1016\/j.maturitas.2020.10.024<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('27','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Louro  J,  Rom\u00e1n  M,  Posso  M,  V\u00e1zquez  I,  Saladi\u00e9  F,  Rodriguez-Arana  A,  Quintana  MJ,  Domingo  L,  Bar\u00e9  M,  Marcos-Gragera  R,  Vernet-Tomas  M,  Sala  M,  Castells  X,  BELE,  IRIS Study  Groups. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('33','tp_links')\" style=\"cursor:pointer;\">Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">PLoS One. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;16<\/span><span class=\"tp_pub_additional_pages\">:e0248930<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_33\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('33','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_33\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('33','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_33\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('33','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_33\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid33755692,<br \/>\r\ntitle = {Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening},<br \/>\r\nauthor = {Louro J and Rom\u00e1n M and Posso M and V\u00e1zquez I and Saladi\u00e9 F and Rodriguez-Arana A and Quintana MJ and Domingo L and Bar\u00e9 M and Marcos-Gragera R and Vernet-Tomas M and Sala M and Castells X and BELE and IRIS Study Groups},<br \/>\r\ndoi = {10.1371\/journal.pone.0248930},<br \/>\r\nissn = {1932-6203},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-01-01},<br \/>\r\njournal = {PLoS One},<br \/>\r\nvolume = {16},<br \/>\r\nnumber = {3},<br \/>\r\npages = {e0248930},<br \/>\r\nabstract = {BACKGROUND: Several studies have proposed personalized strategies based on women's individual breast cancer risk to improve the effectiveness of breast cancer screening. We designed and internally validated an individualized risk prediction model for women eligible for mammography screening.nnMETHODS: Retrospective cohort study of 121,969 women aged 50 to 69 years, screened at the long-standing population-based screening program in Spain between 1995 and 2015 and followed up until 2017. We used partly conditional Cox proportional hazards regression to estimate the adjusted hazard ratios (aHR) and individual risks for age, family history of breast cancer, previous benign breast disease, and previous mammographic features. We internally validated our model with the expected-to-observed ratio and the area under the receiver operating characteristic curve.nnRESULTS: During a mean follow-up of 7.5 years, 2,058 women were diagnosed with breast cancer. All three risk factors were strongly associated with breast cancer risk, with the highest risk being found among women with family history of breast cancer (aHR: 1.67), a proliferative benign breast disease (aHR: 3.02) and previous calcifications (aHR: 2.52). The model was well calibrated overall (expected-to-observed ratio ranging from 0.99 at 2 years to 1.02 at 20 years) but slightly overestimated the risk in women with proliferative benign breast disease. The area under the receiver operating characteristic curve ranged from 58.7% to 64.7%, depending of the time horizon selected.nnCONCLUSIONS: We developed a risk prediction model to estimate the short- and long-term risk of breast cancer in women eligible for mammography screening using information routinely reported at screening participation. The model could help to guiding individualized screening strategies aimed at improving the risk-benefit balance of mammography screening programs.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('33','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_33\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: Several studies have proposed personalized strategies based on women's individual breast cancer risk to improve the effectiveness of breast cancer screening. We designed and internally validated an individualized risk prediction model for women eligible for mammography screening.nnMETHODS: Retrospective cohort study of 121,969 women aged 50 to 69 years, screened at the long-standing population-based screening program in Spain between 1995 and 2015 and followed up until 2017. We used partly conditional Cox proportional hazards regression to estimate the adjusted hazard ratios (aHR) and individual risks for age, family history of breast cancer, previous benign breast disease, and previous mammographic features. We internally validated our model with the expected-to-observed ratio and the area under the receiver operating characteristic curve.nnRESULTS: During a mean follow-up of 7.5 years, 2,058 women were diagnosed with breast cancer. All three risk factors were strongly associated with breast cancer risk, with the highest risk being found among women with family history of breast cancer (aHR: 1.67), a proliferative benign breast disease (aHR: 3.02) and previous calcifications (aHR: 2.52). The model was well calibrated overall (expected-to-observed ratio ranging from 0.99 at 2 years to 1.02 at 20 years) but slightly overestimated the risk in women with proliferative benign breast disease. The area under the receiver operating characteristic curve ranged from 58.7% to 64.7%, depending of the time horizon selected.nnCONCLUSIONS: We developed a risk prediction model to estimate the short- and long-term risk of breast cancer in women eligible for mammography screening using information routinely reported at screening participation. The model could help to guiding individualized screening strategies aimed at improving the risk-benefit balance of mammography screening programs.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('33','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_33\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1371\/journal.pone.0248930\" title=\"Follow DOI:10.1371\/journal.pone.0248930\" target=\"_blank\">doi:10.1371\/journal.pone.0248930<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('33','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ib\u00e1\u00f1ez-Sanz  G,  Mil\u00e0  N,  Vidal  C,  Rocamora  J,  Moreno  V,  Sanz-Pamplona  R,  Garcia  M, research MSIC-SC  group. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('30','tp_links')\" style=\"cursor:pointer;\">Positive impact of a faecal-based screening programme on colorectal cancer mortality risk<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">PLoS One. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;16<\/span><span class=\"tp_pub_additional_pages\">:e0253369<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_30\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('30','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_30\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('30','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_30\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('30','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_30\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid34191813,<br \/>\r\ntitle = {Positive impact of a faecal-based screening programme on colorectal cancer mortality risk},<br \/>\r\nauthor = {Ib\u00e1\u00f1ez-Sanz G and Mil\u00e0 N and Vidal C and Rocamora J and Moreno V and Sanz-Pamplona R and Garcia M and MSIC-SC research group},<br \/>\r\ndoi = {10.1371\/journal.pone.0253369},<br \/>\r\nissn = {1932-6203},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-01-01},<br \/>\r\njournal = {PLoS One},<br \/>\r\nvolume = {16},<br \/>\r\nnumber = {6},<br \/>\r\npages = {e0253369},<br \/>\r\nabstract = {INTRODUCTION: The effectiveness of colorectal cancer (CRC) screening programs is directly related to participation and the number of interval CRCs. The objective was to analyse specific-mortality in a cohort of individuals invited to a CRC screening program according to type of CRC diagnosis (screen-detected cancers, interval cancers, and cancers among the non-uptake group).nnMATERIAL AND METHODS: Retrospective cohort that included invitees aged 50-69 years of a CRC screening program (target population of 85,000 people) in Catalonia (Spain) from 2000-2015 with mortality follow-up until 2020. A screen-detected CRC was a cancer diagnosed after a positive faecal occult blood test (guaiac or immunochemical); an interval cancer was a cancer diagnosed after a negative test result and before the next invitation to the program (\u226424 months); a non-uptake cancer was a cancer in subjects who declined screening.nnRESULTS: A total of 624 people were diagnosed with CRC (n = 265 screen-detected, n = 103 interval cancers, n = 256 non-uptake). In the multivariate analysis, we observed a 74% increase in mortality rate in the group with interval CRC compared to screen-detected CRC adjusted for age, sex, location and stage (HR: 1.74%, 95% CI:1.08-2.82, P = 0.02). These differences were found even when we restricted for advanced-cancers participants. In the stratified analysis for type of faecal occult blood test, a lower mortality rate was only observed among FIT screen-detected CRCs.nnCONCLUSION: CRC screening with the FIT was associated with a significant reduction in CRC mortality.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('30','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_30\" style=\"display:none;\"><div class=\"tp_abstract_entry\">INTRODUCTION: The effectiveness of colorectal cancer (CRC) screening programs is directly related to participation and the number of interval CRCs. The objective was to analyse specific-mortality in a cohort of individuals invited to a CRC screening program according to type of CRC diagnosis (screen-detected cancers, interval cancers, and cancers among the non-uptake group).nnMATERIAL AND METHODS: Retrospective cohort that included invitees aged 50-69 years of a CRC screening program (target population of 85,000 people) in Catalonia (Spain) from 2000-2015 with mortality follow-up until 2020. A screen-detected CRC was a cancer diagnosed after a positive faecal occult blood test (guaiac or immunochemical); an interval cancer was a cancer diagnosed after a negative test result and before the next invitation to the program (\u226424 months); a non-uptake cancer was a cancer in subjects who declined screening.nnRESULTS: A total of 624 people were diagnosed with CRC (n = 265 screen-detected, n = 103 interval cancers, n = 256 non-uptake). In the multivariate analysis, we observed a 74% increase in mortality rate in the group with interval CRC compared to screen-detected CRC adjusted for age, sex, location and stage (HR: 1.74%, 95% CI:1.08-2.82, P = 0.02). These differences were found even when we restricted for advanced-cancers participants. In the stratified analysis for type of faecal occult blood test, a lower mortality rate was only observed among FIT screen-detected CRCs.nnCONCLUSION: CRC screening with the FIT was associated with a significant reduction in CRC mortality.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('30','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_30\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1371\/journal.pone.0253369\" title=\"Follow DOI:10.1371\/journal.pone.0253369\" target=\"_blank\">doi:10.1371\/journal.pone.0253369<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('30','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Agust\u00ed  C,  Mu\u00f1oz  R,  Gonz\u00e1lez  V,  Villegas  L,  Fibla  J,  Mero\u00f1o  M,  Capit\u00e1n  A,  Fern\u00e0ndez-L\u00f3pez  L,  Platteau  T,  Casabona  J. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('29','tp_links')\" style=\"cursor:pointer;\">Outreach HIV testing using oral fluid and online consultation of the results: Pilot intervention in Catalonia<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Enferm Infecc Microbiol Clin (Engl Ed). <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;39<\/span><span class=\"tp_pub_additional_pages\">:3\u20138<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_29\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('29','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_29\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('29','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_29\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('29','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_29\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid32151468,<br \/>\r\ntitle = {Outreach HIV testing using oral fluid and online consultation of the results: Pilot intervention in Catalonia},<br \/>\r\nauthor = {Agust\u00ed C and Mu\u00f1oz R and Gonz\u00e1lez V and Villegas L and Fibla J and Mero\u00f1o M and Capit\u00e1n A and Fern\u00e0ndez-L\u00f3pez L and Platteau T and Casabona J},<br \/>\r\ndoi = {10.1016\/j.eimc.2020.01.020},<br \/>\r\nissn = {2529-993X},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-01-01},<br \/>\r\njournal = {Enferm Infecc Microbiol Clin (Engl Ed)},<br \/>\r\nvolume = {39},<br \/>\r\nnumber = {1},<br \/>\r\npages = {3--8},<br \/>\r\nabstract = {INTRODUCTION: The aim of the intervention was to describe the feasibility and cost-effectiveness of offering HIV testing in outreach interventions and subsequent consultation of the results through a secure web page.nnMETHODS: The HIV test was offered \"in situ\" to men who have sex with men (MSM), migrant sex workers and trans women recruited in places of leisure and sex. Four collaborating NGOs recruited the participants and assisted them to register on the study website (www.swab2know.eu) through a tablet or the smartphone of the same participant. The samples were sent to the reference laboratory and the results were published on the website.nnRESULTS: 834 participants (612 MSMs, 203 women sex workers and 19 trans women) were recruited. In total 22 reagent results (2.6%) were detected: 21 among MSMs (3.4%) and 1 in a trans women (5.3%). While 82.6% of MSMs consulted their outcome, only 39.9% and 26.3% of women sex workers and trans women respectively consulted their outcome CONCLUSIONS: Providing self-sampling in outreach activities, dispatch and analysis in a reference laboratory as well as online communication of test results is feasible. A high proportion of participants with a HIV reactive result\u00a0were detected among MSMs and trans women.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('29','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_29\" style=\"display:none;\"><div class=\"tp_abstract_entry\">INTRODUCTION: The aim of the intervention was to describe the feasibility and cost-effectiveness of offering HIV testing in outreach interventions and subsequent consultation of the results through a secure web page.nnMETHODS: The HIV test was offered \"in situ\" to men who have sex with men (MSM), migrant sex workers and trans women recruited in places of leisure and sex. Four collaborating NGOs recruited the participants and assisted them to register on the study website (www.swab2know.eu) through a tablet or the smartphone of the same participant. The samples were sent to the reference laboratory and the results were published on the website.nnRESULTS: 834 participants (612 MSMs, 203 women sex workers and 19 trans women) were recruited. In total 22 reagent results (2.6%) were detected: 21 among MSMs (3.4%) and 1 in a trans women (5.3%). While 82.6% of MSMs consulted their outcome, only 39.9% and 26.3% of women sex workers and trans women respectively consulted their outcome CONCLUSIONS: Providing self-sampling in outreach activities, dispatch and analysis in a reference laboratory as well as online communication of test results is feasible. A high proportion of participants with a HIV reactive result\u00a0were detected among MSMs and trans women.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('29','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_29\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.eimc.2020.01.020\" title=\"Follow DOI:10.1016\/j.eimc.2020.01.020\" target=\"_blank\">doi:10.1016\/j.eimc.2020.01.020<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('29','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Ib\u00e1\u00f1ez-Sanz  G,  Mil\u00e0  N, de la Pe\u00f1a-Negro LC,  Garcia  M,  Vidal  C,  Rodr\u00edguez-Alonso  L,  Binefa  G,  Rodr\u00edguez-Moranta  F,  Moreno  V. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('28','tp_links')\" style=\"cursor:pointer;\">Proton-pump inhibitors are associated with a high false-positivity rate in faecal immunochemical testing<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">J Gastroenterol. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;56<\/span><span class=\"tp_pub_additional_pages\">:42\u201353<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_28\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('28','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_28\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('28','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_28\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('28','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_28\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid33159805,<br \/>\r\ntitle = {Proton-pump inhibitors are associated with a high false-positivity rate in faecal immunochemical testing},<br \/>\r\nauthor = {Ib\u00e1\u00f1ez-Sanz G and Mil\u00e0 N and de la Pe\u00f1a-Negro LC and Garcia M and Vidal C and Rodr\u00edguez-Alonso L and Binefa G and Rodr\u00edguez-Moranta F and Moreno V},<br \/>\r\ndoi = {10.1007\/s00535-020-01738-z},<br \/>\r\nissn = {1435-5922},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-01-01},<br \/>\r\njournal = {J Gastroenterol},<br \/>\r\nvolume = {56},<br \/>\r\nnumber = {1},<br \/>\r\npages = {42--53},<br \/>\r\nabstract = {BACKGROUND: False-positivity rates in faecal immunochemical test (FIT) can be affected by drug exposure. We aimed to assess the association between proton pump inhibitors (PPI) consumption and false positive (FP) results in a colorectal cancer (CRC) screening programme using electronic prescription records.nnMETHODS: A retrospective cohort study within a population-based screening program for CRC from 2010 to 2016 was performed. Participants with a conclusive FIT result and with prescription electronic data were included. An FP result was defined as having a positive FIT (\u2265\u200920\u00a0\u00b5g haemoglobin\/g faeces) and a follow-up colonoscopy without intermediate or high-risk lesions or CRC. Screening data were anonymously linked to the public data analysis program for health research and innovation (PADRIS) database that recorded patient diseases history and reimbursed medication. PPI exposure was defined as having retrieved at least one dispensation of PPI three months prior to the FIT.nnRESULTS: A total of 89,199 tests (of 46,783 participants) were analysed, 4824 (5.4%) tested positive and the proportion of FP was 53.5%. Overall, 17,544 participants (19.7%) were PPI users prior to FIT performance. PPI exposure increased the probability of obtaining an FP FIT result from 50.4 to 63.3% (adjusted OR 1.39; 95% CI 1.18-1.65). Nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, antibiotics, and laxatives were also associated with an FP result. The effect of PPI was independent and showed a synergistic interaction with nonsteroidal anti-inflammatory drugs.nnCONCLUSION: PPIs increase FIT positivity at the expense of FP results. The recommendation to avoid their use before FIT performance could reduce up to 3% of colonoscopies and 9% of FP results.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('28','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_28\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: False-positivity rates in faecal immunochemical test (FIT) can be affected by drug exposure. We aimed to assess the association between proton pump inhibitors (PPI) consumption and false positive (FP) results in a colorectal cancer (CRC) screening programme using electronic prescription records.nnMETHODS: A retrospective cohort study within a population-based screening program for CRC from 2010 to 2016 was performed. Participants with a conclusive FIT result and with prescription electronic data were included. An FP result was defined as having a positive FIT (\u2265\u200920\u00a0\u00b5g haemoglobin\/g faeces) and a follow-up colonoscopy without intermediate or high-risk lesions or CRC. Screening data were anonymously linked to the public data analysis program for health research and innovation (PADRIS) database that recorded patient diseases history and reimbursed medication. PPI exposure was defined as having retrieved at least one dispensation of PPI three months prior to the FIT.nnRESULTS: A total of 89,199 tests (of 46,783 participants) were analysed, 4824 (5.4%) tested positive and the proportion of FP was 53.5%. Overall, 17,544 participants (19.7%) were PPI users prior to FIT performance. PPI exposure increased the probability of obtaining an FP FIT result from 50.4 to 63.3% (adjusted OR 1.39; 95% CI 1.18-1.65). Nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, antibiotics, and laxatives were also associated with an FP result. The effect of PPI was independent and showed a synergistic interaction with nonsteroidal anti-inflammatory drugs.nnCONCLUSION: PPIs increase FIT positivity at the expense of FP results. The recommendation to avoid their use before FIT performance could reduce up to 3% of colonoscopies and 9% of FP results.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('28','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_28\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1007\/s00535-020-01738-z\" title=\"Follow DOI:10.1007\/s00535-020-01738-z\" target=\"_blank\">doi:10.1007\/s00535-020-01738-z<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('28','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Pons-Rodr\u00edguez  A,  Mart\u00ednez-Alonso  M,  Perestelo-P\u00e9rez  L,  Garcia  M,  Sala  M,  Ru\u00e9  M, en nombre del grupo InforMa, grupo InforMa est\u00e1 formado El  por. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('25','tp_links')\" style=\"cursor:pointer;\">[Informed choice in breast cancer screening: the role of education]<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Gac Sanit. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;35<\/span><span class=\"tp_pub_additional_pages\">:243\u2013249<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_25\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('25','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_25\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('25','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_25\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('25','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_25\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid32173050,<br \/>\r\ntitle = {[Informed choice in breast cancer screening: the role of education]},<br \/>\r\nauthor = {Pons-Rodr\u00edguez A and Mart\u00ednez-Alonso M and Perestelo-P\u00e9rez L and Garcia M and Sala M and Ru\u00e9 M and en nombre del grupo InforMa and El grupo InforMa est\u00e1 formado por},<br \/>\r\ndoi = {10.1016\/j.gaceta.2020.01.002},<br \/>\r\nissn = {1578-1283},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-01-01},<br \/>\r\njournal = {Gac Sanit},<br \/>\r\nvolume = {35},<br \/>\r\nnumber = {3},<br \/>\r\npages = {243--249},<br \/>\r\nabstract = {OBJECTIVE: To evaluate the effect of receiving information about the benefits and harms of breast cancer screening in informed choice, according to educational level.nnMETHOD: Secondary analysis of a randomized, controlled study, in four screening programs, in Catalonia and the Canary Islands (Spain). We analyzed 400 women who were going to be invited to participate for the first time. The intervention group received a decision aid that showed the benefits and harms of screening. The control group received a standard brochure that recommended participating in the screening program. Educational level was grouped into two categories, low and high. The primary outcome was informed choice defined as adequate knowledge and consistency between attitudes and intentions.nnRESULTS: The intervention produced a greater increase in knowledge in women with a high educational level compared to those with a lower educational level. Among women who received the intervention, informed choice was almost three times higher in those with a high educational level (27% versus 11%). No differences were observed between educational levels in decisional conflict, confidence in the decision, anxiety and worry about breast cancer, in the intervention and control groups.nnCONCLUSIONS: A decision aid for breast cancer screening had much more impact on informed choice among women with a high educational level. In women with low educational level, the attitude towards screening improved and there was an increase in the intention to be screened.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('25','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_25\" style=\"display:none;\"><div class=\"tp_abstract_entry\">OBJECTIVE: To evaluate the effect of receiving information about the benefits and harms of breast cancer screening in informed choice, according to educational level.nnMETHOD: Secondary analysis of a randomized, controlled study, in four screening programs, in Catalonia and the Canary Islands (Spain). We analyzed 400 women who were going to be invited to participate for the first time. The intervention group received a decision aid that showed the benefits and harms of screening. The control group received a standard brochure that recommended participating in the screening program. Educational level was grouped into two categories, low and high. The primary outcome was informed choice defined as adequate knowledge and consistency between attitudes and intentions.nnRESULTS: The intervention produced a greater increase in knowledge in women with a high educational level compared to those with a lower educational level. Among women who received the intervention, informed choice was almost three times higher in those with a high educational level (27% versus 11%). No differences were observed between educational levels in decisional conflict, confidence in the decision, anxiety and worry about breast cancer, in the intervention and control groups.nnCONCLUSIONS: A decision aid for breast cancer screening had much more impact on informed choice among women with a high educational level. In women with low educational level, the attitude towards screening improved and there was an increase in the intention to be screened.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('25','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_25\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.gaceta.2020.01.002\" title=\"Follow DOI:10.1016\/j.gaceta.2020.01.002\" target=\"_blank\">doi:10.1016\/j.gaceta.2020.01.002<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('25','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Vives  N,  Farre  A,  Ib\u00e1\u00f1ez-Sanz  G,  Vidal  C,  Binefa  G,  Mil\u00e0  N,  P\u00e9rez-Lacasta  MJ,  Travier  N,  Benito  L,  Espin\u00e0s  JA,  Bagaria  G,  Garcia  M. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('22','tp_links')\" style=\"cursor:pointer;\">Text messaging as a tool to improve cancer screening programs (M-TICS Study): A randomized controlled trial protocol<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">PLoS One. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;16<\/span><span class=\"tp_pub_additional_pages\">:e0245806<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_22\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('22','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_22\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('22','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_22\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('22','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_22\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid33481914,<br \/>\r\ntitle = {Text messaging as a tool to improve cancer screening programs (M-TICS Study): A randomized controlled trial protocol},<br \/>\r\nauthor = {Vives N and Farre A and Ib\u00e1\u00f1ez-Sanz G and Vidal C and Binefa G and Mil\u00e0 N and P\u00e9rez-Lacasta MJ and Travier N and Benito L and Espin\u00e0s JA and Bagaria G and Garcia M},<br \/>\r\ndoi = {10.1371\/journal.pone.0245806},<br \/>\r\nissn = {1932-6203},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-01-01},<br \/>\r\njournal = {PLoS One},<br \/>\r\nvolume = {16},<br \/>\r\nnumber = {1},<br \/>\r\npages = {e0245806},<br \/>\r\nabstract = {BACKGROUND: Short message service (SMS) based interventions are widely used in healthcare and have shown promising results to improve cancer screening programs. However, more research is still needed to implement SMS in the screening process. We present a study protocol to assess the impact on health and economics of three targeted SMS-based interventions in population-based cancer screening programs.nnMETHODS\/DESIGN: The M-TICs study is a randomized controlled trial with a formal process evaluation. Participants aged 50-69 years identified as eligible from the colorectal cancer (CRC) and breast cancer (BC) screening program of the Catalan Institute of Oncology (Catalonia, Spain) will be randomly assigned to receive standard invitation procedure (control group) or SMS-based intervention to promote participation. Two interventions will be conducted in the CRC screening program: 1) Screening invitation reminder: Those who do not participate in the CRC screening within 6 weeks of invite will receive a reminder (SMS or letter); 2) Reminder to complete and return fecal immunochemical test (FIT) kit: SMS reminder versus no intervention to individuals who have picked up a FIT kit at the pharmacy and they have not returned it after 14 days. The third intervention will be performed in the BC screening program. Women who had been screened previously will receive an SMS invitation or a letter invitation to participate in the screening. As a primary objective we will assess the impact on participation for each intervention. The secondary objectives will be to analyze the cost-effectiveness of the interventions and to assess participants' perceptions.nnEXPECTED RESULTS: The results from this randomized controlled trial will provide important empirical evidence for the use of mobile phone technology as a tool for improving population-based cancer screening programs. These results may influence the cancer screening invitation procedure in future routine practice.nnTRIAL REGISTRATION: Registry: NCT04343950 (04\/09\/2020); clinicaltrials.gov.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('22','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_22\" style=\"display:none;\"><div class=\"tp_abstract_entry\">BACKGROUND: Short message service (SMS) based interventions are widely used in healthcare and have shown promising results to improve cancer screening programs. However, more research is still needed to implement SMS in the screening process. We present a study protocol to assess the impact on health and economics of three targeted SMS-based interventions in population-based cancer screening programs.nnMETHODS\/DESIGN: The M-TICs study is a randomized controlled trial with a formal process evaluation. Participants aged 50-69 years identified as eligible from the colorectal cancer (CRC) and breast cancer (BC) screening program of the Catalan Institute of Oncology (Catalonia, Spain) will be randomly assigned to receive standard invitation procedure (control group) or SMS-based intervention to promote participation. Two interventions will be conducted in the CRC screening program: 1) Screening invitation reminder: Those who do not participate in the CRC screening within 6 weeks of invite will receive a reminder (SMS or letter); 2) Reminder to complete and return fecal immunochemical test (FIT) kit: SMS reminder versus no intervention to individuals who have picked up a FIT kit at the pharmacy and they have not returned it after 14 days. The third intervention will be performed in the BC screening program. Women who had been screened previously will receive an SMS invitation or a letter invitation to participate in the screening. As a primary objective we will assess the impact on participation for each intervention. The secondary objectives will be to analyze the cost-effectiveness of the interventions and to assess participants' perceptions.nnEXPECTED RESULTS: The results from this randomized controlled trial will provide important empirical evidence for the use of mobile phone technology as a tool for improving population-based cancer screening programs. These results may influence the cancer screening invitation procedure in future routine practice.nnTRIAL REGISTRATION: Registry: NCT04343950 (04\/09\/2020); clinicaltrials.gov.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('22','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_22\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1371\/journal.pone.0245806\" title=\"Follow DOI:10.1371\/journal.pone.0245806\" target=\"_blank\">doi:10.1371\/journal.pone.0245806<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('22','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Molina-Barcel\u00f3  A,  Moreno Salas  J,  Peir\u00f3-P\u00e9rez  R,  Arroyo  G,  Ib\u00e1\u00f1ez Cabanell  J,  Vanaclocha Esp\u00ed  M,  Binefa  G,  Garc\u00eda  M,  Salas Trejo  D. <\/p><p class=\"tp_pub_title\">[Inequalities in access to cancer screening programmes in Spain and how to reduce them: data from 2013 and 2020.]. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Rev Esp Salud Publica. <\/span><span class=\"tp_pub_additional_year\">2021<\/span><span class=\"tp_pub_additional_volume\">;95<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_21\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('21','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_21\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('21','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_21\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid33496270,<br \/>\r\ntitle = {[Inequalities in access to cancer screening programmes in Spain and how to reduce them: data from 2013 and 2020.]},<br \/>\r\nauthor = {Molina-Barcel\u00f3 A and Moreno Salas J and Peir\u00f3-P\u00e9rez R and Arroyo G and Ib\u00e1\u00f1ez Cabanell J and Vanaclocha Esp\u00ed M and Binefa G and Garc\u00eda M and Salas Trejo D},<br \/>\r\nissn = {2173-9110},<br \/>\r\nyear  = {2021},<br \/>\r\ndate = {2021-01-01},<br \/>\r\njournal = {Rev Esp Salud Publica},<br \/>\r\nvolume = {95},<br \/>\r\nabstract = {OBJECTIVE: The European Commission recommends ensuring equity in cancer screening. The aim of this study was to find out if there were inequalities in access to cancer screening programmes in Spain.nnMETHODS: A transversal study was carried out by means of a survey addressed to the people responsible for breast, colorectal (CRC) and cervical cancer screening programmes in the 19 Autonomous Communities (AC) of Spain in 2013 and 2020. Information was collected on organizational characteristics, inequalities in access and interventions to reduce them. A descriptive analysis was made by AC and time period, by calculating frequencies and percentages, depending on the type of programme (breast, CRC and cervix).nnRESULTS: In 2013, 14 ACs participated for the breast programme, 8 for the CRC and 7 for the cervical programme; and in 2020, 14, 13 and 11 ACs respectively. All breast programmes were population-based in both periods (14\/14 in 2013 and 14\/14 in 2020), as well as CRC ones (8\/8 in 2013 and 13\/13 in 2020), with an increase in cervical cancer programmes (0\/7 en 2013 y 6\/11 en 2020). In both periods, social groups not included in the target population and groups that were less involved were identified, with differences according to the type of programme. A total of 53 interventions were carried out to reduce inequalities in access (27 in breast, 22 in RCC and 4 in cervical), 66% of them aimed at specific social groups (35\/53).nnCONCLUSIONS: Inequalities in access to cancer screening programmes in Spain are identified, as well as interventions to reduce them.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('21','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_21\" style=\"display:none;\"><div class=\"tp_abstract_entry\">OBJECTIVE: The European Commission recommends ensuring equity in cancer screening. The aim of this study was to find out if there were inequalities in access to cancer screening programmes in Spain.nnMETHODS: A transversal study was carried out by means of a survey addressed to the people responsible for breast, colorectal (CRC) and cervical cancer screening programmes in the 19 Autonomous Communities (AC) of Spain in 2013 and 2020. Information was collected on organizational characteristics, inequalities in access and interventions to reduce them. A descriptive analysis was made by AC and time period, by calculating frequencies and percentages, depending on the type of programme (breast, CRC and cervix).nnRESULTS: In 2013, 14 ACs participated for the breast programme, 8 for the CRC and 7 for the cervical programme; and in 2020, 14, 13 and 11 ACs respectively. All breast programmes were population-based in both periods (14\/14 in 2013 and 14\/14 in 2020), as well as CRC ones (8\/8 in 2013 and 13\/13 in 2020), with an increase in cervical cancer programmes (0\/7 en 2013 y 6\/11 en 2020). In both periods, social groups not included in the target population and groups that were less involved were identified, with differences according to the type of programme. A total of 53 interventions were carried out to reduce inequalities in access (27 in breast, 22 in RCC and 4 in cervical), 66% of them aimed at specific social groups (35\/53).nnCONCLUSIONS: Inequalities in access to cancer screening programmes in Spain are identified, as well as interventions to reduce them.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('21','tp_abstract')\">Close<\/a><\/p><\/div><\/div><\/div><h3 class=\"tp_h3\" id=\"tp_h3_2020\">2020<\/h3><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Guillam\u00f3  E,  Travier  N,  Oviedo  GR,  Fonseca-Nunes  A,  Alamo  JM,  Cos  F,  Roca  A,  Ni\u00f1o  O,  Agudo  A,  Javierre  C. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('45','tp_links')\" style=\"cursor:pointer;\">Physical Test to Estimate Suitable Workloads for an Exercise Program in Breast Cancer Survivors<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">J Strength Cond Res. <\/span><span class=\"tp_pub_additional_year\">2020<\/span><span class=\"tp_pub_additional_volume\">;34<\/span><span class=\"tp_pub_additional_pages\">:3593\u20133599<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_45\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('45','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_45\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('45','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_45\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('45','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_45\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid29579014,<br \/>\r\ntitle = {Physical Test to Estimate Suitable Workloads for an Exercise Program in Breast Cancer Survivors},<br \/>\r\nauthor = {Guillam\u00f3 E and Travier N and Oviedo GR and Fonseca-Nunes A and Alamo JM and Cos F and Roca A and Ni\u00f1o O and Agudo A and Javierre C},<br \/>\r\ndoi = {10.1519\/JSC.0000000000002337},<br \/>\r\nissn = {1533-4287},<br \/>\r\nyear  = {2020},<br \/>\r\ndate = {2020-12-01},<br \/>\r\njournal = {J Strength Cond Res},<br \/>\r\nvolume = {34},<br \/>\r\nnumber = {12},<br \/>\r\npages = {3593--3599},<br \/>\r\nabstract = {Guillam\u00f3, E, Travier, N, Oviedo, GR, Fonseca-Nunes, A, Alamo, JM, Cos, F, Roca, A, Ni\u00f1o, O, Agudo, A, and Javierre, C. Physical test to estimate suitable workloads for an exercise program in breast cancer survivors. J Strength Cond Res 34(12): 3593-3599, 2020-Epidemiologic studies suggest that patients with breast cancer who gain weight after diagnosis have a higher risk of recurrence and death. Regular physical exercise can help minimize postdiagnosis weight gain. The objective of the study was to assess the effectiveness of a physical test for individualizing the workloads used during a fitness program. To continuously individualize the intensity of the training, a test was designed and integrated into the sessions. The test consisted in monitoring heart rate and workload during 2 bouts of cycling at moderate intensity. The workload parameters recorded during the tests were later used as reference values to plan the intensity of the next in-person training sessions. The 5 tests conducted during the 12 weeks of the intervention showed significant differences in intensity (F = 3.034, p = 0.047). Compared with the first evaluation, the intensities measured during the third, fourth, and fifth tests presented increases of 9.9% (p = 0.02), 13.2% (p = 0.019), and 17.5% (p = 0.002), respectively. A significant increase in workload with respect to body weight was observed in the physical assessment performed after the program (t = 13.2, p = 0.0001). The peak oxygen consumption with respect to body weight (peak V[Combining Dot Above]O2) achieved by the subjects during the assessment at the end of the program had also increased (t = 9.72, p = 0.0001). The intensity test, introduced in the training sessions along with the physical exercise program, was an easy-to-use, practical tool for monitoring intensity. It allows an adjustment of the workload over the program period that respects the individual progression of each patient.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('45','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_45\" style=\"display:none;\"><div class=\"tp_abstract_entry\">Guillam\u00f3, E, Travier, N, Oviedo, GR, Fonseca-Nunes, A, Alamo, JM, Cos, F, Roca, A, Ni\u00f1o, O, Agudo, A, and Javierre, C. Physical test to estimate suitable workloads for an exercise program in breast cancer survivors. J Strength Cond Res 34(12): 3593-3599, 2020-Epidemiologic studies suggest that patients with breast cancer who gain weight after diagnosis have a higher risk of recurrence and death. Regular physical exercise can help minimize postdiagnosis weight gain. The objective of the study was to assess the effectiveness of a physical test for individualizing the workloads used during a fitness program. To continuously individualize the intensity of the training, a test was designed and integrated into the sessions. The test consisted in monitoring heart rate and workload during 2 bouts of cycling at moderate intensity. The workload parameters recorded during the tests were later used as reference values to plan the intensity of the next in-person training sessions. The 5 tests conducted during the 12 weeks of the intervention showed significant differences in intensity (F = 3.034, p = 0.047). Compared with the first evaluation, the intensities measured during the third, fourth, and fifth tests presented increases of 9.9% (p = 0.02), 13.2% (p = 0.019), and 17.5% (p = 0.002), respectively. A significant increase in workload with respect to body weight was observed in the physical assessment performed after the program (t = 13.2, p = 0.0001). The peak oxygen consumption with respect to body weight (peak V[Combining Dot Above]O2) achieved by the subjects during the assessment at the end of the program had also increased (t = 9.72, p = 0.0001). The intensity test, introduced in the training sessions along with the physical exercise program, was an easy-to-use, practical tool for monitoring intensity. It allows an adjustment of the workload over the program period that respects the individual progression of each patient.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('45','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_45\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1519\/JSC.0000000000002337\" title=\"Follow DOI:10.1519\/JSC.0000000000002337\" target=\"_blank\">doi:10.1519\/JSC.0000000000002337<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('45','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><div class=\"tp_publication tp_publication_article\"><div class=\"tp_pub_info\"><p class=\"tp_pub_author\"> Louro  J,  Rom\u00e1n  M,  Posso  M,  Comerma  L,  Vidal  C,  Saladi\u00e9  F,  Alcantara  R,  Sanchez  M,  Quintana  MJ,  Del Riego  J,  Ferrer  J,  Pe\u00f1alva  L,  Bargall\u00f3  X,  Prieto  M,  Sala  M,  Castells  X. <\/p><p class=\"tp_pub_title\"><a class=\"tp_title_link\" onclick=\"teachpress_pub_showhide('36','tp_links')\" style=\"cursor:pointer;\">Differences in breast cancer risk after benign breast disease by type of screening diagnosis<\/a>. <span class=\"tp_pub_type article\">Journal Article<\/span> <\/p><p class=\"tp_pub_additional\"><span class=\"tp_pub_additional_journal\">Breast. <\/span><span class=\"tp_pub_additional_year\">2020<\/span><span class=\"tp_pub_additional_volume\">;54<\/span><span class=\"tp_pub_additional_pages\">:343\u2013348<\/span>.<\/p><p class=\"tp_pub_menu\"><span class=\"tp_abstract_link\"><a id=\"tp_abstract_sh_36\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('36','tp_abstract')\" title=\"Show abstract\" style=\"cursor:pointer;\">Abstract<\/a><\/span> | <span class=\"tp_resource_link\"><a id=\"tp_links_sh_36\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('36','tp_links')\" title=\"Show links and resources\" style=\"cursor:pointer;\">Links<\/a><\/span> | <span class=\"tp_bibtex_link\"><a id=\"tp_bibtex_sh_36\" class=\"tp_show\" onclick=\"teachpress_pub_showhide('36','tp_bibtex')\" title=\"Show BibTeX entry\" style=\"cursor:pointer;\">BibTeX<\/a><\/span> | <span class=\"tp_pub_tags_label\">Etiquetes: <\/span><\/p><div class=\"tp_bibtex\" id=\"tp_bibtex_36\" style=\"display:none;\"><div class=\"tp_bibtex_entry\"><pre>@article{pmid33023825,<br \/>\r\ntitle = {Differences in breast cancer risk after benign breast disease by type of screening diagnosis},<br \/>\r\nauthor = {Louro J and Rom\u00e1n M and Posso M and Comerma L and Vidal C and Saladi\u00e9 F and Alcantara R and Sanchez M and Quintana MJ and Del Riego J and Ferrer J and Pe\u00f1alva L and Bargall\u00f3 X and Prieto M and Sala M and Castells X},<br \/>\r\ndoi = {10.1016\/j.breast.2020.09.005},<br \/>\r\nissn = {1532-3080},<br \/>\r\nyear  = {2020},<br \/>\r\ndate = {2020-12-01},<br \/>\r\njournal = {Breast},<br \/>\r\nvolume = {54},<br \/>\r\npages = {343--348},<br \/>\r\nabstract = {INTRODUCTION: We aimed to assess differences in breast cancer risk across benign breast disease diagnosed at prevalent or incident screens.nnMATERIALS AND METHODS: We conducted a retrospective cohort study with data from 629,087 women participating in a long-standing population-based breast cancer screening program in Spain. Each benign breast disease was classified as non-proliferative, proliferative without atypia, or proliferative with atypia, and whether it was diagnosed in a prevalent or incident screen. We used partly conditional Cox hazard regression to estimate the adjusted hazard ratios of the risk of breast cancer.nnRESULTS: Compared with women without benign breast disease, the risk of breast cancer was significantly higher (p-value\u00a0=\u00a00.005) in women with benign breast disease diagnosed in an incident screen (aHR, 2.67; 95%CI: 2.24-3.19) than in those with benign breast disease diagnosed in a prevalent screen (aHR, 1.87; 95%CI: 1.57-2.24). The highest risk was found in women with a proliferative benign breast disease with atypia (aHR, 4.35; 95%CI: 2.09-9.08, and 3.35; 95%CI: 1.51-7.40 for those diagnosed at incident and prevalent screens, respectively), while the lowest was found in women with non-proliferative benign breast disease (aHR, 2.39; 95%CI: 1.95-2.93, and 1.63; 95%CI: 1.32-2.02 for those diagnosed at incident and prevalent screens, respectively).nnCONCLUSION: Our study showed that the risk of breast cancer conferred by a benign breast disease differed according to type of screen (prevalent or incident). To our knowledge, this is the first study to analyse the impact of the screening type on benign breast disease prognosis.},<br \/>\r\nkeywords = {},<br \/>\r\npubstate = {published},<br \/>\r\ntppubtype = {article}<br \/>\r\n}<br \/>\r\n<\/pre><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('36','tp_bibtex')\">Close<\/a><\/p><\/div><div class=\"tp_abstract\" id=\"tp_abstract_36\" style=\"display:none;\"><div class=\"tp_abstract_entry\">INTRODUCTION: We aimed to assess differences in breast cancer risk across benign breast disease diagnosed at prevalent or incident screens.nnMATERIALS AND METHODS: We conducted a retrospective cohort study with data from 629,087 women participating in a long-standing population-based breast cancer screening program in Spain. Each benign breast disease was classified as non-proliferative, proliferative without atypia, or proliferative with atypia, and whether it was diagnosed in a prevalent or incident screen. We used partly conditional Cox hazard regression to estimate the adjusted hazard ratios of the risk of breast cancer.nnRESULTS: Compared with women without benign breast disease, the risk of breast cancer was significantly higher (p-value\u00a0=\u00a00.005) in women with benign breast disease diagnosed in an incident screen (aHR, 2.67; 95%CI: 2.24-3.19) than in those with benign breast disease diagnosed in a prevalent screen (aHR, 1.87; 95%CI: 1.57-2.24). The highest risk was found in women with a proliferative benign breast disease with atypia (aHR, 4.35; 95%CI: 2.09-9.08, and 3.35; 95%CI: 1.51-7.40 for those diagnosed at incident and prevalent screens, respectively), while the lowest was found in women with non-proliferative benign breast disease (aHR, 2.39; 95%CI: 1.95-2.93, and 1.63; 95%CI: 1.32-2.02 for those diagnosed at incident and prevalent screens, respectively).nnCONCLUSION: Our study showed that the risk of breast cancer conferred by a benign breast disease differed according to type of screen (prevalent or incident). To our knowledge, this is the first study to analyse the impact of the screening type on benign breast disease prognosis.<\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('36','tp_abstract')\">Close<\/a><\/p><\/div><div class=\"tp_links\" id=\"tp_links_36\" style=\"display:none;\"><div class=\"tp_links_entry\"><ul class=\"tp_pub_list\"><li><i class=\"ai ai-doi\"><\/i><a class=\"tp_pub_list\" href=\"https:\/\/dx.doi.org\/10.1016\/j.breast.2020.09.005\" title=\"Follow DOI:10.1016\/j.breast.2020.09.005\" target=\"_blank\">doi:10.1016\/j.breast.2020.09.005<\/a><\/li><\/ul><\/div><p class=\"tp_close_menu\"><a class=\"tp_close\" onclick=\"teachpress_pub_showhide('36','tp_links')\">Close<\/a><\/p><\/div><\/div><\/div><\/div><div class=\"tablenav\"><div class=\"tablenav-pages\"><span class=\"displaying-num\">98 entries<\/span> <a class=\"page-numbers button disabled\">&laquo;<\/a> <a class=\"page-numbers button disabled\">&lsaquo;<\/a> 1 of 2 <a href=\"https:\/\/icoprevencio.cat\/uc\/publicacions\/?limit=2&amp;tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=&amp;tsr=#tppubs\" title=\"next page\" class=\"page-numbers button\">&rsaquo;<\/a> <a href=\"https:\/\/icoprevencio.cat\/uc\/publicacions\/?limit=2&amp;tgid=&amp;yr=&amp;type=&amp;usr=&amp;auth=&amp;tsr=#tppubs\" title=\"last page\" class=\"page-numbers button\">&raquo;<\/a> <\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":15,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_vp_format_video_url":"","_vp_image_focal_point":[],"footnotes":""},"class_list":["post-6232","page","type-page","status-publish","hentry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"vp_sm":false,"vp_md":false,"vp_lg":false,"vp_xl":false,"vp_sm_popup":false,"vp_md_popup":false,"vp_xl_popup":false},"uagb_author_info":{"display_name":"xesco","author_link":"https:\/\/icoprevencio.cat\/uc\/author\/xesco\/"},"uagb_comment_info":0,"uagb_excerpt":null,"_links":{"self":[{"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/pages\/6232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/comments?post=6232"}],"version-history":[{"count":1,"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/pages\/6232\/revisions"}],"predecessor-version":[{"id":6233,"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/pages\/6232\/revisions\/6233"}],"wp:attachment":[{"href":"https:\/\/icoprevencio.cat\/uc\/wp-json\/wp\/v2\/media?parent=6232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}